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Abstract 
Post-transcriptional regulation of mRNA is an important determinant of net gene 
expression. Tissue factor (TF) is the key stimulus for thrombus formation and plays 
critical roles in atherothrombosis. Little is known about its post-transcriptional regulation. 
Tristetraprolin (TTP) is the most widely studied mRNA-binding protein, and binds to the 
adenylate-uridylate rich elements (AREs) in the 3‘ untranslated region (3‘UTR) of target 
mRNAs and promotes degradation. Poly(ADP-ribose)-polymerase-14 (PARP-14), 
belongs to a family of ~17 proteins with a PARP domain that generates negatively 
charged poly(ADP-ribose) adducts on intracellular proteins – a post-translational 
modification implicated in diverse cellular functions. Preliminary findings in our 
laboratory have identified PARP-14 as a novel RNA-binding protein, and found it to 
regulate inflammatory mRNA. This study sought to establish the roles for TTP and 
PARP-14 in regulating TF mRNA stability in LPS-stimulated monocyte-macrophages.  
 
Preliminary experiments demonstrated that TF mRNA, TF protein and TF mRNA 
stability were increased in  Ttp-/- and  Parp14-/-  macrophages. Similarly, TF expression 
was increased in vivo in Parp14-/- mice. Furthermore, intravital microscopy 
demonstrated accelerated thrombosis following ferric-chloride injury in LPS-stimulated 
Parp14-/- mice. RNP immunoprecipitation, RNA biotin pulldown and co-
immunoprecipitation assays demonstrated an interdependency for PARP-14 and TTP to 
form a ternary complex with TF mRNA. Both proteins interacted within the same 3‘UTR 
segment containing a highly conserved  palindromic ARE (AUAAUUUAUUUAAUA) 
comprising 2 overlapping AUUUAUUUA and UUAUUUAAU nonamers, both of which 
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appeared to be critical in mediating this interaction. Inhibition of p38, which classically 
results in accelerated decay of TTP-regulated transcripts, reduced TF mRNA stability in 
WT but not Ttp-/- or Parp14-/- macrophages. Inhibition of PARP activity reduced TF 
mRNA stability in WT but not in Parp14-/- macrophages. Interestingly, PARP-14 
conferred selectivity for TTP to degrade TF mRNA, as PARP-14 had no effect on TNFα 
expression, an established target of TTP. Similarly, PARP inhibition had no effect on 
TNFα mRNA decay. 
 
These data define novel roles for TTP and PARP-14 in the selective regulation of TF 
mRNA turnover, and demonstrates for the first time how the actions of TTP may be 
selectively regulated. PARP-14 functions as an accessory RNA-binding protein which is 
required for TTP to bind and degrade TF mRNA. Inhibition of either p38 or PARP 
catalytic activity accelerated TF mRNA decay. Thus one may propose that both PARP-
14-mediated ADP-ribosylation and p38-mediated phosphorylation events are necessary 
for inactivating TTP-mediated TF mRNA decay. The selective destabilization of TF 
mRNA via pharmacological inhibition of PARP-14 may offer a novel therapeutic strategy 
in atherosclerosis and cardiovascular disease where thrombosis is linked to TF 
expression. 
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1.1 ATHEROSCELROSIS 
1.1.1 Introduction to atherosclerosis 
Atherosclerosis is a progressive disease which is characterized by the accumulation of 
lipids and fibrous elements within large and medium-sized arteries of the vascular beds 
(aorta, carotid, coronary and peripheral arteries) and represents the pathological basis 
for cardiovascular disease (coronary artery disease, stroke and peripheral vascular 
disease)1, 2. It is not a disease of the 21st century man, as calcified coronary lesions 
have been documented dating back to Egyptian mummies, and as for much of the last 
century, it was widely considered to be a disorder of lipid storage as a natural 
component of aging3. With the advancing modern era of cell biology, atherosclerosis is 
now understood to represent a mutlifactorial complex disease process. In a broad 
outline, it can be considered as a form of chronic inflammation resulting from the 
interaction between modified lipoproteins, macrophages, T cells and normal cellular 
elements of the arterial wall4. Several risk factors such as hyperlipidaemia, diabetes, 
hypertension, smoking, inflammation, age and gender contribute to the development 
and progression of atherosclerosis5.  
 
1.1.2 Burden of atherosclerosis 
Atherosclerosis is associated with significant morbidity and mortality. Cardiovascular 
disease is predicted to be the principal cause of death worldwide by the year 2030, 
accountable for 25 million deaths per year6. Coronary artery disease is now the leading 
cause of death worldwide with a high clinical, social and economic burden. An 
estimated 2.6 million people in the UK have coronary artery disease and accounts for 
over 88,000 deaths per year (an average of 224 people each day or one death every six 
minutes). Approximately 1.3 million people in the UK have had a myocardial infarction, 2 
million people suffer from angina, and over 230,000 new myocardial infarctions are 
diagnosed every year7. 
 
1.1.3 Development of the atherosclerotic plaque 
Inflammation is now recognized as central to the development of atherosclerosis8. As 
early as 1958, experimental observations in rabbits showed that monocytes adhered to  
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the intact endothelium in early atherosclerotic lesions9. Leukocyte recruitment does not 
generally occur in the presence of normal endothelium. The endothelium is a 
metabolically active organ system, and by virtue of its location and size (~700m2 in an 
average sized adult) plays a critical role in maintaining vascular homeostasis by 
regulating thrombotic, inflammatory and reparative responses to local injury10, 11. Thus, 
endothelial dysfunction represents the initial promoter of atherosclerosis12. At the onset 
of atherosclerosis, lipoproteins become trapped by the proteoglycans in the intima and 
accumulate in the arterial wall, resulting in intimal thickening. Endothelial dysfunction 
promotes an inflammatory environment, where the lipoproteins are modified by 
oxidation, lipolysis, proteolysis and aggregation8. Pro-inflammatory cytokines are 
released in response to the infiltrated oxidized lipoproteins to recruit circulating 
monocytes. Cells within the atherosclerotic lesion express many chemotactic factors for 
monocytes. There is overwhelming evidence to support the critical role for MCP-1 as 
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the most important mediator of monocyte recruitment13, 14. Vascular endothelial cells 
produce MCP-1, anchoring it on the cell surface. Monocytes, activated T-cells and 
activated natural killer cells express CCR-2, a receptor for MCP-1, and thus MCP-
1/CCR-2 are important in monocyte recruitment into atherosclerotic lesions15. 
Furthermore, adhesion molecules (ICAM-1, VCAM-1, P-selectin and E-selectin) 
essential for monocyte recruitment are up-regulated on vascular endothelial cells16-18. 
Once monocytes exit the circulation to enter the atherosclerotic lesion, they differentiate 
into macrophages. In atherosclerotic lesions, M-CSF is criticial for monocyte-
macrophage differentiation19. Oxidized lipoproteins are taken up by macrophages via 
macrophage scavenger receptors (SR-A and CD-36)20, where they are transported into 
lysosomes and degraded into amino acids and free cholesterol21. The free cholesterol is 
released back into the cytosol, and given that excess free cholesterol is toxic to 
macrophages22, it is converted to cholesterol esters by acyl CoA: cholesterol 
acyltransferase-1 (ACAT-1) and stored in this form in the cytosol21, 23. This 
intracytoplasmic accumulation of cholesterol ester as membrane-free lipid droplets 
transforms macrophages into foam cells (figure 1-1)22. Foam cells in atherosclerotic 
lesions eventually undergo apoptosis, because intracellular accumulation of free 
cholesterol is toxic to them24. This is mainly seen within the central lipid core of the 
lesion. Macrophages and T cells secrete cytokines and growth factors which promote 
smooth muscle cell migration, proliferation and extracellular matrix production23. This 
growing mass of smooth muscle cells embedded in extracellular matrix results in fibrous 
cap formation that protects the deeper thrombogenic lipid core from contact with the 
circulating blood. Disruption of this fibrous cap results in activation of the coagulation 
cascade and thrombosis. 
 
1.2 COAGULATION CASCADE 
The coagulation cascade is characterized by sequential, rapid and highly localized 
activation of serine proteases resulting in the generation of thrombin, which 
subsequently converts fibrinogen to fibrin. Following endothelial injury, collagen and 
tissue factor (TF) become exposed to the flowing blood. Collagen triggers the 
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accumulation and activation of platelets, whereas TF initiates the generation of thrombin 
via the ―extrinsic pathway‖25.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Platelet activation 
Platelets adhere to the site of endothelial damage via platelet glycoprotein VI that 
interacts directly with collagen, and platelet glycoprotein 1b-V-IX that interacts with 
collagen-bound von Willebrand factor (vWF)26. These platelet-endothelial cell 
interactions result in platelet activation27. Thrombin can directly activate platelets, 
independently of vWF and platelet glycoprotein VI, by cleaving protease-activated 
receptors (PARs)28, 29. Platelet activation results in a conformational change of the 
platelet integrin αIIbβ3, increasing the affinity for its ligands, fibrinogen and von 
Willebrand factor30. This mediates platelet-platelet interactions and recruits platelets to 
the developing thrombus. Activated platelets release granules containing ADP, 
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serotonin, and thromboxane A2 which leads to further platelet activation
31. The activated 
platelet membrane provides a surface rich in negatively charged phosphatidylserine 
(PS) to act as a catalytic surface for activation of coagulation factors25. 
 
1.2.2 Extrinsic pathway 
The ―extrinsic‖ pathway plays an important role in thrombosis, resulting in the rapid 
production of thrombin and subsequent thrombus formation. TF is the key stimulus that 
drives the extrinsic pathway. TF activates factor VII and complexes with its activated 
form (VIIa) and to activate factors IX and X (IXa and Xa). Factor VIIa is a very weak 
serine protease, but upon binding to TF, its catalytic activity is enhanced over a million 
fold. Factor Xa binds with factor V, which converts prothrombin into thrombin. Initially, 
the extrinsic pathway is inefficient as factors VIII and V, the circulating pro-factors for 
the tenase (factor VIIIa-factor IXa) and prothrombinase (factor Xa-factor Va) complexes 
are not activated. The amount of thrombin produced by factor Xa-factor V complex is a 
100 times less that that seen with factor Xa-factor Va complex, and therefore the initial 
yield of thrombin is very small. However, thrombin subsequently activates factors VIII 
and V (factors VIIIa and Va), and the tenase and prothrombinase complexes proceed 
efficiently to generate a large burst of thrombin32. Thrombin cleaves fibrinogen into 
soluble fibrin monomers and also activates factor XIII (factor XIIIa) that cross-links 
soluble fibrin monomers into a fibrin matrix25.  
1.2.3 Intrinsic pathway 
The ―intrinsic pathway‖ or ―contact activation pathway‖ plays a minor role in initiating 
thrombus formation, due to a slower activation process. However, its latent activation 
may play an important role in thrombus propagation. Furthermore, the initial burst of 
thrombin following TF exposure (via the extrinsic pathway) can directly activate 
components of the intrinsic pathway. The intrinsic pathway begins with the formation of 
the primary complex on collagen comprising kininogen, prekallikrein, and factor XII. 
Prekallikrein is converted to kallikrein and this activates factor XII (factor XIIa). Factor 
XIIa activates factor XI (factor XIa) that activates factor IX (factor IXa) which complexes 
with factor VIIIa to from the tenase complex. Thrombin can additionally activate factor XI 
and thus contribute to the intrinsic pathway33.  
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1.2.4 Feedback mechanisms and regulation of thrombosis 
The coagulation cascade is regulated by several naturally occurring anticoagulants, TF 
pathway inhibitor (TFPI), Protein C and anti-thrombin. TFPI inhibits the TF-factor VIIa 
complex, by initially binding with factor Xa, and then TFPI-factor Xa complexes TF-
factor VIIa to form a stable quaternary complex34. In this way, TFPI is also a direct 
inhibitor of factor Xa. TFPI provides a mechanism to ensure that a small procoagulant 
stimulus does not produce an uncontrolled burst of thrombin. However, once the 
coagulation cascade is triggered, thrombin provides a positive-feedback amplification 
mechanism, through the activation of factors V, VIII and XI, and allows the coagulation 
cascade to continue in the absence of functionally active TF35. It is not TFPI, but the 
inhibitory actions of Protein C and anti-thrombin that become more prevalent in 
controlling thrombin generation and eventually switching off the coagulation cascade. 
Protein C is converted to activated Protein C (APC) by the thrombin-thrombomodulin 
complex. APC in association with its cofactor Protein S cleaves and inactivates factors 
Va and VIIIa36. The primary target of anti-thrombin is thrombin, but it can also inactivate 
other coagulation factors, including factors IXa, Xa, XIa, and XIIa25, 36. The coagulation 
cascade is outlined in figure 1-2. 
 
1.3 MONOCYTE-MACROPHAGES IN ATHEROTHROMBOSIS 
 
1.3.1 Plaque instability and rupture 
Plaque rupture is a recognized complication of atherosclerosis. It exposes thrombogenic 
material to the flowing blood and initiates the coagulation cascade and thrombosis 
(hence the term ―atherothrombosis‖)37. Although this can lead to occlusive thrombus 
formation and acute ischaemia, accounting for the most serious clinical manifestations 
of atherosclerosis37, 38, repeated episodes of plaque rupture and thrombosis can 
contribute to asymptomatic plaque growth. If thrombus formation remains mural rather 
than occlusive and its lysis is incomplete, then re-endothelialization followed by 
thrombus organization results in plaque growth39. Similarly, plaque growth can occur 
following intraplaque haemorrhage from plaque neovessels. Cells in the growing plaque 
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receive oxygen by diffusion, but when intimal thickness increases beyond a diffusion 
limit, this stimulates growth of new vessels (neovessels). These neovessels can rupture 
or leak resulting in intraplaque haemorrhage. Consequently, the plaque increases in 
size with the redevelopment of plaque hypoxia and stimulation of further 
neovascularization predisposing to further intraplaque haemorrhage. Thus intraplaque 
haemorrhage can contribute to exponential plaque growth and predispose to plaque 
instability40. 
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It is plaque composition rather than size and severity of the resulting stenosis that plays 
a critical role in plaque rupture 41, 42. In advanced atheromatous plaques, the lipid core 
contains abundant free cholesterol, oxidised lipids and apoptotic cells. This necrotic lipid 
core is rich in TF, which is primarily derived from macrophages and foam cells43. 
Following plaque rupture, TF is the key trigger for initiating thrombosis. Factors 
associated with plaque instability include, a large lipid core, thin fibrous caps, increased 
inflammation of the fibrous cap, increased plaque neovascularization and intraplaque 
haemorrhage(figure 1-3)44, 45. Increased plaque inflammation is central to the 
pathogenesis of plaque rupture46. Ruptured plaques contain more inflammatory cells 
than intact plaques and these primarily include monocytes/macrophages but also 
include activated T cells and mast cells. Increased expression of inflammatory 
mediators such as adhesion molecules, cytokines and chemokines can be 
demonstrated at sites of plaque rupture46, 47. 
 
The fibrous cap of an atherosclerotic plaque protects the deeper thrombogenic lipid core 
from contact with the circulating blood. Its structural components include collagen, 
elastin and proteoglycans that are derived from smooth muscle cells. Thinning of the 
fibrous cap is considered to be a prelude to plaque rupture and fibrous caps from 
ruptured plaques contain less extracellular matrix and fewer smooth muscle cells48. This 
reduction in extracellular matrix can result from decreased synthesis and/or increased 
breakdown. Decreased extracellular matrix synthesis results from a reduction in smooth 
muscle cells with a reduction in their synthetic function48-50. Inflammatory cytokines, 
particularly INF-γ, inhibit collagen synthesis by smooth muscle cells in atherosclerotic 
plaques51. TGF-β is expressed by macrophages, smooth muscle and endothelial cells 
and promotes plaque stability by inducing collagen synthesis. With plaque development, 
there is a reduction in TGF-β receptors and thus a reduction in TGF-β-mediated 
collagen synthesis thereby promoting plaque instability and rupture52. Increased 
extracellular matrix breakdown is attributed to a number of proteases that include 
matrix-degrading metalloproteinases (MMPs), cathepsins, tryptase, elastase and 
chymase that are primarily expressed by macrophages and to a lesser extent by 
smooth muscle and endothelial cells53-58. Studies have consistently demonstrated the 
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colocalization of MMPs in unstable plaques57-59. MMPs can additionally promote plaque 
neovascularization60 that predisposes to plaque haemmorhage and instability. 
 
1.3.2 Monocyte-macrophages as modulators of thrombosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thrombus formation is a dynamic process characterized by a continuous balance 
between thrombotic and fibrinolytic mechanisms. Monocyte-macrophages possess both 
thrombotic and fibrinolytic activity61-72, and thus may modulate thrombus formation 
(figure 1-4). Recent studies examining thrombi from culprit coronary lesions show that 
the age of thrombus can be greater than 7 days73-76. It is important to understand the 
evolution of the developing thrombus and the factors that may govern its fate. What 
factors determine the outcomes of thrombosis are unclear, but in simple terms, 
thrombus propagation probably results from imbalances between thrombotic and 
fibrinolytic activities, at least at a local level, and the contributory role of monocyte-
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macrophages in this setting may be crucial. The formation of a cross-linked fibrin matrix 
approximates cells and allows complex interactions to occur between macrophages, 
platelets and endothelial cells. With up-regulation of adhesion molecules, receptors, 
inflammatory cytokines, secretory enzymes and with activated clotting factors and 
products of the coagulation cascade, there is considerable potential for modulation of 
macrophage function, both in an autocrine and paracrine fashion. Figure 1-5 
summarizes the complex interplaying mechanisms between different cells in 
inflammatory and thrombotic milieu of plaque rupture and thrombosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2a Macrophages and tissue factor 
TF is the key trigger for thrombosis. Monocyte-macrophages are an important source of 
TF in atherothrombosis, both within the plaque and the circulating blood. In the blood, 
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TF is expressed on monocytes and microparticles63. Microparticles (MPs) are small 
membrane vesicles, less than 1000nm in diameter that are derived from activated and 
apoptotic cells. They are predominantly derived from monocytes/macrophages but can 
also be released by lymphocytes, vascular smooth muscle cells, endothelial cells and 
platelets77, 78. They express negatively charged phosphatidylserine (PS) and antigen 
markers representative of cellular origin. PS is a procoagulant phospholipid necessary 
for the assembly of blood clotting enzyme complexes25, and together with TF, 
microparticles serve as catalytic surfaces for thrombosis79. In atherosclerotic plaques, 
the necrotic lipid core is rich in TF, which is primarily derived from apoptotic 
macrophages and foam cells43. In atherosclerosis, monocyte differentiation into 
macrophages is itself associated with a significant increase in TF expression via the NF-
κB and AP1 transcription factor pathways80. CD40 and its ligand, CD40L, are co-
expressed by macrophages and vascular smooth muscle cells66, 81, 82. Oxidised 
lipoproteins increase the expression of CD40 and CD40L83, and increased CD40 
signalling enhances thrombogenicity by decreasing thrombomodulin and increasing TF 
production in vascular smooth muscle cells and macrophages84, 85. In macrophages, the 
activation of protease-activated receptors (PARs)28 and ligation of PSGL-1, Mac-1 and 
TREM-1 receptors67, 86 through macrophage-platelet-endothelial cell interactions results 
in increased expression of TF.  
 
In atherosclerotic plaques, TFPI is co-expressed by endothelial cells, vascular smooth 
muscle cells, macrophages and foam cells70. Both TF and TFPI-positive macrophages 
can be demonstrated within the necrotic core of atherosclerotic plaques87. There are no 
studies that have specifically explored TFPI activity in the context of plaque rupture and 
thrombosis, but differential expression of TF and TFPI has been demonstrated in 
atherosclerotic plaques, thus implicating a role for TFPI in modulating plaque 
thrombogenicity68, 88, 89. This concept may be extended to thrombosis, and a relative 
deficiency of TFPI may promote thrombosis. Macrophages produce elastase and 
cathepsins, which can cleave and inactivate TFPI90, 91, and this provides a potential role 
for macrophages in regulating and modulating thrombosis. 
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1.3.2b Macrophages and thrombin 
Although thrombin is the key effector of the coagulation cascade, it contributes 
significantly to inflammation in atherosclerosis and thrombosis. The predominant 
mechanism mediating this pro-inflammatory response is via activation of PARs. These 
receptors have four sub-types (PAR 1-4) and are expressed on macrophages, 
endothelial cells, vascular smooth muscle cells and platelets71. They require proteolytic 
cleavage for their activation, and although thrombin is the primary activating protease, 
other proteases including factors Xa and VIIa and those derived from macrophages 
(tryptase, cathepsins, MMPs, plasmin) can additionally activate these receptors71, 92 
(table 1-1). Thus, macrophages play important roles in PAR activation, both in a 
paracrine and autocrine fashion, and PAR activation integrates macrophage function 
with neighbouring cells and different components of the coagulation cascade. In 
macrophages, PAR-1, PAR-2 and PAR-3 activation stimulates a pro-inflammatory and 
pro-thrombotic response with increased expression of chemo-attractants (MCP-1), 
inflammatory cytokines (IL-1, IL-6, IL-8), MMPs and TF93-95. 
 
Activation of endothelial PAR-1 and PAR-2 elicits a pro-inflammatory and pro-
thrombotic response with increased expression of adhesion molecules (ICAM-1, VCAM-
1 P-selectin and E-selectin), chemo-attractants (MCP-1), cytokines (IL-6 and IL-8),  
vWF, TF and PAI-192, 96, 97. By stimulating an acute-phase response, IL-6 can further 
promote thrombogenicity by increasing circulating fibrinogen and plasminogen activator 
inhibitor (PA-I)98. Furthermore, endothelial PAR activation induces cell retraction and 
reorganization of cadherins at endothelial junctions, increasing endothelial permeability 
and promoting monocyte extravasation99. Activation of platelet PAR-3 and PAR-4, 
results in granule release, formation of microparticles, secretion of a number of 
cytokines (PDGF, PF4, and RANTES), expression of TF, up-regulation and activation of 
αIIbβ3 complex and increased expression of P-selectin and CD40L
28, 86, 92, 100, 101. 
Thrombin interacts with gp1b and P-selectin, and these may serve to localize thrombin 
to the platelet surface to promote PAR activation102. PAR activation promotes CD40 
signalling and this induces the expression of pro-inflammatory cytokines including IL-1, 
IL-6, and IL-8, adhesion molecules, MMPs and TF83.  
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Thrombin influences all aspects of monocyte-macrophage function and intricately 
modulates their inflammatory, thrombotic and fibrinolytic activity. Conversely, 
macrophages may play important roles in modulating thrombin function. Both platelets 
and macrophages produce PAI-1 and protease nexin-1 (PN-1) that can inhibit thrombin, 
thereby mediating anti-thrombotic effects65. Although PAI-1 predominantly inhibits 
urokinase-type plasminogen activator (uP)A, by binding to vibronectin, it can alter its 
substrate specificity, allowing it to inhibit thrombin103. PN-1 is a serine protease and is a 
powerful inhibitor of thrombin but can also inhibit uPA and plasmin.  In the presence of 
glycosaminoglycans, thrombin becomes the preferential target of PN-1104. PN-1 is a 
more potent thrombin inhibitor than anti-thrombin105, and there is evidence that it exerts 
a predominant anti-thrombotic effect106.  
 
1.3.2c Macrophages and clotting factors 
Macrophages can initiate coagulation via the Mac-1 (CD11b/CD18, αMβ2) receptor
69 and 
through the expression of factor VII activating protein (FSAP)72. Mac-1 is a cell surface 
receptor that is up-regulated by pro-inflammatory cytokines and platelet-macrophage 
interactions through P-selectin/PSGL-1, CD40L/CD40 and TREM-1L/TREM-167. Mac-1 
can bind to factor X and following exposure to ADP, macrophages can catalyse the 
activation of cell-bound factor X to factor Xa, independent of TF and factor VIIa69. FSAP 
is a serine protease, secreted as an inactive zymogen that can be activated by 
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polyanions and uPA72. It is secreted by macrophages, and its expression is increased 
by pro-inflammatory cytokines, particularly IL-1 and IL-6107. It is rapidly inactivated by 
α2-antiplasmin, anti-thrombin, PN-1 and PAI-1, after which it is internalised by receptor-
mediated endocytosis72, 108. The primary substrates for FSAP are factor VII and uPA72, 
and therefore, FSAP plays important roles in initiating the extrinsic pathway and 
mediating fibrinolysis, although there is greater evidence for the later. Another potential 
substrate is fibrinogen, implicating FSAP in fibrin formation72. Immunostaining studies 
show that FSAP is not present in normal arteries, but increased intracellular and 
extracellular FSAP is present in vulnerable atherosclerotic plaques, confined 
predominantly to macrophages107. FSAP inhibits vascular smooth muscle cell 
proliferation by cleaving and inactivating PDGF109, and this in conjunction with its pro-
fibrinolytic actions, may promote plaque instability. 
 
1.3.2d Macrophages and platelets 
During thrombus formation, activated platelets express P-selectin, αIIbβ3, gp1b, JAM-C, 
CD40L and TREM-1 that can bind to receptors on macrophages. Platelet-macrophage 
interactions activate intracellular signalling pathways that stimulate pro-inflammatory 
and pro-thrombotic responses in macrophages85. P-selectin can bind to PSGL-1 on 
monocyte-macrophage derived microparticles, resulting in fusion of microparticles with 
activated platelets110. Platelet-macrophage interactions, through P-selectin/PSGL-1, 
CD40L/CD40 and TREM-1L/TREM-1, up-regulate macrophage integrin expression, 
particularly the Mac-1 receptor. Mac-1 binding to platelet αIIbβ3 is mediated by 
fibrinogen, but can additionally bind with platelet gp1b and JAM-C independently of 
fibrinogen. Ligation of macrophage PSGL-1, Mac-1, CD40 and TREM-1 activates the 
NF-κB transcription factor pathways promoting proinflammatory and prothrombotic 
responses with up-regulation of IL-1β, IL-8, TNF-α, MCP-1 and TF85.   
 
1.3.2e Macrophages and fibrinolysis 
Plasmin is the most important mediator of fibrinolysis, and exists in its inactive form, 
plasminogen, that requires activation by plasminogen activators - tissue PA (tPA) and 
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urokinase-type PA (uPA). tPA-mediated plasminogen activation is primarily involved in 
fibrinolysis in the circulation, whereas uPA activates cell-bound plasminogen by binding 
with a specific cell surface receptor, u-PAR111. Macrophages contribute to fibrinolysis 
through plasmin-dependent and plasmin-independent mechanisms. Besides its 
fibrinolytic function, plasmin can cleave and activate annexin A2 heterotetramer on 
macrophages stimulating a proinflammatory response112. Fibrinolysis is regulated by α2-
antiplasmin and plasminogen activator inhibitors, PAI-1 and PAI-2113, 114. Macrophages 
play important roles in regulating fibrinolysis, contributing to mechanisms that promote 
and inhibit fibrinolysis. Importantly, they produce uPA and tPA, which mediate plasmin-
dependent fibrinolysis, and PAI-1, the predominant inhibitor of fibrinolysis115. TGFβ1 can 
induce the formation of reactive oxygen species (ROS), which can both directly and 
indirectly upregulate the expression of PAI-1116, 117. Ligation of macrophage PSGL-1 
receptor by P-selectin on platelets and endothelial cells can enhance macrophage 
fibrinolytic activity by activating Akt signalling to the mammalian target of rapamycin 
(mTOR) kinase complex, resulting in the upregulation of uPAR118. Macrophages 
express FSAP, which promotes fibrinolysis by activating uPA72.  
 
Macrophages contribute to alternative plasmin-independent fibrinolytic pathways that 
can account for up to a third of total fibrinolysis119, 120. Both soluble and insoluble fibrin 
can bind with Mac-1, and following endocytosis, fibrin is degraded via lysosomal 
cathepsin62, 121. Mac-1 mediated fibrin degradation can account for up to 20% of total 
fibrinolysis122.  Additionally, macrophages release fibrinolytic enzymes that include 
elastase and cathepsins123, 124. Ligation of Mac-1 by fibrin also results in the release of 
elastase, which has potent fibrinolytic properties125. Elastase can cleave plasminogen, 
removing the first 4 kringle domains, to yield mini-plasminogen. Mini-plasminogen is 
readily cleaved by uPA to form mini-plasmin, and compared to plasmin, mini-plasmin is 
more efficient in forming fibrin, and is 10 times less sensitive to inactivation by α2-
antiplasmin126-128. Elastase has further anti-thrombotic characteristics, by cleaving and 
inactivating factors VIIa, VIIIa, IXa, XIIa and XIIIa129, 130. Certain MMPs expressed by 
macrophages possess direct fibrinolytic activity and can further promote fibrinolysis by 
inactivating PAI-1 and α2-antiplasmin
131.  
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1.3.2f Macrophages and MMPs 
MMPs constitute a group of zinc-dependent endopeptidases that degrade most 
components of the extracellular matrix predisposing to plaque instability and rupture. At 
present, there are 23 members of the MMP family. They are synthesized and secreted 
as zymogens that are activated by several proteases including, plasmin, trypsin, 
cathepsins, kallikrein, chymase, thrombin, factor Xa and other MMPs132. Monocytes 
express very little MMPs, but contact with cells and extracellular matrix stimulates PGE2 
production. This acts in an autocrine fashion to activate the monocyte EP4 receptor that 
increases the expression of MMPs133.  
 
Several MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-14) 
are expressed by macrophages in atherosclerotic plaques. The expression of MMPs is 
up-regulated by oxidised lipoproteins, ROS, CD-40L, TNFα and IL-1β through activation 
of the NF-κB pathway134-136. Cytokines exert variable influences on the expression of 
different MMPs. TGF-β and IL-10 down-regulate MMP expression and this may explain 
their atheroprotective effects60. IL-4 down-regulates MMP-1 and MMP-9 production137, 
whilst being a potent stimulus for MMP-12 production138. IFN-γ is a pro-inflammatory 
cytokine that promotes atherosclerosis139, but interestingly, reduces the production of 
MMP-9 and MMP-12137, 140. Tissue inhibitors of matrix MMPs (TIMP) 1-4 are expressed 
in atherosclerotic plaques and regulate extracellular matrix breakdown. Macrophages 
constitutively express TIMPs, and oxidised lipoproteins have been shown to decrease 
TIMP secretion through the autocrine action of IL-8141.  
 
MMPs can promote fibrinolysis with MMP-3 and MMP-7 having direct fibrinolytic activity. 
In addition, MMP-3 specifically inactivates PAI-1 and α2-antiplasmin, further enhancing 
its fibrinolytic effect. On the other hand, MMP-3 and MMP-7 can also inhibit fibrinolysis 
by cleaving uPA to remove the uPAR binding domains, thus preventing uPA from 
activated cell-bound plasminogen. MMP-2 can cleave and inactivate thrombin, thus 
providing an additional mechanism to inhibit thrombus formation131. Certain MMPs 
(MMP-2, MMP-9 and MMP-14) stimulate vascular smooth muscle cell proliferation, and 
therefore confer plaque stability142. Thus, although MMPs are strongly implicated in 
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plaque instability, their diverse functions can both promote and prevent plaque rupture, 
and posses both thrombotic and fibrinolytic characteristics. Which actions predominate 
may depend on the differential expression of MMPs and TIMPs by different cells and 
their levels of activity.  
 
1.3.2g Macrophages and adenosine 
Platelet activation results in the release of α-granules and dense granules that carry 
components critical for thrombus formation. Dense granules contain ADP that 
stimulates further platelet recruitment and activation through platelet ADP receptors, 
P2Y1 and P2Y2143. In addition to endothelial cells and macrophages, platelets serve as 
major sources of extracellular adenosine. Adenosine receptors are present on 
macrophages (A1, A2A, A2B and A3), and through these receptors, adenosine can 
modulate macrophage function. In macrophages, adenosine inhibits the production of 
TNF-α, IL-12, TF and ROS and stimulates the production of IL-1061. Thus adenosine 
provides a negative feedback mechanism in an autocrine and paracrine fashion to limit 
the inflammatory and thrombotic responses in macrophages. 
 
1.3.2h Macrophages and fibrinogen 
Fibrinogen and fibrin are ligands for ICAM-1, Mac-1 (CD11b/CD18, αMβ2) and αVβ2 
(CD11c/CD18) that are expressed on macrophages, lymphocytes and neutrophils, and 
thus acts as adhesion substrates for these cells144-148. In macrophages, both fibrinogen 
and fibrin can stimulate the Mac-1-dependent activation of the NF-κB transcription 
pathway that increases pro-inflammatory cytokines, particularly TNF-α and IL-1β149, 150. 
By binding with fibrin, Mac-1 also provides a mechanism for plasmin-independent 
fibrinolysis122. Fibrinogen can bind TLR-4, expressed on macrophages, that activates 
NF-κB transcription factor pathway, stimulating the expression of pro-inflammatory 
cytokines151. Thus fibrinogen and fibrin, although critical for thrombus formation, can 
additionally induce pro-inflammatory responses in macrophages. 
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1.4 TISSUE FACTOR 
Tissue factor (TF) (thromboplastin/F3/CD142) is a 47kDa transmembrane cell surface 
glycoprotein and is the key trigger for the coagulation cascade152, 153. Besides its critical 
role in coagulation, it plays important roles in angiogenesis, wound healing, intracellular 
signaling, tumour metastasis and inflammation. Its role in angiogenesis, is clearly 
demonstrated by the fact that the TF knockout mouse dies between day 8.5 and 10.5 of 
embryogenesis as a consequence of defects in vascular integrity154. 
 
1.4.1 Structure of TF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The complete gene sequence for human TF gene (12.2kb) was first reported in 1989, 
and is located on chromosome1 at  1p22-23152.   The complete gene sequence for 
murine TF (11.5kb) was reported in 1992 and is located on chromosome 3 at locus 
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52.94cM155. Both the human and murine TF genes are organized into six exons 
separated by five introns152, 155. The human TF gene encodes a 295αα polypeptide 
chain, whilst the murine TF gene encodes a 294αα polypeptide chain. Most of our 
detailed understanding of the structure of TF is centered on human TF156. The human 
TF 295 αα poypeptide chain comprises of a 32αα leader sequence and a  263αα mature 
TF protein (figure 1-6) 152. The mature protein also contains the (1) extracellular domain 
(219 αα); (2) transmembrane domain (23αα); and (3) cytoplasmic domain (21 αα)157-159. 
The extracellular domain comprises of 2 fibronectin type III (FNIII) modules joined by an 
interdomain hinge160. It is classified as a class II cytokine receptor, based on its 
homology to the IFN-γ receptor160. The extracellular domain binds factor VII/VIIa and 
contains 4 potential N-linked glycosylation sites. It contains 4 cysteine residues that 
form 2 disulphide bonds which may be important for factor VII/VIIa binding. The 
cytoplasmic domain contains three serine residues (potential phosphorylation sites), 
and a single cysteine residue that is thioester-linked to palmitate that may contribute to 
anchoring of TF to the membrane161. The cytoplasmic domain also plays important roles 
in intracellular signalling. 
 
 
1.4.2 Distribution of TF 
1.4.2a Tissues 
TF is expressed widely in both vascular and extra-vascular tissues. Under physiological 
conditions, the endothelium expresses very little TF, if at all. Extensive 
immunohistochemical studies of human arteries have failed to detect TF in normal 
vascular endothelium162-164, and others have also noted an absence of endothelial TF in 
diseased atherosclerotic vessels163, 165-167. Similarly, in vivo animal studies have not 
provided consistent evidence for endothelial TF both under physiological and agonist-
induced conditions168-173. However, certain pathological conditions such as invasive 
breast tumours have been reported to induce endothelial TF162. Nevertheless, 
endothelial cells can produce TF in vitro following stimulation with TNFα174, LPS175, IL-
1176, CD40L177, thrombin178, histamine179, oxLDL180 and VEGF181. Within blood 
vessels, TF is constitutively expressed in the vessel wall, confined to adventitial 
43 
 
fibroblasts and medial smooth muscle cells163, 165, 166. This provides a haemostatic 
procoagulant envelope around the vessel wall, ready to activate the coagulation 
cascade when the integrity of the vascular endothelium is disrupted. TF is also 
constitutively expressed in richly vascularized organs such as the placenta, brain, 
kidneys, lungs and heart163.  
 
 
1.4.2b Peripheral blood cells 
Monocytes represent a major source of TF within the circulating blood. Other blood cells 
that have been reported to express TF are neutrophils and eosinophils182, 183. 
Monocytes express TF under basal conditions, and stimulation with TNFα184, LPS185, 
CD40L84, PDGF186, AngII187, oxLDL188 and CRP189 has been shown to upregulate TF 
expression. Perhaps the most widely studied stimulus in this context is LPS, which 
induces monocyte TF expression through both transcriptional and post-transcriptional 
mechanisms190, 191. Disseminated intravascular coagulation (DIC) is a recognized 
complication of severe sepsis, where multiple intravascular thrombotic events result 
from increased monocyte TF expression192. Mature blood eosinophils have been shown 
to express TF under basal conditions, and following stimulation with GM-CSF and PAF, 
TF expression is increased182. On the other hand, neutrophils express very little TF 
under basal conditions183, but may express increased TF following specific stimuli, e.g. 
complement component C5a193. Another important source of blood-borne TF is MPs. 
These small membrane vesicles can express TF, which is derived from the cell 
membranes of their parent cells. Monocytes and platelets represent the major source of 
circulating TF-containing microparticles78. Whether platelets express TF is still a matter 
of controversy. Some investigators have failed to identify TF in platelets, whereas others 
have reported TF in platelet membranes194, 195, in the matrix of α-granules and in the 
open canalicular system183. As platelets do not contain TF mRNA, it is possible that 
platelet TF may be derived from other cells e.g. circulating monocytes and 
neutrophils196. For example, TF-bearing microparticles released from monocytes may 
bind and fuse with activated platelets through a P-selectin/PSGL-1 dependent 
mechanism110. Increased TF-containing microparticles have been demonstrated in 
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acute coronary syndromes (ACS)197, 198, anti-phospholipid syndrome199, sickle cell 
disease200 and sepsis201. Soluble TF is yet another source of TF in the blood. This has 
been identified as an alternatively spliced form of TF (asTF) and is not associated with 
microparticles. This isoform is generated by exon 4 directly splicing onto exon 6 and the 
protein contains most of the extracellular domain of TF but lacks the transmembrane 
domain, rendering it soluble202. asTF is produced in several cell types such as 
monocytes, smooth muscle cells and cancer cells and can be detected in plasma, lungs 
and placenta. As yet, it is still debated whether asTF has any intrinsic procoagulant 
activity203. However, asTF exhibits procoagulant activity when exposed to 
phospholipids, following thrombus initiation, it may be incorporated into the developing 
thrombus, and contribute to thrombus propagation. 
 
1.4.3 “Encrypted” vs. “decrypted” TF 
Many studies have reported a discrepancy between the amount of TF present and the 
amount of procoagulant activity. However, it is becoming increasingly recognized that 
not all cell surface expressed TF is functional. Within a cell, it is TF exposed on the cell 
surface that possesses functional activity. Within intact cells, approximately one third of 
the total cellular TF is inside the cells, whilst two thirds is on the surface, and of this 
fraction, only 50% was found to be active204. This has lead to the concept of inactive 
(―encrypted‖) vs. active (―decrypted‖) forms of TF. Both encrypted and decrypted TF can 
bind FVIIa with similar affinity, but it has been proposed that only the decrypted TF–
FVIIa complex can proteolytically activate the factor X. The molecular differences 
between these two forms and mechanisms responsible for ―activation‖ are not entirely 
clear and remain controversial205. There are many theories to explain how the activity of 
TF may be regulated.  One theory suggests that cell membrane lipid composition plays 
a crucial role in TF decryption, where exposure to clusters of PS activates TF. Whilst PS 
exposure in response to multiple stimuli, such as cell lysis, calcium ionophores and 
apoptotic signals, has been shown to increase TF activity206-209, there is no direct 
experimental evidence of a TF-PS interaction that would translate into a TF 
conformational change to support TF decryption. One may argue that PS may still 
contribute to the initiation of coagulation through direct interaction with FVIIa or FX and 
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as such PS-induced decryption may not involve changes in TF at all. Another theory 
implicates a key role for the Cys186-Cys209 disulfide bond in the TF extracellular domain, 
where shuffling between the reduced and oxidized states of this allosteric bond induces 
a conformational change that supports TF encryption-decryption210, 211. Accordingly, TF 
containing reduced cysteines is ―encrypted‖, whilst intramolecular cystine within the 
bond represents the ―decrypted‖, highly procoagulant form of TF. Disruption of this bond 
by the oxidoreductase activity of protein disulphide isomerase (PDI) has been shown to 
disable coagulation212, 213. Consistent with this observation, oxidation of these cysteine 
residues with resultant formation of the bond has been shown to increase TF activity. 
However, this redox switch model has been recently debated214 as (1) there is no direct 
evidence that the disulfide bond affects TF conformation and subsequent binding and 
activity of FVIIa; (2) the redox agents may have multiple effects on both TF, FVIIa, FX 
and the cellular environment; (3) TF mutants with impaired disulfide bond formation still 
retain procoagulant activity comparable to native TF215; (4) redox modulation can alter 
the phospholipid dynamics at the plasma membrane which may affect coagulation216; 
and (5) in the encrypted TF-VIIa complex, the allosteric cysteines are buried in the 
complex, such that it may not be possible for PDI to modulate their redox status during 
decryption217. Given these inconsistencies, the precise role the cysteine bonds play in 
determining TF activity and function remains controversial.  
 
 
1.4.4 Role of TF in cardiovascular disease 
 
Throughout the process of plaque formation, the inflammatory milieu induces TF 
expression in plaque macrophages, foam cells and smooth muscle cells. TF is found in 
extracellular spaces surrounding cholesterol clefts and within the necrotic core. TF-
containing microparticles are released from monocyte-macrophages and lymphocytes. 
Given that TF is the key stimulus for thrombus formation, all these factors contribute 
significantly to plaque thrombogenicity218. Accordingly, examination of coronary 
atherectomy specimens from patients with ACS have shown increased TF content when 
compared to those with stable coronary disease219. Furthermore, PAR signalling 
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mechanisms provide an important means for TF to mediate cross-talk between 
coagulation and inflammation71. TF may also contribute to plaque development through 
coagulation-independent mechanisms. TF/VIIa complex has been shown to be a 
stimulus for smooth muscle migration in atherosclerotic plaques, and overexpression of 
TFPI has been shown to counter this effect220, 221. TF may promote plaque 
neovascularization154, that may contribute to plaque growth, haemorrhage and 
instability.  
 
Whilst TF within the plaque plays roles in plaque inflammation, development and 
thrombogenicity, it is now recognized that many risk factors for atherosclerosis may 
contribute to increased TF expression. Compared to normoglycaemic individuals, those 
with established diabetes have increased plasma TF activity222, TF-containing MPs223 
and monocyte TF expression223, 224. Accordingly, hyperglycaemia has been shown to 
increase TF expression in monocytes derived from healthy volunteers225, 226. 
Hyperglycaemia results in advanced glycation end products (AGEs) and these can 
interact with receptors for AGE (RAGEs) and induce TF expression in monocytes 
through NFĸB activation227-229. Patients with hypercholesterlolaemia, have increased 
plasma TF activity, that can be inhibited by statin therapy230, 231. Conversely, the 
protective effects of HDL can be demonstrated by the fact that HDL inhibits TF 
expression through activation of the P13K pathway232. Hypertensive patients 
demonstrate increased plasma TF activity, when compared to normotensive patients233. 
Angiontesin II (Ang-II) is a naturally occurring vasoconstrictor produced by the renin-
angiotensin system, and plays an important role in the development of hypertension. 
Ang-II increases TF expression in monocytes and vascular smooth muscle cells-an 
effect mediated by the AT1 receptor234. Consistent with this, angiotensin converting 
enzyme (ACE) inhibitor therapy has been shown to reduce LPS-induced TF expression 
in monocytes235. Smoking has also been shown to increase plasma TF activity, and 
analysis of carotid plaques from smokers were found to have increased TF content 
compared to those from non-smokers236. 
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In patients with ACS, increased TF expression is not limited to the plaque218, 237, 238 but 
also seen in circulating monocytes239. Similarly, plasma TF levels are increased in 
patients with unstable angina compared to those with stable disease. In the context of 
ST-elevation MI, there is a positive correlation between the TIMI score ( a marker of 
risk) and plasma TF levels240. Furthermore, higher plasma levels of TF have been 
shown to correlate with adverse outcomes following non-ST-elevation MI198, 241. In vitro 
stent thrombosis models show that circulating TF plays a critical role in stent 
thrombosis, and in this setting, monocytes appeared to be the main source of TF. 
Monocyte depletion of blood reduced TF staining in thrombi by 83% (p=0.01)242. 
Analysis of TF gene polymorphisms from patients in the FRISC II trial, demonstrated 
that the CG haplotype was associated with a 3-fold increased risk of death, and in these 
subjects, monocytes demonstrated increased TF activity243. 
 
1.4.5 Transcriptional regulation of TF 
 
 
 
 
 
 
 
 
 
 
 
 
The human TF promoter contains binding sites for different transcription factors (figure 
1-7): 2 activated protein-1 (AP-1) binding sites; 1 NFĸB binding site; 3 Egr-1 binding 
sites; 5 Sp1 binding sites244, 245; and 1 nuclear factor for activated T cells (NFAT) 
binding site (overlapping NFĸB binding site)246. The 5‘ of the TF promoter region 
contains a CpG island247, and methylation of this site can prevent TF gene expression in 
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B and T cells152. The transcriptional activity can be broadly classified into constitutive or 
inducible expression. 
 
1.4.5a Constitutive expression 
The Sp1 sites are considered to be responsible for basal constitutive TF expression. 
The three Sp1 binding sites (Sp1III, Sp1IV and Sp1V) are conserved between human, 
mouse, rat and pig. Sp1 is a constitutively expressed transcription factor, and multiple 
Sp1 sites act in synergy, where at least two sites are required for constitutive 
expression244. There are four members of the Sp family of transcription factors: Sp1-4. 
Sp1, Sp3, Sp4 are known to bind to same DNA segment. Sp3 is thought to generally act 
as a repressor of Sp1, and given the levels of Sp1 and Sp3 vary in different cells, the 
cell-specific Sp1:Sp3 ratio may ultimately determine the net basal TF transcription248.  
 
1.4.6b Inducible expression 
There are two regions in the human TF promoter that are implicated in inducible TF 
expression. The first is a distal 56bp enhancer region (-227 to -172), also termed the 
LPS response element, which contains the NFĸB and AP-1 binding sites244, and this 
mediates transcriptional activation following LPS, phorbol ester, TNFα, CD40L and IL-
1 stimulation249-251. This enhancer region is conserved between human and mouse244. 
The second is a more proximal 50bp region (-109 to -59), also termed the serum 
response region, which contains the Egr-1 binding sites, and this mediates 
transcriptional activation in response to serum, shear stress, LPS, phorbol ester, oxLDL,  
and VEGF252-255. LPS, phorbol ester, TNFα, IL-1, CD40L, oxLDL, thrombin and VEGF 
stimulation results in activation of MAPK pathways (p38, ERK and JNK), which leads to 
the activation of transcription factors AP-1 and Egr-1. LPS also activates NFĸB 
signalling through the MyD88-dependent pathway which results in phosphorylation and 
release of the inhibitory component IĸB. LPS, TNFα, histamine and thrombin act 
through activation of all 3 MAPK pathways178, 179, 256, whereas, VEGF only activates p38 
and ERK pathways256. VEGF and TNFα also activate PKC, which can increase TF 
expression either directly through activation of transcription factors or indirectly via 
MAPK activation256. The PI3K pathway is a negative regulator of TF expression257. PI3K 
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phosphorylates PIP2 to form PIP3 which results in the phosphorylation of downstream 
targets, Akt and GSK-3. PIP3 binds Akt allowing it to be phosphorylated by its 
activating kinases, phosphoinositide dependent kinase 1 (PSDK1) and mTORC2. 
Phosphorylation of GSK-3 promotes beta-catenin degradation and inhibits TF protein 
synthesis. In addition to MAPK activation, stimulation with LPS, TNFα, histamine, 
thrombin or VEGF also inhibit the PI3K pathway, thereby providing a cooperative 
mechanism for enhancing TF expression178, 232, 257, 258. 
 
1.4.6 Post-transcriptional regulation of TF 
LPS is the most widely used stimulus to study TF expression, providing a powerful and 
consistent TF induction in different cell types. Although LPS mediates both 
transcriptional and post-transcriptional effects190, it is generally considered that LPS-
induced TF expression is mainly a result of increased mRNA stability191. Following LPS 
stimulation, there is a rapid but transient induction in TF mRNA, with levels peaking at 
2-4 hours, following which the mRNA levels fall rapidly. This time-course provides 
robust post-transcriptional mechanisms where dynamic changes in mRNA stability allow 
rapid increase in steady state mRNA levels followed by a rapid decline. 
 
The TF transcript is considered to be intrinsically unstable152, 259, 260. The 3‘UTR contains 
several AREs that may serve as potential binding sites for ARE-binding proteins, and 
indeed TF mRNA has been assigned to the group III cluster of the ARED database261.  
These AREs are conserved in both human and mouse. TF mRNA levels are ―super-
induced‖ and mRNA stability prolonged by stimulating cells in the presence of 
cycloheximide (a protein synthesis inhibitor), suggesting down-regulation of mRNA 
stability with time by an induced protein260, 262, 263. The TF 3‘UTR has been shown to 
confer instability, and specifically, it has been demonstrated that the destabilizing 
element within the 3‘UTR is confined to the last 150bp sequence260. It is interesting to 
note that this sequence contains a palindromic ARE which comprises 2 overlapping 
nonameric sequences: AUUUAUUUA and UUAUUUAAU, the latter representing a site 
with high predictive binding for ARE-binding proteins264-266. This particular ARE exhibits 
significant conservation throughout different species, further specifying its importance. 
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In a study examining TF mRNA stability in lung epithelial cells, the TF 3‘UTR was 
shown to bind 37 and 87kDa proteins, where the 37kDa protein was postulated to 
confer instability whilst the 87kDa protein was thought to confer stability267. However , to 
date, these proteins have not been characterized. Recently, the roles for microRNAs 
(mir-19 and mir-20) in regulating TF mRNA stability have been reported268.  
 
1.5 POST-TRANSCRIPTIONAL REGULATION 
 
1.5.1 Physiological importance 
Messenger RNA (mRNA) mediates the transfer of genetic information from the cell 
nucleus to ribosomes in the cytoplasm, where it serves as a template for protein 
synthesis. This passage of genetic information from DNA through to the effector protein 
molecule is highly regulated at multiple stages. In addition to transcriptional and 
translational control, there is overwhelming evidence for the role of  mRNA turnover in 
determining net gene expression. Once mRNAs enter the cytoplasm, they are 
translated, stored for later translation, or degraded. The mRNA serves as a template for 
translation, and in general terms, there is positive correlation between the levels of 
mRNA and translated protein. It follows that the levels of steady mRNA present in a cell 
depends on the balance between its rate of formation and rate of decay. The concept of 
mRNA decay gives rise to the concept of mRNA stability and mRNA half-life. When 
mRNA was first discovered in E. Coli over 40 years ago, a key feature of mRNA was its 
unstable nature269. Indeed, mRNA half lives in E. Coli range from 20 seconds to 20 
minutes. In eukaryotes, mRNA turnover is slower with half-lives ranging from 20 
minutes to over 24 hours. Following mRNA transcription and translation, mechanisms 
must be in place to ensure mRNA is degraded after it has performed its function, 
otherwise there would be an exaggerated protein response. This would be particularly 
important following an inflammatory stimulus, to prevent an overwhelming inflammatory 
response thereby limiting chronic inflammation. Following an inflammatory stimulus, 
there is a rapid induction of the immediate response mRNAs, followed by a rapid 
decline in levels. Many such mRNAs are intrinsically unstable. However, the regulation 
of mRNA stability  
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in this setting that provides a means for ―fine tuning‖ gene expression270. Figure 1-8  
shows that by transiently stabilizing an unstable transcript, the steady state levels can 
be increased efficiently, and subsequent destabilization results in rapid decline in levels. 
Regulation of mRNA stability provides a robust mechanism to regulate net gene 
expression, e.g. doubling mRNA half-life can result in100-1000-fold increase in mRNA 
abundance270. What determines mRNA stability and how is this regulated? In the 
broadest terms, mRNA stability is governed by specific sequences in the 3‘UTR of the 
transcripts and their interaction with different RNA-binding proteins, which depending on 
their function, mediate mRNA stabilization or decay. 
 
1.5.2 Adenylate uridylate-rich elements (AREs) 
AREs represent major cis-elements in the 3‘UTR of mRNAs that are essential 
determinants of mRNA stability271-273. Different ARE-binding proteins (ARE-BP) can bind 
these sequences on target mRNAs, and depending on their function, either promote 
stabilization or degradation. A common trait of ARE-containing mRNAs is that they are 
short-lived274 and rapidly disappear once their critical role in gene regulation is 
accomplished - important in processes requiring transient rapid responses such as 
inflammatory and immune responses and cellular proliferation. The first evidence for the 
functional role of AREs was provided by demonstrating rapid mRNA degradation of the 
otherwise stable -globin mRNA, when its 3‘UTR was replaced with the 3‘UTR of GM- 
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CSF275. It is estimated that approximately 7% of human and 5% of murine mRNAs 
contain AREs276. A general feature of functional AREs is that they contain a variable 
number of, often overlapping, AUUUA pentamers, usually in a U-rich context. It has 
been shown that an isolated presence of an AUUUA motif does not guarantee a 
destabilizing function. It has been proposed that the minimal nonameric sequence that 
represents the optimal binding site for a destabilizing protein thereby conferring 
instability is UUAUUUA(U/A)(U/A)264-266. This consensus was based on limited number 
of ARE-containing mRNAs e.g. GM-CSF, TNFα and c-fos etc. However, this sequence 
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does not represent the key minimal core sequence that confers instability, as many 
transcripts with functional AREs do not contain it, e.g. c-myc, c-jun and junB277. 
According to the ARE database (ARED), which contains the complete entries of human 
ARE-containing full-length mRNAs, AREs are classified into 5 groups based on the 
number of continuous AUUUA pentamers: Group I: ≥5; Group II: 4;  Group III: 3; Group 
IV: 2 and group V: 1 AUUUA pentamer261. In ARED, clustering was performed in such a 
way that, for example, Group 1 included not only exact five or more continuous ARE 
pentamers but also those with 10% ambiguity, so that a stretch of 
WUUUAUUUAUUUAUUUAUUUW would also fall in this category. Figure 1-9 gives 
example of transcripts within these groups. 
 
 
1.5.3 mRNA binding proteins 
To date, many mRNA binding proteins that regulate mRNA turnover have been 
identified278. The main ARE-BPs that promote decay of ARE-containing mRNAs include 
tristetraprolin (TTP), butyrate response factor 1 (BRF1), AU-rich binding factor 1 (AUF1) 
and KH-type splicing regulatory protein (KHSRP or KSRP). So far, only Hu protein R 
(HuR) has been shown to play a role in stabilizing ARE-containing mRNAs279. 
  
1.5.4 microRNAs 
Another important mechanism for regulating mRNA turnover is via microRNAs 
(miRNAs). miRNAs are small non-coding RNA molecules that act as post-transcriptional 
repressors by binding to specific target sequences within the 3‘ UTRs of their target 
genes and either block translation or promote mRNA degradation280. miRNAs are 
transcribed by RNA polymerase II as long primary transcripts referred to as ‗pri-
miRNAs‘ that fold into hairpins281. Little is known about the transcriptional regulation of 
pri-miRNAs, except that certain pri-miRNAs are located within introns of host genes, 
including both protein-coding genes and non-coding genes, and might therefore be 
transcriptionally regulated through their host-gene promoters282. In addition, certain 
miRNAs are clustered in polycistronic transcripts, indicating that these miRNAs are 
coordinately regulated during development282. Following transcription, the pri-miRNAs 
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stem-loop is cleaved by Drosha, an RNase III family member, to generate ~70 
nucleotide precursors called pre-miRNAs283. Pre-miRNAs are exported by Exportin-5 (a 
Ran-GTP dependent nucleo/cytoplasmic cargo transporter) to the cytoplasm284, where 
they are further processed by Dicer285, another RNase III enzyme, to generate ~22 
nucleotide single-stranded intermediates that enter effector complexes called miRISC 
(miRNA-containing RNA-induced silencing complex)286. Argonaute2 (AGO2) proteins286, 
287, which directly interact with miRNAs, and glycine-tryptophan protein of 182 kDa 
(GW182) proteins288, 289, which act as downstream effectors in the repression, are key 
factors in the assembly and function of miRISCs. As part of miRISC, miRNAs base-pair 
to target mRNAs and induce their translational repression or degradation290-292. 
Furthermore, there may be functional overlap between ARE- and miRNA-mediated 
pathways. ARE binding proteins may either (1) alter mRNA structure and thereby 
facilitate miRISC binding to mRNA; (2) directly interact with miRISC components; or (3) 
directly interact with the miRNA/mRNA complexes. For example, HuR can bind AREs 
present in c-myc 3′UTR at a site proximal to that recognized by let-7 miRNA, facilitating 
let-7 binding and c-Myc mRNA breakdown293. Similarly, when HuR binds to the ARE in 
the CAT-1 3′-UTR, it can relieve miR-122-mediated translational silencing294. DND1 is 
an ARE-BP that can antagonize the miR-430-mediated translational repression of 
NANOS1 and TDRD7 mRNAs by binding to sequences that overlap with miRNA binding 
sites295. Another example is the cooperation of TTP and miR-16 in TNFα mRNA for 
ARE-mediated mRNA degradation. miR16, contains an UAAAUAUU sequence that is 
complementary to the ARE sequence. TTP does not bind directly with miR-16 but it 
forms a complex with miRISC, which recruits the deadenylase complex and the 
exosome for mRNA degradation296.  
 
1.5.5 mRNA degradation 
There are three major classes of intracellular RNA-degrading enzymes: (1) 
endonucleases that cut RNA internally; (2) 5′ exonucleases that degrade RNA from the 
5′ end; and (3) 3′ exonucleases that degrade RNA from the 3′ end. In mammalian cells, 
mRNAs are formed with two integral stability components — the 5' 7-methylguanosine 
cap and the 3' poly(A) tail. These two structures interact with the cytoplasmic 
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proteins eIF4E and the poly(A)-binding protein (PABP) respectively, to protect the 
transcript from exonucleases and to enhance translation initiation297, 298. To initiate 
decay, either one of these two structures must be compromised or the mRNA must be 
cleaved internally by endonucleases. In mammalian cells, both 3‘ and 5‘ exonucleases 
have been identified, indicating bidirectional degradation, but 3‘-to-5‘ degradation is 
considered to be the major pathway. Deadenylation is the major step in triggering 
mammalian mRNA degradation (figure 1-10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several  deadenylases have been identified in eukaryotes: (1) poly(A) nuclease (PAN)2-
PAN3; (2) carbon catabolite repressor protein 4 (CCR4)-NOT-a complex of 9 proteins of 
which 2 are CCR4 and CCR4-associated factor 1 (CAF1); and (3) poly(A)-specific 
ribonuclease (PARN).  Deadenylation is a biphasic process involving two distinct 
deadenylase complexes- PAN2-PAN3, and CCR4-CAF1. First, the poly(A) tail is slowly 
shortened by the PAN2-PAN3 complex to ~100 nt; then the remaining tail is rapidly 
degraded by the CCR4-CAF1 complex to 8–12 nt299, 300. The first step in deadenylation 
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is unique in that it is reversible — transcripts can be readenylated and return to 
polysomes. Nevertheless, once the mRNA fate is set for destruction, one of two 
irreversible pathways are taken: (1) the 5' cap is removed (decapping) by the Dcp1–
Dcp2 complex. Lsm1-7 is heptameric complex that binds to the 3‘ end of the mRNA and 
induces decapping by the Dcp1-Dcp-2 complex301. Following this, the mRNA is 
degraded in the 5'-to-3' direction by the 5’ exonuclease Xrn1; or (2) the deadenylated 3' 
end is attacked by a large complex of 3'-to-5' exonucleases known as the exosome302, 
with the remaining cap structure being hydrolyzed by the scavenger decapping enzyme, 
DcpS303. PARN is unique in that it has cap-dependent deadenylase activity, i.e. its 
activity is enhanced by the presence of a 5‘ cap, whilst its activity is inhibited by cap-
binding proteins. Decapping and subsequent 5′-to-3′ decay may occur during and/or 
after the second phase of deadenlyation and serves as an additional mechanism 
promoting mRNA degradation, especially where the deadenylation process has been 
inefficient. ARE-BPs have been shown to directly activate deadenylation; decapping; 5‘-
to-3‘ exonucleolytic decay; and 3′-to-5′ exonucleolytic decay304.   
 
1.6 TRISTETRAPROLIN 
TTP (Tis11/Zfp36/NUP475/GOS24) is the most widely studied ARE-BP. It was 
discovered over 20 years ago by screening for genes that could be induced rapidly in 
fibroblasts following stimulation with growth factors and mitogens305-308. Its name 
derives from the fact that it contains three characteristic PPPPG motifs (tris-tetra-
proline).  
 
1.6.1 Structure of TTP 
The human TTP gene is located on chromosome 19 and encodes a 326αα protein and 
the murine gene is on chromosome 7 and encodes a 316αα protein. TTP belongs to the 
TIS11 (tetradeconoyl phorbol acetate (TPA-Induced Sequence 11) family of proteins 
with 2 other members: butyrate response factor 1 (BRF1/Tis11b/ZFP36L1/ERF1) and 
butyrate response factor 2 (BRF2/Tis11d/ZFP36L2/ERF2) which are also ARE-binding 
proteins308. In addition to these well-described members, rodents possess another 
member (ZFP36L3) specifically expressed in the placenta309. The common feature of  
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the Tis11 family members is the presence of two CCCH zinc finger (ZF) motifs 
(CX8CX5CX3H, where X represents various amino acids) each preceded by a conserved 
YKTEL leader sequence307, 310 (figure 1-11). In addition to the ZF motifs, two other 
homologous domains are present in the three proteins. One is a stretch of 14 amino 
acids that contains a functional nuclear export sequence (NES). This sequence is C-
terminal in BRF1 and BRF2, whereas for TTP it is located in the N-terminus of the 
protein. The second homologous motif is located immediately downstream of the ZF 
domains and is composed of the PxLxxSxSFxGxPS sequence, where x represents one 
member of a closely related family of amino acids. The exact function of this domain is 
unknown, but contains (at least for TTP and BRF1) a binding site for 14-3-3 proteins311, 
312. 
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1.6.2 Functions of TTP 
1.6.2a TTP functions as an ARE-binding protein 
Following the discovery of TTP, very little was known about its function until the 
development of the TTP knockout (Ttp-/-) mouse in 1996313. These mice were normal at 
birth, but developed weight loss, severe erosive polyarthritis, myeloid hyperplasia, 
alopecia, conjunctivitis, dermatitis and autoimmunity313. In contrast to TTP knockout 
phenotype, loss of BRF1 induces embryonic lethality with neural tube abnormalities, 
failure of chorioallantoic fusion, and angiogenesis defects314, and loss of BRF2 induces 
lethality within 2 weeks after birth due to diverse haemorrhages, probably caused by 
defective hematopoiesis315. These studies showed that (at least for some of their 
physiological functions) members of the TTP family cannot compensate for each other. 
A link between TTP and TNFα was suggested by the facts that (a) the Ttp-/- phenotype 
could be prevented by treatment of young mice with anti-TNFα antibody313, 316; (b) the 
symmetrical arthritis with erythematous swollen paws, was similar to that observed 
previously in TNFα excess syndromes317, 318; and (c) the direct demonstration of 
increased TNFα expression in the Ttp-/- mice319.  
 
Subsequent studies revealed that TNFα mRNA stability was increased in the Ttp-/- mice, 
and further work revealed that TTP could bind to an ARE in the 3‘UTR of TNFα 
transcript – a process dependent on the two ZFs320. TTP exists in two forms: 
dephosphorylated (active) and phosphorylated (inactive). Initially, it was speculated that 
phosphorylation of TTP would modulate its RNA-binding capacity, however, 
experimental results have been contradictory. Nevertheless, the phosphorylation status 
of TTP, does indeed, regulate its destabilizing function. Although many phosphorylated 
forms exist, phosphorylation of TTP at Ser52 and Ser178 321, 322, leads to binding to 14-3-3 
adaptor protein that reduces its destabilizing activity311, 323. The phosphatase PP2A 
competes with 14-3-3 protein and dephosphorylates TTP, rendering it active324. Thus 
the proportion of TTP in the phosphorylated and dephosphorylated form remains in 
equilibrium (figure 1-12), and the disruption of this equilibrium, through either increased 
or decreased phosphorylation, affects overall TTP activity.  
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1.6.2b TTP regulates mRNA decay 
TTP promotes mRNA degradation by interacting with various components of the 3‘-5‘ 
and 5‘-3‘ mRNA degradation pathways (figure 1-13)325. However, its predominant role in 
mRNA degradation is facilitating deadenylation. PABP protects the mRNA poly(A) tail 
from degradation and is involved in maintaining mRNA circularization through binding to 
eukaryotic translation initiation factor 4G (eIF4G), and may inhibit TTP-directed 
deadenylation326, 327. This TTP–PABP interaction has been further confirmed and 
characterized by yeast two-hybrid analyses and shown to be RNA-independent328. 
Therefore this interaction with TTP may  displace  PABP from the poly(A) tail and 
potentially promote 3′-to-5′ mRNA degradation. 
 
CCR4-NOT deadenylase complex has been implicated in ARE-mediated decay as 
knockdown of CAF1 has been shown to abrogate the deadenylation and decay of the 
ARE-containing α-globin mRNA329, 330. Furthermore, the phosphorylation of TTP has 
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been shown to reduce its ability to promote deadenylation by inhibiting the recruitment 
of CAF1 deadenylase, specifically indicating that the CCR4-NOT complex is responsible 
for TTP-directed deadenylation331. TTP interacts with various components of processing 
bodies (PBs) where mRNA are degraded332. PB-associated proteins that interact with 
TTP include those that are involved in deadenylation (CCR4)333; decapping 
(Dcp1/Dcp2, Edc3 and Xrn1)333, 334 and miRNA-induced silencing (Ago2 and Ago4)296. 
TTP associates with other components of RNA decay enzymes not present in PBs, e.g. 
the  two subunits of the exosome, PM-Scl75 and Rrp4333, 335, 336. In vitro studies 
demonstrate that TTP can also promote deadenylation of ARE-containing mRNAs by 
PARN337. However, given a direct interaction between TTP and PARN has not been 
identified, it is possible that  TTP binding to AREs may modify RNA conformation that 
may favor the recruitment of this deadenylase326, 333, 337. 
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TTP can also associate with cytoplasmic foci called stress granules (SGs). SGs form 
when a cell shuts down  bulk mRNA translation following a cellular stress response. It 
contains untranslated mRNAs which may be stored for later use or transported to PBs  
for degradation. During the stress response, TTP is recruited to SGs in its 
dephosphorylated form, when it is not bound to 14-3-3 protein311. Given that TTP 
interacts with PB components, TTP provides a mechanism for PB and SG interaction338. 
Following phosphorylation of TTP, it is excluded from SGs and consequently PBs are 
released from their tight association with SGs. Interestingly, TTP remains in PBs 
irrespective of its phosphorylation status338. 
 
1.6.2c TTP binds non-ARE segments 
It has been shown that TTP may bind to a subset of mRNAs which contain a CTTGTG 
motif in the 3‘UTR, and deletion of such motif in the 3′-UTR abrogated the TTP 
response in reporter gene experiments339. This observation may be further supported by 
findings from genome wide screening studies, where many TTP-targets have been 
identified but are devoid of AREs340. Alternatively, TTP may associate with other mRNA-
binding proteins that target distinct ARE/non-ARE sequences, or may modulate mRNA 
expression independently of its mRNA-binding activity. A direct interaction between TTP 
and KSRP has been demonstrated, such that interaction with KSRP inhibits its 
recruitment onto the ARE and therefore prevents mRNA degradation via the 
exosome341. Moreover, it has recently been shown that binding of different isoforms of 
AUF1 to TTP via its ZF domain can modulate TTP-binding affinity to its target mRNA 
sequence, thereby promoting TTP-dependent mRNA degradation342.  
 
1.6.2d TTP regulates transcription 
Due to the presence of two putative ZFs, TTP was originally thought to be a 
transcription factor. Although subsequent work focused primarily on its role in mRNA 
turnover, more recent work seems to have sustained this hypothesis. TTP has been 
shown to activate transcription when fused to the GAL4 DNA binding domain343. More 
recently, TTP has been shown to modulate NF-κB signaling.  Following NF-κB 
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activation, TTP can bind to the p65 subunit and impair either its nucleocytoplasmic 
shuttling or its acetylation resulting in attenuation of NF-κB signaling344, 345. 
 
1.6.3 Regulation of TTP activity by p38 MAPK pathway 
AREs provide a means for ARE-binding proteins to bind target mRNA and promote 
degradation or stablisation. However, the function(s) of ARE-binding proteins may be 
modulated, and this allows dynamic regulation of mRNA stability following extracellular 
stimuli. This is primarily mediated by modulating the function of ARE-binding proteins. 
The phosphorylation status of TTP is the key determinant for its function. This is 
mediated by the  p38-MAPK pathway (figure 1-14).  
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The mitogen-activated protein kinases (MAPKs) family comprises three main groups: 
(1) p38 MAPK pathway; (2)  Jun N-terminal kinase (JNK) pathway; and (3) extracellular-
signal-regulated kinase (ERK) pathway, and are involved in most signal transduction 
pathways346. There are 4 members of the p38 MAPK family which are approximately 
60% identical in their amino acid sequence and include: (1) p38α (MAPK14); (2) p38β 
(MAPK11); (3) p38γ [SAPK (stress-activated protein kinase) 3, ERK (extracellular-
signal-regulated kinase) 6 or MAPK12]; and (4) p38δ (SAPK4 or MAPK13), of which the 
p38α being the most widely expressed and studied isoform347-352. The p38 MAPK 
pathway is activated by numerous stimuli including LPS, pro-inflammatory cytokines, 
toxins, UV light and toxins. MAPKs are evolutionarily conserved enzymes, the activation 
of which requires dual phosphorylation of the Thr-X-Tyr motif that is catalysed by 
MAP2K kinases. This phosphorylation on a flexible loop termed the phosphorylation lip 
or activation loop, induces conformational changes that relieve steric blocking and 
stabilize the activation loop, thereby facilitating substrate binding. Of the MAP2K 
kinases, MKK6 can phosphorylate all four p38 isoforms, whereas MKK3 activates p38α, 
p38γ and p38δ, but not p38β352, 353. In addition, p38α can be phosphorylated by MKK4, 
and through autophosphorylation354. The MAP2K kinases are activated by upstream 
kinases, termed MAP3K kinases that include ASK1, DLK1, TAK1, TAO  1 and 2, TPL2, 
MLK3, MEKK  3/4, and ZAK1355. Upstream of the cascade, the regulation of MAP3Ks is 
more complex, involving phosphorylation by STE20 family kinases and binding of small 
GTP-binding proteins of the Rho family as well as ubiquitination-based mechanisms355.  
 
Down-regulation of p38 MAPK activity is critical in regulating signal intensity. 
Termination of kinase activity involves several phosphatases that target the activation 
loop threonine and tyrosine residues, include generic phosphatases that 
dephosphorylate serine/threonine residues (e.g. PP2A and PP2C), or tyrosine residues 
(e.g. STEP (striatal enriched tyrosine phosphatase), HePTP (haemopoietic tyrosine 
phosphatase) and PTP-SL (protein tyrosine phosphatase SL). These lead to 
monophosphorylated forms of p38, which have reduced activity (p38α phosphorylated 
on both Thr180 and Tyr182 is 10–20-fold more active than p38α phosphorylated only on 
Thr180, whereas p38α phosphorylated on Tyr182 alone is inactive)356. p38α activity can 
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also be down-regulated by Wip1, a serine/threonine phosphatase of the PP2C family357. 
The activity of MAPKs is also regulated by the MAPK phosphatase/dual specificity 
phosphatases (DUSP) family358, 359. DUSP 1, 4, 5 and 7 can dephosphorylate p38α and 
p38β, however, the most important negative regulator of p38 activity is considered to be 
DUSP1360, 361.  
 
After activation, MAPKs phosphorylate specific serine and threonine residues of target 
substrates, which include other protein kinases and many transcription factors (figure 1-
13). Of the downstream kinases, MAPKAPK-2/3 are implicated in post-transcriptional 
regulation.  MAPKAPK-2 has been shown to phosphorylate  Ago2 on Ser-387 (a major 
Ago2 phosphorylation site, as mutation of Ser-387 to Ala-387  impairs Ago2 localization 
to PBs)362. The p38 MAPK pathway plays a pivotal role in the regulation of TTP activity. 
Both MAPKAPK-2 and to a lesser extent p38 can phosphorylate and inactivate TTP (the 
primary target for MAPKAPK-2)363. Thus following an inflammatory stimulus, p38 activity 
can stabilize ARE-containing transcripts. However, there is also a parallel induction of 
DUSP1, providing a negative feedback mechanism to limit p38 activation, and this may 
result in subsequent destabilization of these transcripts. This modulation of TTP 
phosphorylation and function results in dynamic changes in mRNA stability allowing 
rapid induction of inflammatory transcripts, followed by a rapid decline, thereby 
preventing a perpetuating inflammatory response. 
 
1.6.4 TTP-regulated genes 
In recent years, many studies have revealed numerous targets for TTP. Microarray 
analysis of RNA from wild-type and TTP-deficient mouse embryonic fibroblast cell lines 
after serum stimulation and treatment with actinomycin D, identified 250 mRNAs that 
were stabilized in the absence of TTP364. Of these genes only 33 containes AREs. In 
one study, a genome-wide approach combining RNA immunoprecipitation and 
microarray analysis identified 137 mRNAs as targets for TTP340. Sequence analysis 
revealed a significant enrichment of AU-rich element motifs, with AUUUA pentamers 
present in 96% and UUAUUUAUU nonamers present in 44% of TTP-associated 
mRNAs. Using a similar strategy, another study identified 393 mRNAs as putative TTP 
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mRNA targets in human dendritic cells339. In this analysis, only 37 of the 393 genes 
identified as putative TTP ligands were present in the ARED database. Whilst these 
studies demonstrate diverse TTP targets, the low percentage of ARE-containing genes 
indicates that TTP is likely to bind to additional non-ARE mRNA sequence elements339, 
as predicted using in vitro binding studies365, as well as with TTP interacting with mRNA 
ligands via a protein bridge, as reported for the iNOS mRNA366. 
 
 
1.7 PARP-14  
1.7.1 Introduction to the PARP superfamily 
Poly(ADP-ribosyl)ation is a unique post-translational modification where negatively 
charged ADP-ribose moieties are adducted onto proteins. This occurs in almost every 
nucleated cell of mammals, plants, lower eukaryotes, but is absent from yeast367. The 
transfer of ADP-ribose to proteins was originally discovered in bacterial toxins such 
as C. diphtheriae toxin, which inactivates eIF-2 by ADP-ribosylation368. Poly(ADP-
ribosyl)ation is of central importance to a wide variety of cellular processes, e.g. DNA 
repair369, 370, transcriptional regulation371, 372, proteasomal protein degradation373, vesicle 
trafficking and apoptosis374. This process is catalyzed by a family of NAD+ ADP-ribosyl 
transferases, the poly(ADP-ribose) polymerases (PARPs).  
 
To date, 17 PARP members have been identified on the basis of homology to PARP1, 
the founding member (figure 1-15)375, 376. Analysis of the catalytic domains of chicken 
PARP1 and murine PARP2 has shown that these proteins have structural homology 
with the active site of bacterial ADP-ribosylating toxin from C. diphtheria377, 378. The -α-
loop--α NAD+ fold which is the most conserved region is considered to be the PARP 
signature379. The PARP domain is located at the C terminus of the protein, except in 
PARP4380. Not all PARP members are enzymatically active and some function as 
mono(ADP-ribosyl) transferases rather than poly(ADP-ribosyl) transferases (PARPs 1, 
2, 4, 5A, 5B catalyze poly(ADP-ribosyl)ation, whereas PARP 3, 10, 14 and 15 catalyze 
mono(ADP-ribosyl)ation). Hence a new nomenclature has been proposed that refers to 
PARPs as ADP-ribosyl transferases (ARTDs)380.  
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The PARP family is divided into four subfamilies based on their domain architectures: 
(1) DNA-dependent PARPs (PARP1,2 and 3); (2) tankyrases (PARP5a and 5b); (3) 
CCCH PARPs (PARP7, 12, 13.1 and 13.2); and (4) macro PARPs (PARP9, 14 and 
15)380. The DNA-dependent PARPs are activated by DNA damage through their DNA-
binding domains381. The tankyrases contain large ankyrin domain repeats that mediate 
protein-protein interaction382. The CCCH PARPs contain ZFs that can bind RNA, as well 
as WWE domains (putative protein-protein interaction motifs that contain two 
tryptophans (W) and a glutamic acid (E)) that can bind PARs. The macroPARPs are 
characterized by 1-3 macrodomains that link to a PARP domain. The macrodomains, 
named through homology to the histone variant macro-H2A, have been shown to bind 
ADP-ribose and facilitate localization of these PARPs to sites of poly- or mono(ADP-
ribosyl)ation383. A summary of all the PARP members is given in table 1-2 380. 
 
1.7.2 Mechanism of ADP-ribosylation 
Of all the PARPs, PARP1 has been most extensively studied in the context of DNA 
damage376. It catalyzes the formation of ADP-ribose from NAD+ (oxidized form of 
nicotinamide) by cleavage of the glycosidic bond between nicotinamide and ribose. 
These ADP-ribose moieties are then covalently attached to glutamate, aspartate and 
lysine residues of target proteins through formation of an ester bond(figure 1-16) 384, 385. 
For poly(ADP-ribosyl)ation, PARP1 catalyzes an elongation and branching reaction 
where additional ADP-ribose units are added through ribosyl-ribosyl linkages eventually 
resulting in the formation of branching polymers. PAR polymers can grow over 200 units 
in size, with branching reactions occurring every 20-50 elongation reactions386, 387. In 
the elongation reaction, the adenine-proximal ribose (A-ribose) units from the PAR 
chain termini are joined in an α(1→2) O-glycosidic bond, whereas in the branching 
reaction, the ADP-ribose junction occurs between two nicotinamide-proximal ribose (N-
ribose) rings. Adduction of ADP-ribose moieties is typically transient as they are rapidly 
degraded predominantly by poly(ADP-ribose) glycohydrolase (PARG), an enzyme with 
both exo- and endoglycosidase activity388, 389. The exoglycosidase activity results in free 
ADP-ribose monomers, whilst the endoglycosidase activity results in the formation of 
free poly(ADP-ribose) polymers. There are three isoforms of PARG in mammalian cells, 
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PARG99, PARG102 and PARG110 (99, 102 and 110kDa respectively). PARG99 and 
PARG110 localize to the cytoplasm, whereas PARG110 predominantly localizes to the 
nucleus390. Free ADP-ribose monomers are potent at glycating proteins and therefore 
can result in protein damage391. This is prevented by ADP-ribose pyrophosphatase that 
converts the ADP-ribose monomers to AMP and ribose 5-phosphate392. Other PAR-
degrading enzymes include ARH (ADP-ribosyl hydrolase) and NUDIX (nucleoside 
diphosphate linked to another moiety X) family of proteins393. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7.3 Cellular functions of ADP ribosylation 
PARs are bulky, negatively charged and flexible, and these features make them suitable 
for post-translational signals capable of mediating rapid cellular responses. ADP 
ribosylation can regulate two broad classes of cellular processes, protein-nucleic acid 
and protein-protein interactions. The highly negative charge resembling nucleic acids 
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can allow PARs to repulse DNA/RNA as well as attracting DNA/RNA binding proteins. 
ADP-ribosylation of target proteins can result in  formation of a molecular scaffold that 
allows recruitment and promotes interactions between cellular proteins. In the context of 
PARP1, following DNA damage, the PAR chains and branches result in a complex 
scaffold which allows recruitment of different components of DNA repair components, 
ATM and e3 SUMO ligase, both of which contain PAR-binding domains394. ATM 
interacts with IĸB kinase-γ, triggering its activation through SUMOlyation and 
phosphorylation. Thus the PAR scaffold helps promote NF-ĸB signaling following DNA 
damage394. PAR-dependent scaffold also affects the formation and function of SGs. 
Following a stress response, the RNA-binding PARPs cooperate with PARP5A and 
macroPARPs to help form SGs. This can be elegantly demonstrated by the fact that 
over-expression of any one these PARPs results in SG formation and that this can be 
inhibited by over-expression of the cytoplasmic PARGs395. Various RNA-binding 
proteins, e.g. Ago2, G3BP1, and TIA-1 have been shown to be modified by ADP-
ribosylation, and such modification may allow recruitment of RNA-binding proteins to 
SGs, thus functioning as a scaffold for protein recruitment395. Other important examples 
of PAR scaffolds in the cell include spindle pole protein recruitment by PARs at the 
mitotic spindle during mitosis396 and Cajal bodies, a nuclear organelle enriched in 
nucleic acid-binding proteins397. PARs play an important role in ubiquitinylation and 
subsequent degradation of target proteins398, 399. This is exemplified by RNF146, a 
PAR-binding E3 ligase, which plays an important role in tankyrase-dependent protein 
degradation pathway. RNF146 can bind PARs through its WWE domain, and 
subsequently ubiquitinylate the protein, targeting it for degradation400. Many other 
ubiquitin ligases contain WWE domains, which permits PAR-dependent 
ubiquitinylation398. 
 
 
1.7.4 Current understanding of PARP-14 
PARP-14 is one of the three macroPARPs and will be the focus of this thesis. Most of 
our current understanding on the biology of PARPs is primarily centered on PARP-1. As 
yet, there is very little published data on the structure and function(s) of PARP-14. Work 
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in our laboratory identified PARP-14 by subtractive hybridisation of cDNA from TNF-
activated versus unstimulated porcine aortic endothelial cells.  
 
1.7.4a Structure of PARP-14 
PARP-14 is a ~205kDa protein, where the linear domain structure is identical in both 
human and mouse401. The published salient features are three macro domains; a WWE 
domain; and a C-terminal PARP domain (catalytically active). In addition, work in our 
department has identified three previously unrecognized KH-like domains and a RRM 
domain in PARP-14. We have shown that PARP-14 associates with RNA via its N-
terminal RRM domain. Typically an RRM is structurally characterized by the packing of 
two helices on a 4-stranded sheet with 1α23α4 topology402, 403. The sheets 
are thought to contact RNA, whilst the helices may interact with associated proteins 
(e.g. RRM2 of PTB binds Raver1). KH domains are common in RNA-binding proteins, 
and indeed may contact RNA directly404. However the three PARP-14 KH-like domains 
do not have a canonical GxxG motif between the andhelices that is considered 
crucial for RNA binding of KH domains (hence we have named them ―KH-like‖)405. They 
may therefore mediate protein-protein interactions rather than bind RNA directly.  
 
1.7.4b Functions of PARP-14 
Research into the biology of PARP family proteins has mainly focused on their nuclear 
functions, especially of PARP-1. In comparison, the biology of the other ―orphan 
PARPs‖ has received much less attention. PARP-14 deficient mice have been 
generated and found to be viable and to support a role for nuclear PARP-14 as a co-
activator of IL-4/Stat-6-mediated transcription in B lymphocytes401, 406, 407. In this context, 
PARP-14 acts as a transcriptional switch by ADP-ribosylating HDAC 2 and 3, which are 
then released from IL-4 responsive promoters to allow access of histone acetyl 
transferases. Recently, several PARP family members, including PARP-14, have been 
shown to be expressed in the cytoplasm and have roles in RNA regulation395, 408. 
However, in unpublished work, we have found that PARP-14 plays a role in regulating 
mRNA stability of the chemokine IP-10 following IFN stimulation.  
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1.8 HYPOTHESIS AND AIMS 
1.8.1 Development of the hypothesis 
The TF 3‘UTR contains several AREs. The final palindromic ARE is highly conserved 
with sequences predicted to have high affinity for RNA-binding proteins. Despite 
significant advances in molecular biology and our understanding of the regulatory 
mechanisms in mRNA turnover, the precise molecular mechanisms involved in ARE-
mediated TF mRNA decay have not been fully elucidated. In particular: (i) although p38 
signaling plays an important role in TF expression, whether it regulates TF mRNA 
stability has not been clearly defined; (ii) although there are AREs in the 3‘UTR that 
appear to be functional, the role of ARE-binding proteins has not been investigated; and 
(iii) whether or not other inducible proteins besides ARE-binding proteins are required is 
not known. 
 
With the above background in TF, TTP and PARP-14, the following hypothesis was 
formulated: 
 
“TTP and PARP-14 regulate TF mRNA stability” 
 
1.8.2 Aims 
This hypothesis would allow us to test whether a key established protein in post-
transcriptional regulation (TTP) and a novel protein in RNA biology (PARP-14) would 
regulate TF, an important protein in thrombosis and cardiovascular biology. To 
strategically dissect this study, the following aims were set: 
 
1. To establish the effect of p38 inhibition on TF expression and mRNA stability 
Given that p38 activity is an important regulator of TTP activity and function, the first 
stage was to establish the effect of p38 inhibition on TF mRNA and protein expression 
and its effect on TF mRNA decay. The precise role for TTP in regulating TF mRNA and 
protein expression was investigated and, specifically, its effect on TF mRNA stability. 
The interaction of TTP with TF 3‘UTR and specific interactions with AREs were 
determined. [CHAPTER 3] 
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2. To determine the role for PARP-14 in regulating TF expression and mRNA 
stability 
Preliminary work in our department has identified the role for PARP-14 in regulating 
mRNA stability of the chemokine IP-10, and that TF expression was increased in LPS-
stimulated Parp14-/- murine macrophages. Thus, the role of PARP-14 in regulating TF 
mRNA and protein expression was investigated and, specifically, its effect on TF mRNA 
stability. Furthermore, the effect of PARP-14 deficiency on TF expression and 
thrombosis was examined in vivo. The interaction of PARP-14 with TF 3‘UTR and 
specific interactions with AREs were determined. [CHAPTER 4] 
 
3. To determine the TTP-PARP-14 interaction and its relevance to the  regulation 
of TF mRNA stability 
Having established the roles for TTP and PARP-14 in the post-transcriptional regulation 
of TF, the precise molecular mechanisms underlying their interaction and the 
interdependency of both proteins was examined. Furthermore, the role of PARP-14 
enzymatic activity, i.e. ADP ribosylation, on the regulation of TF mRNA stability was 
tested both in the absence and presence of p38 inhibition. Finally, the roles for PARP-
14, ADP ribosylation, and the TTP-PARP-14 complex was tested for TNFα, a well-
established TTP-regulated transcript. [CHAPTER 4] 
 
4. To establish the effect of glucocorticoids on TF expression 
Glucocorticoids (GCs) are negative regulators of p38 activity and have been used as 
experimental tools to study p38-dependent post-transcriptional regulatory mechanisms, 
particularly in the setting of TTP-regulated transcripts. Having established a role for p38 
activity in the post-transcriptional regulation of TF, whether these results would be 
applicable to GCs was investigated. The candidate GC used for this analysis was 
dexamethasone (Dex). [CHAPTER 5] 
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1.8.3 Structure of thesis 
In the following chapters, a detailed section on generic methods and experimental 
protocols is presented. This is followed by three results chapters, each comprising of a 
small introduction, abbreviated methods specific to the chapter; experimental findings 
and results; and a discussion focusing specifically on the results. This is followed by a 
general discussion chapter where all the findings from the three results chapters are 
collated and discussed in the context of the wider literature. This is followed by a 
conclusions chapter which closes the thesis. 
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Chapter 2 
 
 
General methods & protocols 
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2.1 PRIMARY HUMAN MONOCYTE ISOLATION AND CULTURE 
2.1.1 Reagents 
Sodium citrate (Sigma-Aldrich, Gillingham, UK); PBS (Invitrogen, Paisley, UK); 
Histopaque-1077 (Sigma-Aldrich, Gillingham, UK); 0.5M EDTA (Invitrogen, Paisley, 
UK); Bovine Serum Albumin (BSA, Invitrogen, Paisley, UK); Iscove's Modified 
Dulbecco's Media (IMDM, Invitrogen, Paisley, UK); Fetal Calf Serum (FCS, Innov-
Research, Missouri, USA); CD14 MicroBeads (Miltenyi Biotec, Surrey, UK) 
 
2.1.2 Isolation of PBMCs 
Monocytes were isolated from citrated venous blood derived from healthy donors (with 
local ethical approval) with citrate:blood ratio of 1:9. 50mL of venous blood was 
venesected from a large vein in the antecubital fossa and immediately citrated. The 
citrated blood was centrifuged at 400g for 20 minutes at room temperature, and the 
platelet rich plasma (PRP) supernatant was removed from the cell fraction. The cell 
fraction (~30 mL was divided into 2 portions and each made up to 35mL using PBS. 
Peripheral blood mononuclear cells were (PBMCs), were isolated from the cell fraction 
by Ficoll–Paque density-gradient centrifugation using Histopaque-1077. 2 x 15mL  
Histopaque-1077 was placed into 2 x 50mL tubes respectively, and the 35mL PBS-
blood  mixture was carefully pipetted over the Histopaque-1077 into each tube ensuring 
that the interface between the two layers was not disrupted. The tubes were centrifuged 
at 800g for 20 minutes at room temperature. The buffy coat and surrounding fluid was 
carefully pipetted from each tube without disrupting the red cell fraction and centrifuged 
at 800g for 10 minutes at room temperature to pellet the PBMCs. The PBMCs were 
pooled from both tubes, and washed with PBS twice by centrifuging at 300g for 10 
minutes at room temperature. 
 
2.1.3 Labeling with magnetic CD14 Microbeads 
The PBMCs were resuspended in 10mL MACS buffer (0.5% BSA-PBS, 2mM EDTA) 
and counted using light microscopy. The suspension was centrifuged at 300g for 10 
minutes at 4°C, the supernatant completely removed and the PBMC pellet resuspended 
in 80µL MACS buffer per 107 cells. 20µl CD14 Microbeads per 107 cells were added to 
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the cell suspension and thoroughly mixed followed by an incubation at 4°C for 15 
minutes. The cells were resuspended in ice cold 10mL MACS buffer, centrifuged at 
300g for 10 minutes at 4°C and the supernatant was completely aspirated. The cells 
were resuspended in 500µL ice cold MACS buffer.  
 
2.1.4 Magnetic separation using MS column 
Magnetic separation was performed using a MACS Separator (Miltenyi Biotec, Surrey, 
UK) according to the manufacturer's instructions. Briefly, a magnetic MS column 
(Miltenyi Biotec, Surrey, UK)  was placed in a magnetic field and primed with 500µl 
MACS buffer. The cell suspension was applied to the column. Following this, the 
column was washed with 0.5mL aliquots of MACS buffer 3 times. The unlabelled 
effluent cells were collected at the bottom of the column and discarded. Next, the 
magnetic column was removed from the magnetic field, placed into a 15mL collection 
tube. 1mL PBS was placed into the column and using the supplied plunger, the labeled 
cells were immediately flushed out of the column. The cells were immediately added to 
9mL IMDM [10% FCS] and counted. Depending on the experimental protocol, the 
concentration of the cells was adjusted with the culture medium and plated out into 
tissue culture plates. The plates were placed in a 37°C incubator with 5% 
CO2 atmosphere overnight to allow the monocytes to adhere, ready for experiments the 
following day. 
 
 
2.2 BONE-MARROW DERIVED MACROPHGE ISOLATION AND CULTURE 
2.2.1 Reagents 
Dulbecco's minimal essential medium (DMEM, Invitrogen, Paisley, UK); FCS (Innov-
Research, Missouri, USA); PBS (Invitrogen, Paisley, UK); L-Glutamine (Sigma-Aldrich, 
Gillingham, UK); Penicillin (Sigma-Aldrich, Gillingham, UK); Streptomycin (Sigma-
Aldrich, Gillingham, UK); L929 Conditioned medium 
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2.2.2 Mice 
Ttp−/− mice were generated as previously described313. Ttp−/− mice were of mixed 129 
and C57BL/6 background and maintained as heterozygous breeding pairs. The Parp14-
/- mice were generated as previously described406, and had a C57BL/6 background, and 
maintained as heterozygous breeding pairs. All experiments were conducted using age- 
and sex-matched wild-type (WT) progeny as littermate controls. 
 
2.2.3 Bone marrow culturing medium 
For culturing bone marrow cells, the ―bone marrow culture medium‖ referred to in this 
protocol comprises of DMEM, 10% FCS, 2 mM L-Glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin and 10% L929-conditioned medium, a source of 
granulocyte/macrophage colony-stimulating factor. 
 
2.2.4 Harvesting bones from mice 
Femurs  and tibia were obtained from 15-20 week old C57BL/6 mice. The mice were 
sacrificed using cervical dislocation. After euthanasia, the mice were sprayed with 70% 
ethanol and the femurs were dissected using sterile scissors, cutting through the knee 
joints as well as through the pelvic bone close to the hip joint. The tibia were dissected 
in a similar fashion cutting through the knee joints as well as through the calcaneum. 
Muscles connected to the bones were removed using sterile gauze and the epiphyses 
were removed using sterile scissors and forceps. The bones were placed into a 
polypropylene tube containing sterile PBS on ice. The bones were placed in 70% 
ethanol for 1 minute, and then immersed into bone marrow culture medium.  
 
2.2.5 Preparing bone marrow cell suspension 
The bones were then flushed with a syringe filled with bone marrow culture medium to 
extrude bone marrow into 15 mL sterile tubes. The tubes were centrifuged at 300g for 
10 minutes at room temperature to pellet the bone marrow. 10ml of bone culture 
medium was added and a 5 ml pipette was used to gently homogenize the bone marrow 
cells. This suspension was applied to a 70µM cell strainer to obtain a uniform single-cell 
bone marrow cell suspension. 
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2.2.6 Culturing bone marrow cells 
1mL of bone marrow cell suspension was added to 19mL bone marrow culture medium  
into a T75 culture flask and placed in a 37°C incubator in a 5% CO2 atmosphere. In this 
way, 10 x T75 flasks were obtained per mouse, and the cells were cultured for 6 days . 
On day 6, the overlying culture medium was removed to ensure removal of dead cells 
and debris. 20mL PBS was added, the adherent macrophages were harvested by 
scraping. The cells were counted and the cell suspension was centrifuged at 300g for 
10 minutes. The cells were resuspended in the bone marrow culture medium at a 
density dependent on the experimental protocol, and plated in culture dishes/flasks for 
experiments to be conducted on day 7. 
 
2.3 RNA EXTRACTION 
2.3.1 Reagents required 
-mercaptoethanol (Sigma-Aldrich, Gillingham, UK); Molecular grade ethanol (Sigma-
Aldrich, Gillingham, UK); RLT lysis buffer (Qiagen, Crawley, UK); RW1 buffer (Qiagen, 
Crawley, UK); R-PE buffer (Qiagen, Crawley, UK); RNase-free DNase (Qiagen, 
Crawley, UK); Molecular grade water (Invitrogen, Paisley, UK); RNase-free DNase 1 
(Qiagen, Crawley, UK): Proteinase K (Qiagen, Crawley, UK); Trizol reagent (Sigma-
Aldrich, Gillingham, UK); Chloroform (Sigma-Aldrich, Gillingham, UK); Isopropanolol 
Sigma-Aldrich, Gillingham, UK); 20 µg/µl Ultra-pure Glycogen (Invitrogen, Paisley, UK). 
 
2.3.2 Extraction of RNA from cells 
Following the experimental treatment of cells, the culture supernatants were removed 
and cells washed in 1mL aliquots of ice cold PBS in the tissue culture wells to remove 
overlying medium, ensuring the adhering cells were not disrupted. 350µL RLT lysis 
buffer, freshly supplemented with 1% -mercaptoethanol, was added to the cells. The 
RLT buffer was gently pipetted up and down ensuring dissociation of cells from the 
tissue culture plate. The RLT lysates were transferred to 1.5mL RNase-free eppendorfs. 
RNA was subsequently isolated using RNeasy Mini kits (Qiagen, Crawley, UK) 
according to manufacturer‘s instructions, incorporating an on-column DNase digestion 
using RNase-free DNase. Briefly,  the samples were initially homogenized by passing 
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the lysate at least 5 times through a blunt 20-gauge needle (0.9 mm diameter) fitted to 
an RNase-free syringe, following which the lysates were added to an equal volume of 
70% ethanol (~350µL). The samples were mixed well and applied to the RNeasy spin 
columns (Qiagen, Crawley, UK). The columns were spun on a table-top centrifuge at 
13000g for 30 seconds. The flow-through was discarded. 350 μl of RW1 buffer was 
added to the RNeasy spin column and centrifuged at 13000g for 15 seconds, again 
discarding the flow-through. 80µl of RNase-free DNase 1 was added to the spin column 
membrane and allowed to incubate for 15 minutes at room temperature, followed by a 
repeat wash with 350 μl of RW1 buffer and centrifugation at 13000g for 15 seconds, 
again discarding the flow-through. 500 μl of RPE-buffer was then added to the RNeasy 
spin column and centrifuged at 13000g for 30 seconds, again discarding the flow-
through. A second wash step with 500 μl of RPE-buffer was performed followed by 
centrifugation at 13000g for 2 minutes, again discarding the flow-through. The RNeasy 
spin column was placed in a new 2 ml collection tube and centrifuged at 13000g for 1 
minute to remove any residual wash buffer. The RNeasy spin column was now placed 
in a new 1.5 ml RNase-free eppendorf, and  50 μl RNase-free water was added directly 
to the spin column membrane, ensuring the pipette tip did not touch the membrane, and 
centrifuged at 13000g for 1 minute to elute the RNA. The concentration and quality of 
the RNA were determined using Nanodrop 1000 (Thermo Scientific, Loughborough, 
UK), ensuring a 260/280 ratio >1.8 and a 260/230 ratio >1.9. 
 
2.3.3 Extraction of RNA from tissues 
All tissue samples were immediately snap-frozen and stored at -80°C until RNA 
extraction. For the extraction of RNA from tissues, 30mg tissue samples were initially 
homogenized in 300µL RLT buffer (supplemented with 1% -mercaptoethanol) using 
the TissueLyser and 5mm stainless steel beads (Qiagen, Crawley, UK) according to the 
manufacturer‘s instructions. Briefly, the tissue samples with the RLT buffer and stainless 
steel beads were placed into 2mL RNase-free eppendorfs and placed into the 
TissueLyser adapter set (2 x 24). The TissueLyser was operated for 2 min at 20Hz. The 
adapter set was disassembled and the tubes rearranged so that the tubes nearest to 
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the TissueLyser were now outermost, and the adapter set re-assembled.  The 
TissueLyser was operated for another 2 min at 20Hz. 
 
RNA was subsequently isolated using the RNeasy Fibrous Tissue Mini kit (Qiagen, 
Crawley, UK) according to manufacturer‘s instructions, again incorporating an on-
column DNase digestion using RNase-free DNase. Briefly, the homogenate was 
carefully pipetted into new 2mL eppendorfs, discarding the remaining tube with the 
stainless steel bead. 590 μl RNase-free water was added to the lysate. 10 μl proteinase 
K solution was then added, thoroughly mixed and incubated at 55°C for 10 minutes. The 
lysates were centrifuged at 10,000g for 3 minutes at room temperature. The 
supernatant (~900µL) was carefully removed and placed into a new microcentrifuge 
tube, avoiding the transfer of the pellet. Next 450µL 100% ethanol was added to the 
cleared lysate, making the total volume of the lysate ~1.4mL. 700µL of the lysate was 
applied to the RNeasy spin column, and centrifuged at 13000g for 30 seconds. The 
flow-through was discarded and the remainder of the lysate was applied to the columns 
followed by a repeat spin, again discarding the flow-through. 350 μl of RW1 buffer was 
added to the RNeasy spin column and centrifuged at 13000g for 15 seconds, discarding 
the flow-through. The subsequent steps were as for RNA extraction from cells (see 
above). 
 
2.3.4 RNA extraction using Trizol reagent 
This method of RNA extraction was used following the RNP immunoprecipitation assays 
(see below), where the RNA was extracted from supernatants. 300µL of supernatant 
was added to 500µL of Trizol reagent in a 1.5mL eppendorf. This mixture was left at 
room temperature for 5 minutes and then briefly vortexed. Next, 100µL chloroform was 
added and briefly vortexed and allowed to stand at room temperature for 15 minutes. 
Following this, the mixture was centrifuged at 17,000g for 30 minutes at 4°C. The 
aqueous phase (top layer) was carefully removed and transferred to a fresh 1.5mL 
eppendorf. Next, an equal volume (~300µL) of isopropanolol was added. This was 
briefly vortexed and left overnight at -20°C. The addition of 1µL glycogen was optional, 
facilitating the visibility of the RNA pellet. The following day, the tube was centrifuged at 
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17000g for 30 minutes at 4°C to pellet the RNA. The supernatant was completely 
removed, and the RNA pellet was resuspended in 500µL 70% ethanol, and centrifuged 
at 17000g for 15 minutes at 4°C. The supernatant was completely removed, and the 
RNA pellet air-dried for 15-20 minutes. The RNA pellet was resuspended in 15-25µL 
water. The concentration and quality of the RNA were determined using Nanodrop 1000 
(Thermo Scientific, Loughborough, UK), ensuring a 260/280 ratio >1.8 and a 260/230 
ratio >1.9. 
 
 
2.4 FIRST STRAND cDNA SYNTHESIS 
2.4.1 Reagents required 
10 mM dNTP Mix (Roche Diagnostics, Sussex, UK); 100pM Oligo dT (Eurofins, 
Ebersberg, Germany); Molecular grade water (Invitrogen, Paisley, UK); 5X First-Strand 
Buffer  (Invitrogen, Paisley, UK); 0.1 M DTT (Invitrogen, Paisley, UK); SuperScript™ III 
Reverse Transcriptase (200 units/µl) (Invitrogen, Paisley, UK) 
 
2.4.2 Protocol 
1µg of total RNA was used for first strand cDNA synthesis using  SuperScript III reverse 
transcriptase enzyme according to the manufacturer‘s reverse transcriptase protocol. To 
minimize pipetting errors for multiple reactions, 2 master mixes were made. Master mix 
A comprised 1µL dNTP and 1µL oligo dT per reaction. Master mix B comprised 4µL first 
strand buffer, 1µL DTT, 1µL water and 1µL SuperScript III reverse transcriptase (added 
just before use). 11µL RNA was added to 2µL of mastermix A, and reaction mixture 
vortexed and briefly centrifuged. The reaction mixture was heated to 65°C for 5 min 
following which the reaction was immediately placed on ice for 1 minute. Next, 7µL of 
master mix B was added, reaction mixture vortexed and briefly centrifuged and 
incubated at 50°C for 60 minutes, followed by inactivation at 70°C for 15 minutes using 
a thermal cycler (Applied Biosystems, Warrington, UK). The cDNA was stored at -20°C 
until use. 
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2.5 QUANTITATIVE REVERSE-TRANSCRIPTASE PCR (qRT-PCR) 
2.5.1 Reagents 
Molecular grade water (Invitrogen, Paisley, UK); 10pM forward and reverse primers 
(Eurofins, Ebersberg, Germany); iQ SYBR green PCR Fastmix (VWR, Lutterworth, UK) 
 
2.5.2 Protocol  
Comparative qRT-PCR was performed using 5 µL template cDNA (1:20 dilution with 
molecular grade water), 0.5 µL forward primer, 0.5 µL reverse primer, 6.5µL molecular 
water and 12.5 µL SYBR green PCR Fastmix, with a total volume of 25µL per reaction. 
Reactions were performed in triplicate in Hard-Shell ® 96-well PCR plates (Biorad-
Laboratories, Hercules, CA) using Biorad CFX96 Thermal Cycler (Biorad-Laboratories, 
Hercules, CA). The gene specific primer sequences, their amplicon lengths and reaction 
conditions are listed in table 2-1 . Primers were designed and optimized such that  they 
all required the same reaction conditions. A typical reaction protocol incorporating a 
melt curve analysis is shown in figure 2-1.  All primers were validated with standard 
curves for serial cDNA dilutions (10-fold dilutions), negative control (water only 
template) and non-reverse transcription controls (to exclude genomic DNA 
contamination). The slopes of the standard curves were calculated using BioRad CFX 
Manager Software Version 1.6 (Biorad-Laboratories, Hercules, CA), and slopes 
between -3.1 to -3.6 giving reaction efficiencies between 90 to 110% were considered 
acceptable. As part of the optimization protocol, the products of the reaction were 
separated in a 1% agarose gel containing ethidium bromide and visualized under UV 
light to confirm the amplicon length respectively. Figure 2-1 illustrates the validation of 
the primers using the murine TF primers as an example, with construction of a standard 
curve for murine TF with appropriate controls, and the RT-PCR products as  run on a 
1% ethidium bromide gel. 
 
2.5.3 Data analysis 
Data was analysed using BioRad CFX Manager Software Version 1.6 (Biorad-
Laboratories, Hercules, CA). All reactions were performed in triplicate, and the mean 
threshold cycle values (CT values) were calculated per sample for the test gene and  
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housekeeping control gene. Data was validated using 2 housekeeping controls, GAPDH 
and HPRT. Relative gene expression was calculated by comparing the number of 
thermal cycles that were necessary to generate threshold amounts of product using the 
ΔΔCt method409. 
 
2.6 WESTERN BLOTTING ANALYSIS 
2.6.1 Reagents 
Cell Lytic M Cell lysis buffer (Sigma-Aldrich, Gillingham, UK); Cell Lytic MT Cell lysis 
buffer (Sigma-Aldrich, Gillingham, UK); Protease inhibitor cocktail (Sigma-Aldrich, 
Gillingham, UK); NuPAGE® LDS Sample Buffer (4x) (Invitrogen, Paisley, UK); PBS 
(Invitrogen, Paisley, UK); 20x running buffer MES /Tris-Acetate (Invitrogen, Paisley, 
UK); 20x transfer buffer (Invitrogen, Paisley, UK); Full range molecular weight rainbow 
marker (GE Healthcare, Amersham, UK); Methanol (Sigma-Aldrich, Gillingham, UK); 
Tween-20 (Sigma-Aldrich, Gillingham, UK); ECL (Plus)™ Western Blotting Detection 
Reagents (GE Healthcare, Amersham, UK); 5% dried milk powder (Sainsburys, London, 
UK); 20% SDS solution (Sigma-Aldrich, Gillingham, UK); Molecular grade water 
(Invitrogen, Paisley, UK); 0.5M TRIS-HCl (pH 6.8) (Ambion); -mercaptoethanol 
(Sigma-Aldrich, Gillingham, UK); Stripping buffer (Invitrogen, Paisley, UK) 
 
2.6.2 Buffers 
 Running buffer (1L): 50mL 20x running buffer + 950mL water 
 Transfer buffer (1L): 50mL 20x transfer buffer + 900mL water + 100mL methanol 
 PBS-T (1L): 999mL water + 1mL Tween-20 
 Blocking buffer (100mL): 100mL PBS (0.1% Tween) + 5g 5% dried milk powder 
 Stripping buffer (100mL): 77.5mL water + 10mL 20% SDS + 12.5mL 0.5M TRIS 
(pH=6.8) +800µL -mercaptoethanol 
 
2.6.3 Preparation of cell lysates 
Following the experimental protocol and treatment of cells, the supernatant culture 
medium was removed and cells were gently washed twice in ice-cold PBS to remove 
culture medium, ensuring the adherent cells were not disrupted. The cells were lysed 
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with 100µL of Cell Lytic M lysis buffer with 1µL of protease inhibitor cocktail using a 
plastic policeman. The lysates were carefully transferred to 1.5mL eppendorfs, and left 
on ice for 10 minutes. The lysates were centrifuged at 17,000g for 20 minutes at 4ºC to 
pellet cell debris. The supernatant was carefully removed and stored at -80ºC until 
analysis.  
 
2.6.4 Preparation of tissue lysates 
All tissue samples were immediately snap-frozen and stored at -80°C until preparation 
of tissue lysates. 50-100mg of tissue were added to 300µL of Cell Lytic MT lysis buffer 
and 3 µL protease inhibitor cocktail into a 2mL eppendorf. The sample was 
homogenized by adding a stainless steel bead (Qiagen, Crawley, UK) and operating a 
TissueLyser (Qiagen, Crawley, UK) for 2 min at 20Hz. The tubes were centrifuged at 
17,000g for 20 minutes at 4ºC to pellet cell debris with the stainless steel bead. The 
supernatant was carefully removed and stored at -80ºC until analysis. 
 
2.6.5 Preparation of samples 
The concentrations of protein lysates were determined using a Jenway Genova Life 
Science Analyser (Bibby Scientific Limited, Stone, UK)  with direct uv mode (260:280nm 
ratio). 20µg of protein was used per sample, and each sample was added to 4x SDS 
loading buffer (supplemented with 2.5% -mercaptoethanol) at a ratio of Vsample:Vloading 
buffer = 3:1. The samples were boiled at 100°C for 4 minutes and placed on ice.  
 
2.6.6 Gel Electrophoresis 
A Novex XCell II Mini Gel System (Invitrogen, Paisley, UK) was used. The proteins were 
separated by gel electrophoresis in pre-cast polyacrylamide gels (Invitrogen, Paisley, 
UK). Depending on the size of the proteins, the precast gels were chosen appropriately. 
For separation of higher molecular weight proteins (>150kDa), NuPAGE® Novex 3-8% 
Tris-Acetate Gels were used, otherwise NuPAGE® Novex® 4–12% Bis-Tris Gels were 
used. The running buffer was chosen in accordance with the gel system used (MES 
running buffer for 4–12% Bis-Tris Gels and Tris-Acetate running buffer for 3-8% Tris-
Acetate Gels. The pre-cast gels were rinsed with water, positioned into the Mini-Cell gel 
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tanks such that the notched ―well‖ side of the cassette faced inwards toward the buffer 
core. The gels were seated on the bottom of the Mini-Cell and locked into place with the 
gel tension Wedge. If one gel was being used, the plastic buffer dam replaced the 
second gel cassette. Ensuring a tight seal, the upper buffer chamber (inner side) was 
filled with the appropriate 1x running buffer to a level exceeding that of the level of the 
wells. Similarly, the lower buffer chamber (outer side) was filled with 600 ml of the 
appropriate 1x running buffer. 5-10µL of the molecular weight marker was added to the 
first well (5µL for 15 lane gels systems and 10µL for 10 lane gel systems). Protein 
samples were added carefully to the remaining wells. The electrophoresis conditions 
were dependent on the gel system used. For NuPAGE® Novex 4-12%Bis-Tris Gels with 
MES Running Buffer, the voltage was set to 150-200V, which resulted in an 
approximate running time of 45-60 minutes. For NuPAGE® Novex 3-8% Tris-Acetate 
Gels, the voltage was set to 120-150V, which resulted in an approximate running time of 
60-90 minutes. Following the electrophoresis, the cassettes were removed from the 
Mini-Cell gel tank. 
 
2.6.7 Preparation for blotting gels 
The polyvinylidene difluoride membranes (Millipore, Dundee, UK) were cut to the same 
size as the blotting pads and immersed in methanol. The methanol was discarded and 
the membrane was immersed in 1x transfer buffer. 2 similarly sized filter papers were 
cut and added to the transfer buffer. The three bonded sides of the cassettes were 
separated by inserting the gel knife into the gap between the cassette‘s two plates.  The 
gel was carefully removed and placed in transfer buffer (same container as the 
membrane and filter papers). In a separate container 6-8 blotting pads were immersed 
in 1x transfer buffer.  
 
2.6.8 The blotting protocol 
3 soaked blotting pads were placed on the cathode (-) core of the blot module. A pre-
soaked filter paper was placed on top of the pads ensuring to remove any air bubbles. 
The gel was carefully placed over the filter paper in the correct orientation. The 
membrane was positioned over the gel followed by the second pre-soaked filter paper 
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ensuring to remove any trapped air bubbles. 3 soaked blotting pads were placed over 
the second filter paper. The anode (+) core was placed on top of the pads. The blot 
module held firmly together was positioned into the into the guide rails on the lower 
buffer chamber of the Mini-Cell gel tank. The gel tension Wedge was inserted into the 
lower buffer chamber and locked into position. The blot module was filled with 1x 
transfer buffer, until the gel/membrane assembly was fully immersed. The outer buffer 
chamber was filled with 600-700mL water. The transfer was performed at 30V constant 
for 90 minutes. 
 
2.6.9 Blocking the membrane 
Following the transfer process, the membrane was carefully removed and allowed to air 
dry for 15 minutes. The membrane was immersed in 20mL blocking buffer for 1 hour at 
room temperature, or overnight at 4°C.  
 
2.6.10 Primary and secondary antibodies 
After blocking the membrane, the primary antibody was added in blocking buffer at the 
recommended concentration and incubated according to the recommended instructions. 
Following this, the membrane was washed with 20mL PBS-T for 10 minutes (3 times). 
HRP-conjugated secondary antibodies were then added to the membranes in blocking 
buffer at recommended concentrations and incubated for 1 hour at room temperature. 
The membranes were washed with 20mL PBS-T for 10 minutes (3 times). For list of 
primary and secondary antibodies used please see table 2-2. 
 
2.6.11 Detection using chemiluminescence 
The Amersham ECL detection reagent was prepared by mixing an equal volume of 
detection solution 1 with detection solution 2 allowing sufficient total volume to cover the 
membranes (the recommended final volume required is ~0.125 ml/cm2 membrane). The 
excess PBS-T from the washed membrane was drained, and placed on a transparency 
film with the protein side facing up. The mixed detection reagent was pipetted onto the 
membrane and incubated for 1 minute at room temperature. The excess detection 
reagent was removed by blotting using filter paper. Another transparency was 
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positioned over the membrane and transferred to an X-ray film cassette. Film exposure 
was conducted in a dark room. A sheet of autoradiography film (Sigma-Aldrich, 
Gillingham, UK) was placed on top of the membrane. The cassette was closed for the 
duration of exposure and the film was developed using X-O-Mat processor (Kodak, 
Cambridge, UK). 
 
2.6.12 Stripping and reprobing a membrane 
To reprobe the membrane, the membrane was immersed in 100mL striping buffer at 
50°C with gentle agitation. The membrane was washed 2 times with PBS-T for 10 
minutes prior to proceeding to blocking and application of primary and secondary 
antibodies as above. 
 
2.6.13 Protein quantification 
Protein quantification was performed using densitometry using ImageJ software 
(National Institutes of Health, Bethesda, Maryland, USA). The immunodensity of the 
protein band was normalized to the immunodensity of tubulin. 
 
 
2.7 TF ACTIVITY ASSAY 
2.7.1 Reagents 
Pooled human platelet poor plasma (PPP); Pooled murine PPP (Seralab, Sussex, UK); 
Factor VII-deficient human PPP (Alphalabs, Eastleigh, UK); Corn trypsin inhibitor 
(Sigma-Aldrich, Gillingham, UK); Sodium citrate (Sigma-Aldrich, Gillingham, UK); 1M 
CaCl2 (Sigma-Aldrich, Gillingham, UK);  Chromgenic TF activity assay (Abcam); 
Relipidated TF (Innovin®, Dade Behring, Milton-Keynes, UK); N-octyl β-D-
glucopyranoside (Sigma-Aldrich, Gillingham, UK); 1M HEPES (Sigma-Aldrich, 
Gillingham, UK); 5M NaCl (Ambion, Paisley, UK); Molecular grade water (Invitrogen, 
Paisley, UK) 
 
2.7.2 Buffers 
 HN-Buffer (25mM HEPES, 175mM NaCl) – for 10mL HN buffer: 250µL 1M 
HEPES + 350 µL 5M NaCl + 9.4mL water 
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 15mM N-octyl β-D-glucopyranoside – 8.8mg N-octyl β-D-glucopyranoside + 1mL 
HN-buffer 
 
2.7.3 Principle of the turbimetric assay 
Many clotting assays exist to assess the thrombogenicity of cells in culture. The most 
commonly used is a turbimetric clotting assay, where clot formation can be assessed by 
following changes in clot turbidity as it forms, using absorption spectrophotometry (A405). 
A turbimetric clot assay was used to determine TF activity, with minor adaptation of a 
validated one-step plasma recalcification clotting assay410. Figure 2-2a shows a clot 
turbidity curve. The lag phase of the turbidity curve (Tlag) is the time to exponential 
increase in clot turbidity, representing the time required for fibrin protofibrils to grow to 
sufficient length to allow lateral aggregation to occur, and is the most sensitive clot 
turbimetric parameter411. The maximum rate of turbidity change (Vmax), i.e. the steepest 
portion of the curve, corresponds to the peak clotting rate. By determining the steepest 
portion of turbidity curve, the intersection point of a tangent drawn at this point to the 
arbitrary baseline absorbance (ABSmin) line corresponds to Tlag
411, 412. The maximum 
absorbance at plateau (ABSmax) reflects the number of protofibrils per fibre
411, 412. The 
clot turbidity curves were modelled mathematically using TableCurve2D v5.0 (Systat) 
where ABS was a function of T, ABS=f(T), to determine Vmax, TVmax, ABSmax and ABmin. 
Using Vmax, TVmax and ABSmin, Tlag was derived using coordinate geometry: 
 
 
 
 
 
In general, if the turbimetric profiles shift to the left, this is indicative of increased 
procoagulant activity, whilst a shift to the right is indicative of reduced procoagulant 
activity (figure 2-2b). The intrinsic coagulation pathway has a delayed onset due to a 
slower activation process33 (figure 2-2c).     
 
 
Tlag = 
Vmax 
ABSmin – [f(Tvmax) – Vmax.TVmax] 
where ABS=f(T) 
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2.7.4 Plasma preparation for turbimetric assay 
For assessing procoagulant activity of human cells, pooled citrated human PPP was 
used. Platelet rich plasma (PRP) was obtained from citrated venous blood 
(citrate:blood=1:9) following centrifugation at 400g for 20 minutes at room temperature. 
PPP was made by centrifuging PRP at 5000g for 20 minutes at 4°C. Pooled normal 
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PPP was formed by pooling PPP from 10 different healthy human volunteers. For 
assessing procoagulant activity of murine cells, human plasma cannot be used, as 
murine TF cannot effectively activate human VII413. Using mouse plasma for clot 
turbibity assays has been variably reported, but the disadvantage is that mouse plasma 
is darker and less clear compared to human plasma. This does not result in the 
characteristic clot turbimetric profiles to allow reliable derivation of clot turbimetric 
parameters. Thus, a combination of citrated pooled human PPP (as above) and murine 
PPP (available commercially from Seralab, UK) was used (human plasma:mouse 
plasma = 9:1). The 10% mouse plasma provides sufficient factor VII for clot formation to 
subsequently occur (see below).  
 
 
2.7.5 Determining TF activity of cells in culture 
To determine TF activity of cells in culture, cells were cultured in 96 well plates (cell 
density=2x104 cells per well) according to the experimental protocol. Following the 
experiment, the supernatant was removed, with the cells remaining adherent to the 
base of the wells, and washed with PBS twice to remove any culture medium and 
serum. The surface of the cells provided procoagulant stimulus for the subsequent 
clotting reaction. 100 μL of the citrated plasma was added to the wells and recalcified 
with 2 μL of 1.0M CaCl2 to initiate clotting (20mM final well concentration). Clotting was 
assessed using clot turbidity by measuring absorbance (A405) every minute for 60 
minutes in a spectrophotometer (Synergy HT, Biotek, Potton, UK) with internal 
thermostatic control at 37°C. The clot turbidity curves were modeled mathematically 
using TableCurve2D v5.0 (Systat, Chicago, IL, USA) where ABS was a function of T, 
ABS=f(T), to determine Tlag. A TF standard curve was generated using relipidated TF 
(Innovin®) to provide a correlation between Tlag and TF concentration. The 
concentration of TF in the Innovin® preparation was initially determined using a 
chromogenic TF activity assay (see below). Each experimental condition was performed 
in triplicate providing 3 Tlag values and, therefore, 3 TF activity values accordingly. The 
mean TF activity values were used for subsequent analyses. 
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2.7.6 Determining TF activity of tissue samples 
To determine TF activity of tissues samples, tissue were harvested and snap frozen and 
stored at -80°C until analysis. The tissue sample were dissolved in 300µl 15 mM N-octyl 
β-D-glucopyranoside in HN-Buffer in 2mL round-bottomed eppendorfs. The tissues 
were homogenized by adding a stainless steel bead (Qiagen, Crawley, UK) and 
operating a TissueLyser (Qiagen, Crawley, UK) for 2 min at 20Hz. The tubes were 
centrifuged at 17,000g for 20 minutes at 4ºC to pellet cell debris with the stainless steel 
bead. The supernatant (homogenate) was carefully removed and transferred to a fresh 
eppendorf, followed by repeat centrifugation at 17,000g for 20 minutes at 4ºC to pellet 
any remaining debris. The homogenate was carefully transferred to a fresh eppendorf. 
Total protein content of the tissue homogenates was determined and homogenates 
were made to a working concentration of 1 mg/mL total protein using HN-Buffer as a 
dilutent. 5µL of the homogenate was mixed with 100µl citrated plasma as above and 
recalcified. TF activity was determined as above. 
 
2.7.7 Chromogenic TF activity assay 
A chromogenic TF activity assay (Abcam, Cambridge, UK) was used to determine the 
TF concentration of the Innovin® preparation, as TF concentration of this commercially 
available preparation is not provided. First, the TF standards were made using the stock 
TF preparation (250pM) with sample dilutent which were provided in the assay kit. The 
standards used were 250, 125, 62.5, 31.25, 15.63 and 0pM TF. All reactions were 
performed in triplicate. For the total number of wells, a master mix was made using 
reagents provided in the kit which comprised of 50µL assay dilutent, 10µL factor VII and 
10µL factor X per well. 70µL of this master mix was added to each well. 10µL of TF 
standard or sample was added to each well and allowed to incubate at 37°C for 30 
minutes. Next, 20µL of factor Xa substrate (provided in the kit) was added to each well 
and gently mixed. The absorbance (A405) was measured in a spectrophotometer 
(Synergy HT, Biotek, Potton, UK) with internal thermostatic control at 37°C. A standard 
curve was constructed using the A405 values and TF concentration and modeled 
mathematically using TableCurve2D v5.0 (Systat). The TF concentration of the 
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Innovin® preparation was determined from the standard curve. The TF concentration of 
the Innovin preparation was used to prepare [TF]-Tlag standard curve. 
 
2.7.8 Validation experiments for turbimetric clot assay 
 
2.7.8a Investigating [CaCl2] for plasma re-calcification 
The concentration of CaCl2 for re-calcifying plasma was based on standard 
concentrations used in our laboratory. As a validation exercise, the effect of increasing 
calcium concentrations was investigated on the intrinsic coagulation cascade, where 
100µL human PPP was recalcified and clot turbimetric profiles were established. The 
clot turbidity curves were modeled mathematically to determine Tlag, Vmax and ABSmax. 
The concentrations of CaCl2 used were 10-50mM. Figure 2-3 shows the clot turbimetric 
profiles and analyses of Tlag, Vmax and ABSmax. It is interesting to note for concentrations 
ranging from 10-25mM there was no significant change in clot turbimetric profiles, 
however beyond these values there was a suggestion that excess CaCl2 was inhibiting 
intrinsic coagulation. For CaCl2 > 35mM, the Tlag was increasing; for CaCl2 > 25mM, the 
Vmax was decreasing; and for CaCl2 > 30mM, the ABSmax was decreasing. These results 
indicate that the a concentration of 20mM CaCl2 used for re-calcification represents 
concentration at the higher end of concentration range where little adverse effect is 
observed on clot turbimetric parameters. The observation that increasing CaCl2 
concentration beyond 25-30mM appears to have an inhibitory effect on intrinsic 
coagulation certainly warrants an explanation. One possibility is that the excess positive 
charge provided by the Ca2+ ions may neutralize the negative charge on the surface of 
the wells that is important for contact activation in the intrinsic pathway. 
 
2.7.8b Validation of murine TF turbimetric assay 
In experiments where murine TF needed to be quantified, a combination of citrated 
pooled human PPP (as above) and mouse PPP (as above) was used (human 
plasma:mouse plasma = 9:1). The rationale for using this combination is that (a) human 
plasma cannot be used, as murine TF cannot effectively activate human VII413; and (b) 
using mouse plasma for clot turbidity assays has the disadvantage that it is darker and  
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less clear compared to human plasma resulting in sub-optimal clot turbimetric profiles to 
allow reliable derivation of clot turbimetric parameters. For this reason, a small amount 
of mouse plasma (10%) was added to human plasma to provide sufficient factor VII for 
clot formation to subsequently occur, whilst still retaining the clearer nature of human 
plasma, making it favorable for optimal turbimetric profiling. Figure 2-4a demonstrates 
this principle where different combinations of 100µL citrated plasma were added to wells 
containing LPS stimulated murine macrophages (1µg/mL for 8 hours) - a source of 
murine TF. Following removal of the culture medium, the adherent LPS-stimulated  
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murine macrophages were washed with PBS and 100µL PPP was added and re-
calcified, allowing clot turbimetric profiles to be established. All experiments were 
conducted in the presence of corn trypsin inhibitor (70µg/mL) which inhibits the intrinsic 
coagulation pathway. The corn trypsin inhibitor was added to the plasma before adding 
the plasma to the wells. Efficient clotting, representative of extrinsic coagulation, did not 
 
96 
 
occur using either pooled human PPP or using pooled human VII-deficient PPP. It is 
important to note that some clotting was seen at with T lag ~ 15min, and given that 
intrinsic coagulation was inhibited using corn trypsin inhibitor, this may represent very 
weak extrinsic coagulation, as murine TF has been reported to activate human factor VII 
to some extent413. However adding 10% murine plasma to VII-deficient human plasma 
and pooled human plasma completely restored clotting. Using corn trypsin inhibitor 
(70µg/mL) effectively abolishes the intrinsic coagulation cascade, and obviates any 
issues where the intrinsic coagulation cascade may confound interpretation of these 
results. This principle is demonstrated in figure 2-4b, where corn trypsin inhibitor 
abolished coagulation of re-calcified factor VII-deficient plasma. The factor VII deficient 
plasma was also validated by experiments where the addition of exogenous TF did not 
accelerate coagulation (figure 2-4c). 
 
2.7.8c Determining sensitivities of the crude clot turbimetric parameters 
Amongst the different turbimetric parameters, Tlag, Vmax and ABSmax are the most 
commonly used. Of these, Tlag represents the most sensitive clot turbimetric 
parameter411. Whilst Tlag has been used as the index parameter against which a TF 
standard curve is generated to provide a concentration of TF, it is important to have an 
understanding of how these turbimetric parameters behave throughout a range of TF 
concentrations. To test this, different concentrations of exogenous TF (Innovin®) were 
used. The neat concentration of the commercially available preparation was arbitrarily 
set at 1. 10-fold serial dilutions were made using PBS (10-4U to 1U). 100µL of TF 
solution was added to each well of a 96-well plate and allowed to incubate at 37°C for 1 
hour. This allowed the TF to become adsorbed onto the plate surface. After the 
incubation period, the TF solution was removed carefully using a pipette and washed 
once with 100µL PBS. 100 μL of the citrated plasma was added and re-calcified. Clot 
turbimetric profiles were established, and turbidity curves were modeled mathematically 
to determine Tlag, Vmax and ABSmax. In these set of experiments corn-trypsin inhibitor 
was not used, and thus the clot turbimetric profile with [TF]=0 represents intrinsic 
coagulation. Figure 2-5a shows the turbimetric profiles throughout the range of TF 
concentrations. With increasing TF concentrations the curves shift to the left in keeping 
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with increased procoagulant activity. Analysis of the clot turbimetric profiles 
demonstrates Tlag being the most sensitive clot turbimetric parameter, being able to 
detect differences throughout the TF concentration spectrum including very low TF 
concentrations (figure 2-5b). Vmax appears to the next most sensitive, but was not able 
to detect differences below 10-2U (figure 2-5c). ABSmax appeared to be the least 
sensitive parameter (figure 2-5d). These experiments corroborate previously reported 
findings, and support the use of Tlag as the index turbimetric parameter against which 
TF standard curves can be generated411.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.8 MOUSE TNFα ELISA 
TNFα proteins levels in cell culture supernatants and mouse sera were measured using 
a mouse TNFα Duo-set sandwich ELISA kit (RND systems, Abingdon, UK) according to 
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the manufacturer‘s instructions. Briefly, 96 wells plates were coated overnight with 
100µL of goat anti-mouse TNFα antibody (144 µg/mL) at room temperature, dependent 
on the final number of wells required (all samples or standards were tested in triplicate). 
The wells were washed with wash buffer [PBS (0.05% Tween)] and blocked with 1% 
BSA in PBS at room temperature for 1 hour. The wells were washed with wash buffer 
and the sample or standard was added and incubated for 2 hours at room temperature. 
The standards were prepared from the stock TNFα provided in the kit, and the 
concentrations used for the standard were 2000, 1000, 500, 250, 125, 62.5 and 31.25 
pg/mL. The wells were washed with wash buffer and 100µL of biotinylated goat anti-
mouse TNFα (72 µg/mL) was added and incubated for 2 hours at room temperature. 
The wells were washed with wash buffer and 100µL of Streptavidin-HRP antibody was 
added and incubated for 20 minutes at room temperature (avoiding light). The wells 
were washed and 100µL of Substrate Solution was added to each well and incubated 
for 20 minutes at room temperature. 50 µL of Stop Solution (2 N H2SO4) was added. the 
optical density of each well was determined immediately (A450) using a 
spectrophotometer (Synergy HT, Biotek, Potton, UK). A standard curve was constructed 
using the A450 values and TNFα concentration and modeled mathematically using 
TableCurve2D v5.0 (Systat, Chicago, IL, USA). The TNFα concentration of the samples 
were determined from the standard curve. 
 
2.9 FLOW CYTOMETRIC ANALYSIS 
2.9.1 Detection of murine TF 
The cells were treated according to the experimental protocol, following which the 
culture medium was removed. The cells were washed twice with 500µL ice cold PBS. 
The PBS aliquots were added above the cells and carefully removed using a pipette 
without disrupting the adherent cells. 500µL ice cold PBS was added to each well and 
the cells harvest by scraping. The cell suspensions were transferred to 1.5mL 
eppendorfs, and washed with 1 mL aliquots of ice cold PBS  each time centrifuging on a 
table top centrifuge at 8000g for 5 minutes at 4°C. Following the final wash, the cells 
were resuspended in 100µL of PBS. The cells were blocked with goat serum (Dako UK 
Ltd, Cambridge, UK) at 1:50 dilution for 30 minutes at 4°C , and stained for 30 minutes 
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at 4°C with either 1µg/ml rabbit IgG control antibody (Santa Cruz, Insight Biotechnology, 
Wembley, UK) or 1µg/ml rabbit anti-mouse TF antibody (American Diagnostica, Alere, 
Manchester, UK) with 1 mL aliquots of ice cold PBS  each time centrifuging on a table 
top centrifuge at 8000g for 5 minutes at 4°C. Following the final wash, the cells were 
resuspended in 100µL of PBS and stained with  1µg/ml FITC-conjugated F(ab')2 
fragment of goat anti-rabbit antibody (Invitrogen, Paisley, UK) for 30 minutes at 4°C 
.The cells were again washed with 1 mL aliquots of ice cold PBS  twice, and 
resuspended in 500 μl PBS for flow cytometric analysis. The cells were read on a 
Coulter EpicsXL flow cytometer, FL1–600V, FL2–600V. The maximum event rate was 
set to 10,000. Data were analyzed and presented using WinMDI software (Scripps 
Research Institute, CA, USA). Relative mean fluorescence intensity (RLMFI) values 
were obtained as ratio of the geometric mean of the fluorescence intensity with anti-TF 
antibody to the geometric mean of fluorescence intensity obtained with the control 
antibody. 
 
2.9.2 Detection of human TF 
The supernatant culture medium was removed and cells washed twice in cold PBS, and 
harvested in 500µL ice cold PBS (as above). For detection of surface human TF 
expression, the cells were incubated with either FITC-conjugated TF or FITC-
conjugated isotype control antibodies (AdD Serotec, Kidlington, UK) for 30min at 4ºC. 
The cells were washed with cold PBS and resuspended in 500µL cold PBS and 
subjected to flow cytometric analysis. The cells were read on a Coulter EpicsXL flow 
cytometer, FL1–600V, FL2–600V. The maximum event count was set at 10,000. Data 
were analyzed and presented using WinMDI software (as above). 
 
2.10 RNP IMMUNOPRECIPTATION 
2.10.1 Reagents 
2M KCl (Ambion, Paisley, UK); 5M NaCl (Ambion, Paisley, UK); 1M MgCl2 (Ambion, 
Paisley, UK); 1M HEPES; 100mM TRIS (pH=7.4) (Calbiochem. Nottingham, UK); 
IGEPAL (Sigma-Aldrich, Gillingham, UK); RNase Out (Invitrogen, Paisley, UK); 
Superasin (Ambion, Paisley, UK); Protease inhibitor cocktail (Sigma-Aldrich, Gillingham, 
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UK); 1M DTT (Ambion, Paisley, UK); Protein-G agarose beads (Sigma-Aldrich, 
Gillingham, UK); 10mg/mL Proteinase K (Qiagen, Crawley, UK); RNase-free DNase 1 
(Qiagen, Crawley, UK); 20% SDS (Sigma-Aldrich, Gillingham, UK); Molecular grade 
water (Invitrogen, Paisley, UK) 
 
2.10.2 Buffers 
 Polysome Lysis buffer (100mM KCl, 5mM MgCl2, 10mM HEPES, pH 7.0, 0.5% 
NP-40) – for 50mL buffer: 0.5mL 1M HEPES + 2.5mL 2M KCl + 250µL 1M MgCl2 
+ 1.25mL 20% IGEPAL +45.5mL water 
 NT-2 Buffer (50mM Tris–HCl (pH 7.4), 150mM NaCl, 1mM MgCl2 and 0.05% NP-
40) – for 50mL buffer: 25mL 100mM TRIS + 1.5mL 5M NaCl + 50µL 1M MgCl2 + 
125µL 20% IGEPAL + 23.325mL water 
 
2.10.3 Preparation of RNP lysate from cultured cells 
RNP immunoprecipitation was performed as previously described for 
immunoprecipitation of TTP using rabbit anti-TTP (H-120, Santa Cruz, Insight 
Biotechnology, Wembley, UK)414. Briefly, the cells were seeded in T75 culture flasks at 
a density of 1x107 cells per flask and treated as per the experimental protocol. The 
overlying culture medium containing dead cells and debris was removed. 20mL ice cold 
PBS was added to the flask. The adherent cells were removed by scraping. The cell 
suspension was transferred to 50mL tube and centrifuged at 300g for 10 minutes at 
4°C. The supernatant was completely aspirated. The cells were washed again in 50mL 
ice cold PBS and pelleted and transferred to a 1.5mL eppendorf. The cells were 
pelleted and lysed with 500µL polysome lysis buffer (1mL of buffer supplemented with 
1µL 1M DTT, 10µL RNase Out, 10µL Superasin and 10µL protease inhibitor cocktail 
immediately prior to use). The lysis buffer was added to the pellet and gently mixed by 
pipetting up and down (without vortexing). The lysate was kept on ice for 15 minutes 
and centrifuged at 17000g at 4°C for 30 minutes to pellet cell debris. The supernatant 
was carefully removed. Protein concentration was determined and adjusted with lysis 
buffer to achieve a concentration of 3mg per 100µl. 100 µl of lysate were aliquoted and 
either used immediately for immunoprecipitation or stored at -80°C until use.  
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2.10.4 Preparation of beads 
100µL of Protein-G agarose beads were used per immunoprecipitation reaction. 2 x 
100µL beads were transferred to 2 x 1.5mL RNase-free eppendorfs (for control and 
anti-TTP antibody reactions respectively) and centrifuged at 10,000g for 30 seconds at 
4°C. The supernatant was completely removed and 4 washing steps were repeated, 
each time resuspending in 500µL NT-2 buffer, centrifuged at 10,000g for 30 seconds at 
4°C and completely aspirating the supernatant. The beads were resupended in 200µL 
NT-2 buffer and 20µg of the protein-specific antibody or IgG control was added to each 
of the tubes. The tubes were mixed with rotation overnight at 4°C. The following day, 
the beads were washed with 1mL aliquots of ice-cold NT-2 buffer at 14000g for 5 
minutes at 4°C (5 times). After the final wash, the NT-2 buffer was completely removed 
and the beads were ready to use. 
 
2.10.5 Immunoprecipitation of RNPs 
700µL NT-2 buffer was added to the pre-coated beads. In a separate tube 10µL 0.1 
DTT, 10µL RNase Out and 33µL 0.5M EDTA was added and mixed. The mix was then 
added to the pre-coated beads. 100µL of the lysate was added and the total volume 
made up to 1mL with ice-cold NT-2 buffer. The tube was mixed with rotation for 1 hour 
at 4°C. Following the incubation, the beads were pelleted at 5000g for 5 minutes at 4°C. 
The beads were washed with 1mL aliquots of ice-cold NT-2 buffer and pelleted at 5000g 
for 5 minutes at 4°C (5 times). After the final wash the beads were incubated in 100ml of 
NT2 buffer containing 20U of RNase-free DNase I at 37°C for 10 minutes to remove 
genomic DNA contamination. 1mL ice cold NT2 buffer was added and centrifuged at 
5000g for 5 minutes at 4°C. In a separate tube 5µL 10mg/mL Proteinase K, 0.5µL 20% 
SDS and 100µL NT-2 buffer were added and mixed. The mix was then added to the 
beads and incubated at 55°C for 15 minutes with mixing. The beads were pelleted by 
centrifugation at 500g for 5 minutes and the supernatant collected (~100µL). A further 
200µL of NT-2 buffer was added to the beads and beads were pelleted by centrifugation 
at 5000g for 5 minutes and again the supernatant collected (~200µL). Both 
supernatants were combined (total supernatant volume ~300µL).  
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2.10.6 RNA extraction and cDNA synthesis 
RNA was extracted from the supernatants using Trizol preparation (as above). The final 
RNA pellet was resuspended in 22µL of water. RNA concentration and quality was 
determined using Nanodrop 1000 (Thermo Scientific, Loughborough, UK). 11µL of RNA 
was used for first strand cDNA synthesis (as above), whilst the remaining RNA was 
stored at -80°C for use as non-RT controls in subsequent control PCR reactions.  
 
2.10.7 Analysis of protein-bound mRNAs  species 
Gene specific primers used for qRT-PCR were used to determine the presence or 
absence of protein-bound mRNA species and control transcripts (HPRT and GAPDH). 
The reaction protocol used was identical to the qRT-PCR reactions with SYBG green 
(as above), but the cDNA dilutions used were 1:10 and reactions were performed in 
duplicate. To determine specificity for mRNA, the samples were run in parallel with non-
RT samples to control for genomic DNA contamination. The PCR reaction products 
were separated in a 2% agarose gel containing ethidium bromide and visualized under 
UV light. 
 
2.11 CLONING OF TF 3’UTR 
2.11.1 Reagents 
10pM Forward and reverse PCR primers (Eurofins, Ebersberg, Germany); Advantage 2 
DNA Polymerase (Clontech, Oxford, UK); Advantage 2 PCR buffer (Clontech, Oxford, 
UK); 10mM dNTP mix (Roche Diagnostics, Sussex, UK); DNA gel loading buffer 
(Invitrogen, Paisley, UK); 1kB Plus DNA ladder (Invitrogen, Paisley, UK); 10X Tris-
Borate-EDTA (TBE) buffer (Invitrogen, Paisley, UK); Ultrapure agar (Invitrogen, Paisley, 
UK); 10mg/mL Ethidium bromide (Sigma-Aldrich, Gillingham, UK); Gel extraction Kit 
(Qiagen, Crawley, UK); Isopropanolol (Sigma-Aldrich, Gillingham, UK); (pCRII-TOPO 
vector (Invitrogen, Paisley, UK); Salt solution (200 mM NaCl, 10 mM MgCl2) (Invitrogen, 
Paisley, UK); One Shot TOP10 Electrocompetent E. Coli (Invitrogen, Paisley, UK); Agar 
(Sigma-Aldrich, Gillingham, UK); LB Broth (Sigma-Aldrich, Gillingham, UK); Molecular 
grade water (Invitrogen, Paisley, UK); Kanamycin (Invitrogen, Paisley, UK) 
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2.11.2 Amplification of DNA sequences 
The murine and human TF 3‘UTR sequences/truncations/mutations were amplified from 
total murine or human macrophage cDNA with PCR primers listed in tables 2-3 and 2-4 
using the Advantage 2 PCR cloning kit (Clontech) according to the manufacturer‘s 
protocol. For the template, cDNA from 2 hour LPS-stimulated macrophages was used at 
a 1:10 dilution. The PCR reaction comprised of 1µL forward primer, 1µL reverse primer, 
1µL template, 1µL 10mM dNTP mix, 1µL Advantage 2 DNA polymerase, 40µL water 
and 5µL Advantage 2 PCR buffer (total reaction volume = 50 µL). The components 
were placed in PCR tubes followed by brief spin and placed in a thermal cycler (Applied 
Biosystems, Warrington, UK) using the following protocol: 94°C (1 minute) followed by 
30 cycles of 94°C (30 seconds), 60°C (30 seconds) and 72°C (1 minute).  
 
2.11.3 Preparation of agarose gels 
Agarose gels were prepared by adding the appropriate amount of ultrapure agarose to 
1xTBE buffer and heating in a microwave until the agarose was fully dissolved. For ―x‖ 
% gels, ―x‖ grams of ultrapure agarose was added per 100mLs of 1x TBE buffer. The 
agarose solution was allowed to cool to 50-60°C and 4µl of 10mg/ml ethidium bromide 
was added per 100ml agarose solution. A gel caster was prepared with the appropriate 
comb(s) to make the wells and sealed, following which the agarose-ethidium bromide 
gel solution was carefully poured into the gel caster under a fume hood. The gel was 
allowed to set and solidify for 30 minutes, before removal of the gel caster and combs. 
The gel was immersed into 1X TBE buffer in an electrophoresis tank, ensuring the wells 
were positioned at the cathode pole of the tank.  
 
2.11.4 Purification of amplified DNA sequences 
The PCR reaction products were separated in a 1% agarose gel containing ethidium 
bromide and visualized under UV light, and the corresponding PCR fragment was 
carefully excised using a clean scalpel under UV guidance. The excised DNA band was 
carefully transferred to a 1.5mL eppendorfs and kept on ice. The DNA was 
subsequently extracted using Gel Extraction Kit (Qiagen, Crawley, UK) according to the 
manufacturer‘s instructions. Briefly, 300µL of Buffer QG was added to the excised gel 
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band and incubated at 50°C for 10 minutes to dissolve the gel. 100µL isopropanolol was 
added and mixed by pipetting, and then the total volume applied to a gel extraction spin 
column. The spin columns were centrifuged at 13000g for 1 minute, and the flow-
through discarded. 0.5mL Buffer QG was added to the column and centrifuged at 
13000g for 1 minute, again discarding the flow-through. 0.75mL of buffer PE was added 
to the spin column and centrifuged at 13000g for 1 minute, again discarding the flow-
through, followed by repeat dry centrifugation at 13000g for 1 minute to remove any 
excess wash buffer. The spin column was placed in a clean 1.5mL eppendorfs, and 
30µL of water was applied to the spin column membrane, allowed to incubate for 1 
minute at room temperature before a final centrifugation at 13000g for 1 minute to elute 
the DNA. The concentration and quality of the DNA were determined using Nanodrop 
1000 (Thermo Scientific, Loughborough, UK), ensuring a 260/280 ratio >1.8. 
 
2.11.5 Cloning reaction 
All DNA fragments in this study were cloned into the pCRII-TOPO vector (Invitrogen, 
Paisley, UK) using the TOPO TA Cloning Kit (Invitrogen, Paisley, UK) using the 
manufacturer‘s protocol. The map for the pCRII vector is shown in figure 2-6. This 
vector was chosen as it contains T7 and SP6 promoters appropriate for in vitro RNA 
transcription to generate sense and anti-sense strands. It contains both kanamycin and 
ampicillin resistance for choice of selection in E. coli. The cloning reaction comprised of 
2µL DNA, 2µL water, 1µL salt solution and 1µL of pCRII vector (total reaction volume = 
6µL). The components were placed in a 0.2mL PCR tube and briefly spun and allowed 
to incubate at room temperature for 20 minutes. 
 
2.11.6 Transformation of bacteria 
All transformations were performed using One Shot TOP10 Electrocompetent E. Coli 
(Invitrogen, Paisley, UK) according to the manufacturer‘s instruction. Firstly, one vial of 
bacteria was taken and allowed to thaw on ice for 10 minutes. Next, 2µL of the cloning 
reaction was taken and gently added to the bacteria and mixed by swirling using a 
pipette tip (no vortexing), and placed on ice for 30 minutes. Following the incubation, the 
cells were heat-shocked for 30 seconds at 42°C without shaking, and immediately 
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transferred to ice. 250 µL of S.O.C. medium (held at room temperature) was added to 
the reaction mixture. The tube cap was closed tightly and placed horizontally in a 
shaking incubator  (200 rpm) at 37°C for 1 hour.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.11.7 Preparation of agar plates 
Agar was prepared by adding 1 agar tablet per 50mL of sterile water and autoclaved. As 
a general rule 30mL of agar solution was deemed appropriate per agar plate. Following 
the autoclave process, the agar was allowed to cool to 50-60°C at which point the 
appropriate volume of antibiotic (50-100µg/mL ampicillin or kanamycin, depending on 
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the vector resistance) was added to the agar under sterile conditions. The agar was 
carefully poured into sterile agar plates in sterile conditions (dedicated tissue culture 
hood) and allowed to set for 30 minutes. After the 1 hour transformation reaction, the 
bacterial suspension from each transformation was taken and 120µL of the suspension 
was spread on each agar plate under sterile conditions, and incubated overnight at 
37°C without shaking.  
 
2.11.8 Analyzing the colonies 
The LB broth medium was made by adding 1 tablet of LB broth tablet per 50mL sterile 
water followed by autoclaving. 50 µg/mL ampicillin or kanamycin was added to LB broth 
depending the required resistance. 5mL of LB broth was added to sterile tubes. 
Approximately 10 colonies were selected per agar plate, and using a sterile pipette tip, 
carefully transferred to the LB broth under sterile conditions, ensuring no cross 
contamination between the colonies occurred. The LB broth was incubated overnight in 
a shaking incubator  (200 rpm) at 37°C. The following day, DNA was extracted from the 
colonies using Plasmid Mini Kit (Qiagen, Crawley, UK) according to the manufacturer‘s 
instructions. Briefly, the bacteria were pelleted in 1.5mL eppendorfs from the overnight 
bacterial culture by centrifuging at 10000g for 3 minutes at room temperature. The 
bacterial pellet was resuspended in 250µL Buffer P1 (ensuring RNase had been added 
prior to use). 250µL Buffer P2 was added and mixed thoroughly by vigorously inverting 
the sealed tube 4–6 times. The lysis reaction was not allowed to proceed for more than 
5 minutes. 350µL Buffer N3 was added and mix immediately and thoroughly by 
vigorously inverting 4–6 times, and incubate on ice for 5 minutes. The tubes were 
centrifuged at 17000g for 10minutes, and the supernatant carefully transferred to a 
QIAprep spin column and centrifuged at 17000g for 1 minute, discarding the flow-
through. 500µL Buffer PB was added to the spin column and centrifuged at 17000g for 1 
minute, discarding the flow-through. Next, 750µL Buffer PE was added to the spin 
column and centrifuged at 17000g for 1 minute, discarding the flow-through. The 
column was centrifuged for an additional 1 minute to remove residual wash buffer, and 
transferred to clean 1.5mL eppendorf. 50μl of water was carefully pipette onto the spin 
column membrane and left to incubate at room temperature for 1minute before final 
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centrifugation at 17000g for 1minute to elute the purified DNA plasmids. The 
concentration and quality of the DNA were determined using Nanodrop 1000 (Thermo 
Scientific, Loughborough, UK), ensuring a 260/280 ratio >1.8. The plasmids were 
sequenced using establish M13 (-20) sequencing primers (forward: 
GTAAAACGACGGCCAG, reverse: CAGGAAACAGCTATGAC). 
 
2.11.9 Generation of ARE mutant sequences 
Both mouse and human TF 3‘UTR contain 4 conserved ARE segments. For the 
purpose of this study, the murine TF 3‘UTR was used for detailed ARE analyses. The 
final palindromic ARE was found to be functional in the TF 3‘UTR, and thus mutations 
relating to this ARE were constructed. This palindromic ARE (AUAAUUUAUUUAAUA) 
comprises 2 overlapping AUUUAUUUA and UUAUUUAAU nonamers. 4 mutant 
sequences were generated (AREMut1-4) which tested whether the complete palindromic 
sequence or the individual nonamers had functional importance: ARE Mut1, 
GGGAUUUAUUUAAUA; ARE Mut2, AUAAUUUAUUUAGGG; ARE Mut3, 
AUAAGGGAUUUAAUA; and ARE Mut4, AUAAUUUAGGGAAUA. The ARE was close to 
the 3‘ end of the sequence, and this property was utilized in generating the mutant 
sequences, employing larger than usual reverse primer sequences. The PCR primers 
for cloning the different ARE mutants and corresponding WT sequence are shown in 
table 2-4. The PCR amplification reactions, cloning, transformation, plasmid 
purifications and sequencing were as detailed above.  
 
2.12 GENERATION OF BIOTINYLATED TRANSCRIPTS 
2.12.1 Reagents 
Restriction enzymes: EcoRV, Sac1 and HindIII (Promega, Southampton, UK); 10x 
Restriction enzyme buffers D, E and J (Promega, Southampton, UK); Acetylated BSA 
(Promega, Southampton, UK); Molecular water (Sigma); Phenol:Chloroform:Isoamyl 
Alcohol 25:24:1 (Sigma-Aldrich, Gillingham, UK); Chloroform:Isoamyl 
alcohol 24:1(Sigma-Aldrich, Gillingham, UK); Ethanol (Sigma-Aldrich, Gillingham, UK); 
3M Sodium acetate (Ambion, Paisley, UK); 20 µg/µl Ultra-pure Glycogen (Invitrogen, 
Paisley, UK); SP6 or T7 polymerase (Roche Diagnostics, Sussex, UK); Biotinylated 
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oligonucleotides mix (Roche Diagnostics, Sussex, UK); RNase inhibitor (Roche 
Diagnostics, Sussex, UK); DNase 1 (Roche Diagnostics, Sussex, UK); 10X transcription 
buffer (Roche Diagnostics, Sussex, UK); 0.5M EDTA (Ambion, Paisley, UK) 
 
2.12.2 Linearization of the plasmid 
For generation of both sense anti-sense RNA strands for the respective DNA sequence, 
the dual promoter sites in the pCRII vector were utilized, where the T7 and SP6 
reactions would give the sense and anti-sense RNA strand depending on the orientation 
of the insert (figure2-6). First, 3μg pCRII vector was linearized by restriction digestion 
using enzymes dependent on the insert, ensuring the insert sequence did not contain 
any restriction sites. Using intact non-linearized plasmid DNA would otherwise result in 
heterogenous transcripts of varying lengths. For the murine sequences, restriction 
digestion was with either Hind III or EcoRV; and for human sequences, restriction 
digestion was with either Sac1 or EcoRV, all according to manufacturer‘s instructions. 
The restriction digestion reaction for 3μg intact plasmid comprised the following: 42µL 
water, 6µL 10X buffer, 6µL acetylated BSA, 3µL (3μg) plasmid and 3μL restriction 
enzyme. The choice of buffer was dependent on the restriction enzyme used and 
compatibility according to the manufacturer‘s protocol (EcoRV-Buffer D; HindIII-Buffer 
E; and Sac1-Buffer J). The separate restriction digest reactions were set up in 0.2mL 
PCR tubes and briefly spun, and incubated at 37°C for 90 minutes. The integrity of the 
linearized bands were visualized in a 1% agarose gel containing ethidium bromide and 
visualized under UV light. 
 
2.12.3 Purification of DNA using phenol-chloroform extraction 
The restriction digest reaction was made up to 300µL using molecular water in a 1.5mL 
eppendorf. Next, 300µL of Phenol:Chloroform:Isoamyl Alcohol  (lower layer) was added, 
vortexed and centrifuged at 17000g for 15 minutes at 4°C. Following this, the top 
aqueous layer was carefully removed and transferred to a new 1.5mL eppendorf. Next, 
250µL Chloroform:Isoamyl Alcohol was added, vortexed and centrifuged at 17000g for 
15 minutes at 4°C. Again, the top aqueous layer was carefully removed and transferred 
to a new 1.5mL eppendorf. 25µL 3M sodium acetate solution and 625µL of 100% 
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ethanol was added and vortexed and left for overnight precipitation at -20°C. The 
addition of 1µL glycogen was optional, facilitating the visibility of the DNA pellet. The 
following day, the tube was centrifuged at 17000g for 30 minutes at 4°C to pellet the 
DNA. The supernatant was completely removed, and the DNA pellet was resuspended 
in 500µL 70% ethanol, and centrifuged at 17000g for 15 minutes at 4°C. The 
supernatant was completely removed, and the pellet air-dried for 15-20 minutes. The 
DNA pellet was resuspended in 15-20µL water. The concentration and quality of the 
DNA were determined using Nanodrop 1000 (Thermo Scientific, Loughborough, UK), 
ensuring a 260/280 ratio >1.8. 
 
2.12.4 In vitro transcription of RNA 
1μg of the linearized DNA was in vitro transcribed using the SP6/T7 transcription kit 
(Roche Diagnostics, Sussex, UK) in the presence of biotinylated oligonucleotides 
according to the manufacturer‘s in vitro transcription protocol. SP6 or T7 polymerase 
was used according to the orientation of the insert and restriction digest enzyme used 
ensuring the sequence was in direct continuity with the respective SP6/T7 promoter 
site. The in vitro transcription reaction was set up as follows: 1µg linearized DNA (1-
10µL dependent on the concentration), 2µL biotinylated oligonucleotides mix, 1µL RNA 
inhibitor, 2µL 10X transcription buffer, and 2µL of the appropriate polymerase (Sp6 or 
T7). The reaction volume was made up to 20µL using molecular water. The components 
were added to 0.2mL PCR tube and briefly spun, followed by an incubation at 37°C for 
2 hours. Next, 2µL DNase 1 was added and incubated at 37°C for 15 minutes. This 
ensured the DNA template for RNA was destroyed. Finally, the reaction was inactivated 
by the addition of 0.8µL 0.5M EDTA and heated at 65°C for 10 minutes. The biotinylated 
transcripts were extracted from the reaction mixture using ethanol precipitation. The 
reaction mixture was transferred to a 1.5mL eppendorfs, and volume made up to 250µL 
using water. 25µL 3M sodium acetate solution and 625µL of 100% ethanol was added 
and vortexed and left for overnight precipitation at -20°C. The addition of 1µL glycogen 
was optional, facilitating the visibility of the RNA pellet. The following day, the tube was 
centrifuged at 17000g for 30 minutes at 4°C to pellet the RNA. The supernatant was 
completely removed, and the RNA pellet was resuspended in 500µL 70% ethanol, and 
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centrifuged at 17000g for 15 minutes at 4°C. The supernatant was completely removed, 
and the RNA pellet air-dried for 15-20 minutes. The RNA pellet was resuspended in 15-
20µL water. The concentration and quality of the RNA were determined using Nanodrop 
1000 (Thermo Scientific, Loughborough, UK), ensuring a 260/280 ratio >1.8 and a 
260/230 ratio >1.9. 
 
2.13 RNA-BIOTIN PULLDOWN ASSAY 
2.13.1 Reagents 
Dynabeads® M-280 Streptavidin (Invitrogen, Paisley, UK); 100mM TRIS pH=7.4 
(Calbiochem, Nottingham, UK); 5M NaCl (Ambion, Paisley, UK); 1M MgCl2 (Ambion, 
Paisley, UK); Triton X-100 (Sigma-Aldrich, Gillingham, UK); RNase Out (Invitrogen, 
Paisley, UK); Superasin (Ambion, Paisley, UK); Protease inhibitor cocktail (Sigma-
Aldrich, Gillingham, UK); 1M DTT (Ambion, Paisley, UK); 2M NaF (Sigma-Aldrich, 
Gillingham, UK); 1M NaVO4 (Sigma-Aldrich, Gillingham, UK); SDS Loading buffer 
(Invitrogen, Paisley, UK) 
 
2.13.2 Buffers 
 Lysis buffer (Triton 0.5%, 10mM TRIS, 2.5mM MgCl2 and 150mM NaCl) – for 
50mL buffer: 250µL Triton, 5mL 100mM TRIS, 125µL MgCL2, 1.5mL 5M NaCl 
and 43.125mL water) 
 
2.13.3 Preparation of lysates 
To determine proteins bound to the TF 3‘UTR, an RNA-biotin pulldown assay was used 
as previously described, with minor adaptation415. Briefly, the cells were seeded in T75 
culture flasks at a density of 1x107 cells per flask and treated as per the experimental 
protocol. The overlying culture medium containing dead cells and debris was removed. 
20mL ice cold PBS was added to the flask. The adherent cells were removed by 
scraping. The cell suspension was transferred to 50mL tube and centrifuged at 300g for 
10 minutes at 4°C. The supernatant was completely aspirated. The cells were washed 
again in 50mL ice cold PBS and pelleted and transferred to a 1.5mL eppendorf. The 
cells were pelleted and lysed with 1mL of lysis buffer supplemented with 1µL 1M DTT, 
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10µL RNase Out, 10µL Superasin, 2µL 2M NaF, 1µL 1M NaVO4 and 10µL protease 
inhibitor cocktail immediately prior to use). The lysis buffer was added to the pellet and 
gently mixed by pipetting up and down (no vortexing). The lysate was kept on ice for 15 
minutes and centrifuged at 17000g at 4°C for 30 minutes to pellet cell debris. The 
supernatant was carefully removed. Protein concentration was determined and adjusted 
with lysis buffer to achieve a concentration of 1mg/mL. 100 µl of lysate were aliquoted 
and either used immediately or stored at -80°C until use. 
 
2.13.4 Preparation of beads 
20µL of magnetic streptavidin beads were used per reaction. The beads were isolated 
from the storage medium using magnetic separation and washed with 500µL aliquots of 
ice cold lysis buffer (3 times), using magnetic separation. The beads were resuspended 
in the original volume (20µL per reaction) of lysis buffer and placed on ice. 
 
2.13.5 RNP isolation 
For each sample of RNA, 2 parallel reactions were performed – one for the sense RNA 
and one for the anti-sense (control) RNA strand. All reaction were performed in 0.2mL 
PCR tubes. First, 1µL RNase Out, 1µL Superasin and 1µL 0.1M DTT were added to 
each of the tubes. 100μl of lysate was added to each tube, followed by 2μg of either the 
sense or anti-sense biotinylated transcript. The contents were briefly spun and 
incubated at 4°C for 1 hour with rotation. Next, 20μl of the prepared magnetic 
streptavidin-coated beads were then added to each tube and incubated at 4°C for 1 
hour with rotation. Following this, the beads were separated using magnetic separation 
and washed 5 times in ice cold lysis buffer. The proteins bound to the beads/transcripts 
were eluted by boiling the beads in 30µL 1x SDS loading buffer at 100°C for 4 minutes. 
The candidate RNA binding proteins were detected using Western blotting and 
immunodetection methods as described above. The anti-sense strands in this study did 
not contain any AREs and therefore served as an internal controls for their respective 
reactions. The experiment was further controlled by detecting for tubulin which serves 
as a marker for non-specific binding. 
 
112 
 
2.14 CO-IMMUNOPRECIPITATION ASSAY 
2.14.1 Reagents 
Dynabeads® Protein G (Invitrogen, Paisley, UK); 100mM TRIS pH=7.4 (Calbiochem, 
Nottingham, UK); 5M NaCl (Ambion, Paisley, UK); 1M MgCl2 (Ambion, Paisley, UK); 
Triton X-100 (Sigma-Aldrich, Gillingham, UK); RNase Out (Invitrogen, Paisley, UK); 
Superasin (Ambion); Protease inhibitor cocktail (Sigma-Aldrich, Gillingham, UK); 1M 
DTT (Ambion, Paisley, UK) 
 
2.14.2 Buffers 
 IP lysis buffer (0.5% Triton, 20mM TRIS, 150mM NaCl) - for 50mL buffer: 250µL 
Triton, 10mL 100mM TRIS, 1.5mL 5M NaCl and 38.5mL water 
 IP wash buffer (0.5% Triton, 20mM TRIS, 150mM NaCl) - for 50mL buffer: 50µL 
Triton, 10mL 100mM TRIS, 1.5mL 5M NaCl and 38.7mL water 
 
2.14.3 Preparation of lysates 
The cells were seeded in T75 culture flasks at a density of 1x107 cells per flask and 
treated as per the experimental protocol. The overlying culture medium containing dead 
cells and debris was removed. 20mL ice cold PBS was added to the flask. The adherent 
cells were removed by scraping. The cell suspension was transferred to 50mL tube and 
centrifuged at 300g for 10 minutes at 4°C. The supernatant was completely aspirated. 
The cells were washed again in 50mL ice cold PBS and pelleted and transferred to a 
1.5mL eppendorf. The cells were pelleted and lysed with 1mL of lysis buffer, 
supplemented with 1µL 1M DTT, 10µL RNase Out, 10µL Superasin and 10µL protease 
inhibitor cocktail immediately prior to use. The lysis buffer was added to the pellet and 
gently mixed by pipetting up and down (no vortexing). The lysate was kept on ice for 15 
minutes and centrifuged at 17000g at 4°C for 30 minutes to pellet cell debris. For 
experiments were RNase treatment was necessary, RNase A (Invitrogen, Paisley, UK) 
was added to the lysis buffer (prior to lysis) at a final concentration of 5μg/mL. The 
supernatant was carefully removed. Protein concentrations were determined and 
adjusted with lysis buffer to achieve a concentration of 2mg/mL. 500 µl of lysate were 
aliquoted and either used immediately or stored at -80°C until use. 
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2.14.4 Preparation of beads 
50µL of magnetic streptavidin beads were used per reaction. The beads were isolated 
from the storage medium using magnetic separation and washed with 500µL aliquots of 
ice cold IP lysis buffer (3 times), using magnetic separation. The beads were 
resuspended in the original volume (50µL per reaction) of IP lysis buffer and placed on 
ice. 
 
2.14.5 Immunoprecipitation 
For each reaction, 500μL of lysate was used. The lysate was added to either 5μg of 
protein specific antibody or 5μg IgG control and incubated at 4°C for 1 hour with 
rotation. 50µL of prepared magnetic protein G beads were added to the antibody-lysate 
mixture and incubated for 15 minutes at room temperature with rotation. The beads 
were isolated using magnetic separation and washed with ice cold IP wash buffer (3 
times). The proteins bound to the beads were eluted by boiling the beads in 20-30µL 1x 
SDS loading buffer at 100°C for 4 minutes. The (co-)immunoprecipitated proteins were 
detected using Western blotting and immunodetection methods as described above. 
 
2.15 INTRAVITAL MICROSCOPY & FERRIC CHLORIDE INJURY MODEL 
All in vivo procedures were covered by approval from the UK Home Office. WT and 
Parp14-/- mice were injected with LPS 10 μg i.p. or a corresponding volume of the saline 
vehicle control.  Anaesthesia was induced 4 hours after LPS injection by administration 
of ketamine (150mg/kg i.p. Fort Dodge Animal Health, Southampton, UK) and xylazine 
(7.5mg/kg i.p. Bayer Healthcare, Newbury, UK). The mouse cremaster muscle was 
prepared for intravital microscopy as described previously416. Briefly, the cremaster was 
dissected free of skin and fascia, opened longitudinally, and then pinned out flat against 
the viewing platform of a plexiglass stage. The preparation was mounted on an 
Olympus BW61WI microscope with a water-immersion objective lens (magnification of 
x40; LUMPlan FI/R, Olympus, Japan), which was used to observe the arterioles in the 
cremaster muscle. Superfusion of the cremaster muscle with bicarbonate-buffered 
solution (BBS; g/L: 7.71 NaCl, 0.25 KCl, 0.14 MgSO4, 1.51 NaHCO3, and 0.22 CaCl2, 
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pH 7.4, at 37°C, gassed with 5% CO2/95% N2) at a rate of 2 ml/min began immediately. 
After the preparation of the cremaster muscle, the mice were allowed to recover from 
surgical preparation for 30 minutes. Then, induction of thrombus formation was 
performed in randomly chosen arterioles. Due to the rapid spreading of ferric chloride 
solution only 1 arteriole per preparation was observed within each animal.  Microscopic 
images were acquired by a black-and-white camera (model CoolSNAP HQ 
(Photometrics, Tucson, AZ, US), coupled to a Windows XP-based computer for 
recording by Slidebook 4.2 (Intelligent Imaging Innovations, Inc., Denver, CO, US) for 
off-line evaluation. Resting blood flow was monitored in individual arterioles (diameter 
range 30-50μm), followed by superfusion with 30μl of a 25M ferric chloride solution 
(Sigma-Aldrich, Gillingham, UK)417. Recording of vessels was discontinued after blood 
flow in the vessel ceased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
2.16 LIST OF PRIMERS FOR qRT-PCR 
 
Table 2-1: Primers for qRT-PCR 
 
 
Gene Primers for qRT-PCR 
Human TF 418 Forward: GAGTGTATGGCCCAGGAGAA 
Reverse: GCCAGGATGATGACAAGGAT 
Human TNFα Forward: GCCCATGTTGTAGCAAACCCTC 
Reverse: ATCTCTCAGCTCCACGCCATT 
Human HPRT Forward: TTGGTCAGGCAGTATAATCC 
Reverse: GGGCATATCCTACAACAAAC 
Human GAPDH Forward: CAAGGTCATCCATGACAACTTTG 
Reverse: GGGCCATCCACAGTCTTCTG 
Mouse TF (primer set 1) Forward: AGCCTGCCAATCCTAGCTCAGAG 
Reverse: CGGTTTCCGTTCGTCCTAACGTGAC 
Mouse TF (primer set 2) 171 Forward: TCAAGCACGGGAAAGAAAAC 
Reverse: CTGCTTCCTGGGCTATTTTG 
Mouse TNFα Forward: AGCCCACGTCGTAGCAAACCA 
Reverse: CGGGGCAGCCTTGTCCCTTG 
Mouse TTP 419 Forward: AATCCCTCGGAGGACTTTGGAACA 
Reverse: AGTTGCAGTAGGCGAAGTAGGTGA 
Mouse PARP-14 Forward: TCCGCCTGGTAGAAGAAG 
Reverse: GCCCACATCAACAGAGAC 
Mouse HPRT Forward: GTTAAGCAGTACAGCCCCAAAATC 
Reverse: TCAAGGGCATATCCAACAACAAAC 
Mouse GAPDH Forward: CAAGGTCATCCATGACAACTTTG 
Reverse: GGGCCATCCACAGTCTTCTG 
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2.17 LIST OF ANTIBODIES 
 
 
Table 2-2: Antibodies used in this study 
 
 
ANTIBODY SUPPLIER DILUTION 
PRIMARY ANTIBODIES 
Rabbit anti-mouse TF 420 American Diagnostica, (Alere, 
Manchester, UK) 
1:1000 (WB) 
1:10 (FC) 
Rabbit anti-PARP14 Eurogenetec, Seraing, Belgium 1:700 
Rabbit anti-TTP (SAK21A) 
421 
Kennedy Institute of Rheumatology, 
Oxford, UK 
1: 2000 (WB) 
Rabbit anti-TTP (H-120) Santa Cruz (Insight Biotechnology, 
Wembley, UK ) 
1:200 (WB) 
 
Goat anti-TTP (N-18) Santa Cruz (Insight Biotechnology, 
Wembley, UK ) 
1:1000 (WB) 
Rabbit anti- total p38 MAPK Cell Signalling (New England 
Biolabs, Hitchin, UK) 
1:1000 (WB) 
Rabbit anti-phospho-p38 
MAPK 
Cell Signalling (New England 
Biolabs, Hitchin, UK) 
1:1000 (WB) 
Rabbit anti- total JNK MAPK Cell Signalling (New England 
Biolabs, Hitchin, UK) 
1:1000 (WB) 
Rabbit anti-phospho-JNK 
MAPK 
Cell Signalling (New England 
Biolabs, Hitchin, UK) 
1:1000 (WB) 
Mouse anti-human TF 
(IgG1) 
Abcam, Cambridge, UK 1: 500 (WB) 
Mouse anti-human TF 
(IgG1) 
(FITC-conjugated) 
AdD Serotec, Kidlington, UK 1:50 (FC) 
Mouse IgG1 isotype control 
(FITC-conjugated) 
AdD Serotec, Kidlington, UK 1:50 (FC) 
SECONDARY ANTIBODIES 
Rabbit anti-goat-HRP Dako UK Ltd, Cambridge, UK 1:2000 (WB) 
Rabbit anti-mouse-HRP Dako UK Ltd, Cambridge, UK 1:2000 (WB) 
Goat anti-rabbit-HRP Dako UK Ltd, Cambridge, UK 1:2000 (WB) 
Goat anti-rabbit 
F(ab')2 fragment-FITC 
Invitrogen, Paisley, UK, Paisley, UK 1:200 (FC) 
 
WB=Western blotting 
 
FC= Flow cytometry 
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2.18 LIST OF PRIMERS FOR CLONING 
 
Table 2-3: Primers for cloning the murine and human TF 3’UTR 
 
Sequence PCR Primers (forward and reverse) 
ARE WT 
Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTAAATAAATTATCTCAAAATATAC 
ARE Mut1 
Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTAAATAAATCCCCTCAAAATATAC 
ARE Mut2 
Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTACCCTAAATAAATTATCTCAAAATATAC 
ARE Mut3 
Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTAAATAACCCATCTCAAAATATAC 
ARE Mut4 
Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTCCCTAAATTATCTCAAAATATAC 
 
 
Table 2-4: Primers for generating mutants for final ARE in murine TF 3’UTR 
 
Sequence PCR Primers (forward and reverse) 
ARE WT Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTAAATAAATTATCTCAAAATATAC 
ARE Mut1 Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTAAATAAATCCCCTCAAAATATAC 
ARE Mut2 Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTACCCTAAATAAATTATCTCAAAATATAC 
ARE Mut3 Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTAAATAACCCATCTCAAAATATAC 
ARE Mut4 Forward: AGGAAAGGCTGAAGCCG 
Reverse: CCCAATCACCTTTATTTATATAAAAGTATATTCCCTAAATTATCTCAAAATATAC 
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Chapter 3 
 
Results: 
TTP regulates TF mRNA stability 
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3.1 INTRODUCTION 
Regulation of TF gene transcription provides one of the primary mechanisms for 
governing its level of expression and hence cellular procoagulant activity. In monocytes 
and macrophages, TF gene transcription is stimulated by inflammatory cytokines (e.g. 
IL-1, TNFα) or by LPS 249-251.  LPS activates macrophages via toll-like receptor 4, and 
is commonly used as a canonical stimulus for studying TF expression. Following LPS 
stimulation, increased transcription of the TF gene occurs via the activation of AP-1, 
NFĸB and Egr-1 transcription factor pathways. However, following LPS stimulation, 
increased levels of TF mRNA are transient, with peak levels occurring at 2-4 hours 
followed by a rapid decline. This time-course implies robust post-transcriptional 
mechanisms that destabilize and degrade TF mRNA, the control of which is likely to be 
as important as the transcriptional regulation in ultimately determining the net gene 
expression. 
 
TF mRNA transcripts are intrinsically unstable, but show a transient increase in stability 
over two hours following LPS treatment in THP-1 monocytic cells190 and in endothelial 
cells191, providing a means for fresh mRNA transcripts to be converted into TF protein 
259, 260. The TF 3‘UTR contains several AREs that may serve as potential binding sites 
for ARE-binding proteins, and indeed TF mRNA has been assigned to the group III 
cluster of the ARED database261.  These AREs are functional and conserved in both 
human and mouse. Although, the roles for microRNAs in regulating TF mRNA stability 
have recently been reported268, the precise molecular mechanisms involved in ARE-
mediated TF mRNA decay have not been fully elucidated. The p38 pathway is one of 
the three MAPK pathways that affect mammalian gene expression347-352. LPS 
stimulation results in phosphorylation and activation of p38, which promotes 
inflammatory gene response through both transcriptional and post-transcriptional 
mechanisms. The p38 pathway stabilizes mRNA by activating MAPKAPK-2 that 
subsequently phosphorylates and inactivates TTP (the primary target for MAPKAPK-2) 
363. TTP is the most widely studied mRNA binding proteins that classically binds to a 
consensus nonamer ARE sequence, UUAUUUA(A/U)(A/U), in the 3‘UTR of target 
transcripts promoting their degradation264-266. Following analyses of the putative AREs 
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we hypothesized that TTP, a well established ARE-binding protein, would bind and 
regulate the TF transcript. In this chapter, the specific roles for p38 and TTP in the post-
transcriptional regulation of TF were investigated. 
 
3.2 METHODS 
Detailed generic methods have been described in Chapter 2. In this section, the 
methods and experimental protocols specific to this chapter are briefly described. 
 
3.2.1 Primary human monocyte isolation and culture 
Monocytes were isolated from citrated venous blood derived from healthy donors (with 
local ethical approval). PBMCs were isolated from the cell fraction by Ficoll–Paque 
density-gradient centrifugation and CD14+ monocytes were separated using magnetic 
separation with CD14 MicroBeads and a MACS Separator column.  Monocytes were 
plated into tissue culture plates according to the experimental protocol in IMDM with 
10% FCS (25x104 cells/well in 24 well plates, 2X104/well in 96-well plates or 
1x107cells/T75 flask) and incubated overnight in a 37°C incubator, for experiments the 
following day.  
 
3.2.2 Bone marrow-derived macrophage (BMDM) isolation and culture 
WT and Ttp-/- mice were sacrificed using cervical dislocation. Bone marrow cells were 
flushed from the femur and tibia and cultured in bone marrow culture medium for 6 
days. On day 6, the cells were harvested, resuspended in the bone marrow culture 
medium, and plated in culture dishes/flasks as per the experimental protocol (25X104 
cells/well in 24 well plates or 1x107cells/T75 flask) and incubated overnight in a 37°C 
incubator, for experiments the following day. 
 
3.2.3 RNA extraction and quantitative reverse-transcriptase PCR (qRT-PCR) 
RNA was isolated from cells using RNEasy Mini kits, incorporating an on-column DNase 
digestion using RNase-free DNase. 1µg of total RNA was used for cDNA synthesis 
using  SuperScript III reverse transcriptase protocol. Comparative qRT-PCR was 
performed using SYBR green and gene specific primers (table 2-1). Data was 
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normalized to 2 housekeeping controls, GAPDH and HPRT. For mouse TF mRNA 
expression, data were validated using 2 primer sets. Relative gene expression was 
calculated using the ΔΔCt method409. 
 
3.2.4 mRNA decay experiments 
All mRNA decay experiments were performed with an identical protocol. Cells were 
stimulated with LPS 1µg/mL. Actinomycin D (5µg/mL) was added at 2 hours following 
LPS stimulation to induce transcriptional arrest. The 2 hour time point was chosen for 2 
reasons: (a) TF mRNA levels peak at 2-4 hours following LPS stimulation, and (b) TF 
mRNA half-life has previously been shown to be very stable up to 2 hours following LPS 
stimulation in THP-1 cells (t½~120minutes), following which the t½ rapidly declines. A 
relatively stable baseline decay profile would thus allow one to better observe the 
destabilizing effects of particular treatments, e.g. p38 inhibitors. For p38 inhibition, the 
following compounds were used: SB203580, SB202190, BIRB796 and LY2228800. 
Where SB203580/SB202190 compounds were used, an inactive analogue compound 
SB202474 was used as a control. In experiments specifically examining the effect of 
these signaling inhibitors on mRNA decay, the inhibitors were all added at the time of 
actinomycin D, except for BIRB796 and LY2228800 which were added 15 minutes prior 
to actinomycin D due to their slower onset of action. Following actinomycin D, RNA was 
isolated at time 0, 15, 30, 60 and 90 minutes. mRNA was quantified using qRT-PCR, 
and levels were normalized to levels at time 0. Both HPRT and GAPDH levels remained 
stable following transcriptional arrest, validating the use of these housekeeping genes 
for mRNA decay analyses (data not shown). The mRNA decay profiles were modeled 
mathematically using non-linear regression analysis and mRNA half-lives calculated. 
 
3.2.5 Western blotting analysis 
Following the experimental protocol, the cells were lysed with 100µL of Cell Lytic M lysis 
buffer with 1µL of protease inhibitor cocktail. The lysates were centrifuged at 17,000g 
for 20 minutes at 4ºC to pellet cell debris. The supernatants were carefully removed and 
stored at -80ºC until analysis. A Novex XCell II (Invitrogen) mini gel system was used. 
20µg of protein was used per lane, and proteins were separated by gel electrophoresis 
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using pre-cast polyacrylamide gels, and electrotransferred to polyvinylidene difluoride 
membranes. The membranes were blocked using blocking buffer and primary and 
secondary antibodies were applied in blocking buffer at the appropriate dilutions (table 
2-2). Protein bands were detected using chemiluminescence. Protein quantification was 
performed using densitometry using ImageJ software (National Institute of Health 
Bethesda, Maryland, USA) normalized to tubulin.  
 
3.2.6 TF activity assays 
A turbimetric clot assay was used to determine TF activity. Cells were cultured in 96 
well plates (cell density=2x104 cells per well) according to the experimental protocol. 
The supernatant was removed and cells were washed with PBS twice. 100 μL of the 
citrated PPP was added to the wells and recalcified with 2 μL of 1.0M CaCl2 to initiate 
clotting. Clot turbidity was measured by absorbance (A405) every minute for 60 minutes 
in a spectrophotometer (Synergy HT, Biotek) with internal thermostatic control at 37°C. 
The clot lag time (Tlag) was determined and correlated to a TF standard curve generated 
using relipidated TF (Innovin®, Dade) to determine TF activity. 
 
3.2.7 RNP immunoprecipitation 
Cells were seeded in T75 culture flasks at a density of 1x107 cells per flask and 
stimulated with LPS 1µg/mL for 2 hours. Cells were washed with ice cold PBS twice, 
lysed with polysome lysis buffer supplemented with RNase and protease inhibitors and 
centrifuged at 17000g  at 4°C for 30minutes to pellet cell debris.100 µl (3mg protein) of 
lysate was incubated for 2 hours with 100 µl of preswollen Protein-G agarose beads 
(Sigma-Aldrich) precoated with either 20µg of rabbit anti-TTP (H-120) or normal rabbit 
IgG. The beads were washed with NT2 buffer and then incubated in 100ml NT2 buffer 
containing 0.1% SDS and 0.5 mg/ml proteinase K (15 minutes, 55°C). The beads were 
pelleted, and the supernatant carefully removed. RNA was extracted using Trizol 
reagent. cDNA synthesis and qRT-PCR was performed using gene-specific primers as 
above. To determine specificity for mRNA, the samples were run in parallel with non-RT 
samples to control for genomic DNA contamination. The PCR reaction products were 
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separated in a 2% agarose gel containing ethidium bromide and visualized under UV 
light. 
 
3.2.8 In vitro transcription 
The murine and human TF 3‘UTRs, truncated and mutant 3‘UTR segments were 
amplified from total murine or human macrophage cDNA with PCR primers listed in 
tables 2-3 and 2-4 using the Advantage 2 PCR cloning kit and cloned using the TOPO 
TA Cloning Kit into the pCRII-TOPO vector. The plasmids were purified using Plasmid 
Miniprep Kit (Qiagen), linearized by restriction digestion using (Hind III or EcoRV for the 
murine sequences, and Sac1 or EcoRV for human sequences). Biotinylated transcripts 
were formed using the SP6/T7 transcription kit in the presence of biotinylated 
oligonucleotides. For competition experiments where cold (non-biotinylated transcripts 
were necessary, the in vitro transcription reaction was performed replacing the 
biotinylated nucleotide mix with a standard non-biotinylated nucleotide mix. The RNA 
was purified from the reaction mixture using ethanol precipitation. 
 
3.2.9 RNA-biotin pulldown assays 
Cell lysates were produced from LPS-stimulated murine and human macrophages. The 
cells were seeded in T75 culture flasks at a density of 1x107 cells per flask and 
stimulated with LPS 1µg/mL for 2 hours. In experiments where p38 inhibition was 
necessary, SB203580 1µM was added 15 minutes prior to lysis. The adherent cells 
were harvested by scraping, washed twice with ice cold PBS and lysed with 1mL lysis 
buffer supplemented with RNase and protease inhibitors. 100μl (100μg protein) of 
lysate was incubated with either the sense or anti-sense biotinylated transcript (2μg) for 
1 hour. In the competition experiments, parallel reactions were set up  where 1, 5 and 
10 fold excess cold transcripts were added in addition to the 2µg of biotinylated WT 
3‘UTR transcripts. 20μl of magnetic streptavidin-coated beads (Dynabeads®, 
Invitrogen) were added and incubated at 4°C for 1 hour. Following 1 hour incubation, 
the Dynabeads® were added according to the standard protocol, and the associated 
proteins resolved by Western blotting as above. The beads were separated using 
magnetic separation, washed with lysis buffer and boiled in 1x SDS loading buffer at 
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100°C for 4 minutes. The proteins were detected using Western blotting and 
immunodetection. 
 
3.2.10 Statistical analyses 
All continuous variables were expressed as mean ± SEM. Statistical analyses were 
performed using GraphPad Prism v5.0 (GraphPad Software, San Diego, CA, USA) and 
Microsoft Excel 2007 (Microsoft, Washington, USA). All continuous variables were 
confirmed to be normally distributed by the Shapiro-Wilk statistic. Thus for comparison 
of groups, the unpaired Student‘s t-test (2-tailed) was used. Statistical significance was 
set at p<0.05. 
 
3.3 RESULTS 
 
3.3.1 p38 inhibition reduces TF expression in primary human monocytes 
Monocytes were stimulated with LPS (1µg/mL) and concurrently treated with increasing 
concentrations (0.1, 1 and 10µM) of SB202190, SB203580 and SB202474. TF mRNA 
levels were determined at 2 hours following LPS stimulation, and TF activity and protein 
levels were determined at 8 hours following LPS stimulation (figures 3-1 and 3-2). Using 
the control analogue compound SB202474, there was no significant difference in TF TF 
activity (figures 3-1a,b), mRNA levels (figure 3-2a) and TF protein levels (figure 3-2b).  
However, p38 inhibition with SB202190 and SB203580 was associated with a 
significant reduction in TF mRNA, TF activity and TF protein levels. Following LPS 
stimulation there was a 13% (p=0.03), 45% (p=0.002), and 60% (p<0.001) reduction in 
TF mRNA levels at 2 hours; and a 57% (p=0.005), 87% (p<0.001) and 90% (p<0.001) in 
TF activity levels at 8 hours with SB203580 at 0.1,1 and 10µM respectively. Similarly, 
following LPS stimulation there was a 11% (p=0.24), 55% (p<0.001), and 68% 
(p<0.001) reduction in TF mRNA levels at 2 hours; and a 77% (p=0.001), 92% 
(p<0.001) and 94% (p<0.001) reduction in TF activity levels at 8 hours with SB202190 
at 0.1, 1 and 10µM respectively. In general terms, TF activity serves a surrogate marker 
for TF protein levels. However, to confirm the findings for TF activity, western blotting 
analyses were also performed to assess TF protein levels at 8 hours following LPS  
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stimulation with each compounds (SB202474, SB203580 and SB202190) 0.1, 1 and 
10µM respectively. In keeping with the TF activity data, figure 3-2 confirms that 
SB202474 has no effect on LPS-induced TF protein expression whilst SB203580 and 
SB202190 produce a concentration-dependent reduction in TF protein levels. Based on 
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previously published literature, SB203580 and SB202190 compounds have been used 
in concentrations up to 25µM, and non-specific effects on other kinases, particularly 
JNK have been reported with higher concentrations. Given this, and based on published 
data, a concentration of 1µM was chosen for use in subsequent experiments. To test 
whether these compounds were specific for p38 inhibition at this concentration, 
phospho-p38:total p38 and phospho-JNK:total JNK ratios were determined by Western 
blotting following LPS stimulation (1µg/mL for 90 minutes) followed by a 30 minute 
incubation with 1µM SB compound. Figure 3-3 shows the phospho-p38:total p38 and 
phospho-JNK:total JNK ratios as determined by densitometric analyses.  Both 
SB2023580 and SB202190 at 1µM were found to be specific for p38 inhibition with little 
effect on JNK, whilst SB202474 had no significant effect. 
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3.3.2 p38 inhibition reduces TF mRNA stability in primary human monocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To specifically address the role of p38 activation in the post-transcriptional regulation of 
TF, TF mRNA decay profiles were established following LPS stimulation both in the 
absence and presence of p38 inhibitors. Monocytes were stimulated with LPS (1µg/mL), 
and actinomycin D (5µg/mL) was added at 2 hours to induce transcriptional arrest. 
Given the rapid onset of action of the SB compounds, SB202474, SB202190 and 
SB203580 1µM were added concurrently with actinomycin D, to minimize any effect on 
mRNA transcription. Given that these compounds were water soluble, water was added 
as a vehicle control to the control arm of the experiment. TF mRNA levels were 
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quantified at time 0, 15, 30, 60 and 90 minutes after actinomycin D and TF mRNA 
decay profiles determined. The TF mRNA half-life in the absence of any SB compound 
was 166±30minutes. With the control analogue SB202474, there was no significant 
difference in TF mRNA half-life, 148±25 minutes (p=0.72). With the p38 inhibitors, 
SB203580 and SB202190, there was a significant reduction in TF mRNA half-life to 
35±4minutes (p=0.007) and 40±10 minutes (p=0.01) respectively (figures 3-4 a,b). To 
exclude a compound class effect, other novel p38 inhibitors, BIRB796 and LY2228800 
were tested. These compounds are insoluble in water, and were therefore dissolved in 
DMSO, necessitating the use of DMSO as a vehicle control in the control arm of the 
experiments. These compounds were dissolved such that the final DMSO concentration 
was 0.5% of the final volume in the wells. The TF mRNA half-life was 120±8minutes in 
the control arm of the experiment. With the specific p38 inhibitors, BIRB796 1µM and 
LY2228800 1µM, there was a significant reduction in TF mRNA half-life to 
65±10minutes (p=0.007) and 58±5 minutes (p=0.001) respectively (figures 3-4 c,d). 
Collectively, these data indicate that the p38 MAPK pathway post-transcriptionally 
regulates TF expression, and that specific inhibition of p38 reduces TF mRNA stability. 
 
3.3.3 TF mRNA stability falls with increasing duration of LPS stimulation 
TF mRNA decay kinetics have previously been reported in LPS-stimulated THP-1 cells, 
where TF mRNA half-life was found to be very stable up to 2 hours following LPS-
stimulation (t½~120 minutes) following which the half-life falls rapidly to 25±5 minutes 
by 4-6 hours190. These data would suggest that LPS stabilizes TF mRNA when TF 
mRNA levels are increasing and that this effect contributes to the overall rate and 
magnitude of the TF mRNA response. Given that important difference exist between 
THP-1 cells and primary human monocytes422, similar detailed analyses of TF mRNA 
kinetics have not been reported in primary human monocytes or murine macrophages. 
Thus, TF mRNA decay curves were determined in LPS-stimulated primary human 
monocytes and WT murine macrophages, where actinomycin D was added 2 hours, 4 
hours and 6 hours following LPS stimulation (1µg/mL). In primary human monocytes, TF 
mRNA half-lives fell progressively with increasing duration of LPS stimulation (t½= 
141±2, 88±16 and 36±18 minutes at 2, 4 and 6 hours respectively (r2=0.998) (Figures 3- 
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5a,b). A similar pattern was observed with murine macrophages (t½= 52±8, 26±7 and 
15±6 minutes at 2, 4 and 6 hours respectively (r2=0.948) (Figures 3-5c,d). Given the 
above observation that p38 activity modulates TF mRNA half-life, one possible 
explanation would be the decline in phospho-p38 levels, i.e. p38 activity, with time 
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following LPS stimulation. To demonstrate this, total and phospho-p38 levels were 
determined using western blotting analyses at 2, 4 and 6 hours following LPS 
stimulation. Figure 3-5e shows a progressive reduction in phospho-p38 levels over 6 
hour period, providing a potential explanation for the observed reduction in TF mRNA 
half-life over this period. 
 
3.3.4 TTP deficiency results in increased TF expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If p38 inhibition reduces TF mRNA stability, then one can propose that the p38 MAPK 
pathway is phosphorylating and inactivating an mRNA-binding protein. Potential targets 
for which such a mechanism would be applicable are TTP, AUF1 and KSRP. Given the 
strong association with p38 activity and TTP function, and the bioinformatic analyses 
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the putative AREs upon which the original hypothesis was based, the potential role for 
TTP in regulating TF expression was examined. Given that TTP negatively regulates its 
targets, then if TTP does regulate TF expression, then the absence of TTP should 
increase TF expression. Thus, steady state TF mRNA and protein levels were 
determined in WT and Ttp-/- murine macrophages. Murine macrophages were 
stimulated with LPS 1µg/mL and TF mRNA levels were determined. There was no 
statistically significant difference in the  basal levels of TF mRNA in Ttp-/- compared to 
WT macrophages. To establish the TF mRNA induction profiles and allow easier 
comparison between WT and Ttp-/- cells, TF mRNA levels in both WT and Ttp-/- 
macrophages were normalized to levels in the unstimulated WT macrophages within 
each experiment. Figure 3-6a shows that TF mRNA levels were significantly increased 
in Ttp-/- vs. WT macrophages at 2 and 6 hours after LPS stimulation (p<0.05). Perhaps 
the most widely studied transcript in the context of TTP is TNFα, and TTP deficiency is 
known to result in increased TNFα expression. In a series of control parallel 
experiments, TNFα mRNA levels were measured following LPS stimulation in WT and 
Ttp-/- macrophages following LPS stimulation, as above. Figure 3-6b confirms increased 
TNFα mRNA levels in Ttp-/- macrophages, corroborating previously published findings. 
TF protein levels were determined using western blotting analyses. Figure 3-6c shows 
that TF protein levels were significantly increased in Ttp-/- vs. WT macrophages in 
resting cells and following LPS stimulation.  
 
3.3.5 p38 inhibition reduces TF mRNA stability in a TTP-dependent manner 
The increased TF expression in Ttp-/- macrophages, could be a result of increased 
transcription; increased TF mRNA stability; or both. As demonstrated above TNFα 
expression is increased in Ttp-/- macrophages and this may account for increased TF 
transcription. Thus to dissect this, the specific role for TTP in regulating TF mRNA 
stability was examined. Murine macrophages were stimulated with LPS 1µg/mL and 
actinomycin D (5µg/mL) was added at 2 hours to induce transcriptional arrest. As 
above, SB202190 and SB203580 1µM were added concurrently with actinomycin D, to 
minimize any effect on mRNA transcription and TF mRNA decay profiles were 
determined (figure 3-7). In WT murine macrophages, the TF mRNA half-life was 97±15 
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minutes. p38 inhibition with SB2023580 1µM and SB202190 1µM resulted in a 
significant reduction in TF mRNA half-life to 43±10 minutes (p=0.016) and 35±7 minutes 
(p=0.012) respectively. Compared to WT macrophages, in the Ttp-/- macrophages, there 
was a significant increase in TF mRNA half-life to 352±82 minutes (p=0.016), and p38 
inhibition with either SB203580 or SB202190 had no significant effect on TF mRNA half-
life, with mRNA half-lives of 301±52 minutes (p=0.618) and 360±57 minutes (p=0.944) 
respectively. These data (a) confirm a similar effect of p38 inhibition on TF mRNA 
stability as seen in human monocytes; (b) provide evidence that TTP regulates TF 
mRNA stability; and (c) confirm that the effect of p38 inhibition is TTP-dependent.  
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Both TNFα and TTP mRNA stability is regulated by TTP, and these transcripts are 
known to be destabilized through the inhibition of p38363. Thus in a series of control 
parallel experiments, designed primarily to demonstrate the effect of p38 inhibition on 
established TTP target transcripts, TNFα and TTP mRNA decay profiles were 
established in LPS-stimulated WT murine macrophages, and the effect of p38 inhibition 
on decay profiles was examined. The experimental protocol was as above. Figure 3-8 
confirms that p38 inhibition with SB203580 1µM results in significant reduction in TNFα 
and TTP mRNA stability in LPS-stimulated murine macrophages as expected. 
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3.3.6 TTP interacts with TF mRNA 
Having demonstrated that TTP regulates TF mRNA stability, it was crucial to establish 
whether TTP indeed interacts with TF mRNA. This was tested using RNP 
immunoprecipitation assays. RNP immunoprecipitation was performed using a rabbit 
anti-TTP (H-120) and rabbit IgG control antibody using lysates prepared from LPS-
stimulated human monocytes. Following immunoprecipitation, the mRNA species  
bound to TTP were separated, reverse transcribed to form cDNA templates, and then 
amplified using TF and TNFα specific primers. TNFα was chosen as it is known to bind 
TTP and would serve as a positive control. HPRT and GAPDH were also amplified 
using the appropriate primers to control for non-specific pulldown. The PCR products 
were visualized on a 2% agarose gel with ethidium bromide. To ensure that the 
amplified products were not as a result of amplification of genomic DNA, parallel control 
PCR reactions were conducted on pulled down material that had not been reverse 
transcribed (no RT control). Figure 3-9a demonstrates that both the human TNFα and 
TF transcripts were bound to TTP, which was not observed with the IgG control. This 
confirmed that TTP associates with TF mRNA in human monocytes. To test whether 
TTP interacts with TF mRNA in murine macrophages, RNP immunoprecipitation was 
performed again using the rabbit anti-TTP (H-120) antibody and rabbit IgG control using 
lysates prepared from LPS-stimulated WT and Ttp-/- macrophages. Figure 3-9b 
demonstrates again that both the murine TNFα and TF transcripts were bound to TTP, 
which was not observed with the IgG control or from lysates from Ttp-/- macrophages. 
The RNP immunoprecipitation assays therefore confirmed that TTP interacts with TF 
mRNA in both human and murine macrophages. 
 
3.3.7 TTP interacts with TF 3’UTR 
Having determined that TTP interacts with TF mRNA, to specifically test whether TTP 
associates with TF 3‘UTR, an RNA-biotin pulldown assay was used. TF 3‘UTR 
sequences for both mouse and human TF 3‘UTR were cloned and corresponding 
biotinylated sense and anti-sense RNA strands were synthesized using in vitro 
transcription. The anti-sense strand served as an internal control for each reaction. The 
biotinylated RNA strands were incubated with lysates prepared from LPS-stimulated  
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murine macrophages. The biotinylated transcripts were captured using Dynabeads® 
and the associated proteins resolved by Western blotting. Figure 3-9c shows that TTP 
associates with murine TF 3‘UTR in lysates prepared from WT macrophages. The 
experiment was controlled by detecting for tubulin which serves as a marker for non-
specific binding. The 3‘UTR sequence is highly conserved between mouse and human. 
To test whether inter-species specificity exists for the TTP and TF 3‘UTR interaction, an 
RNA-biotin pulldown assay was performed where biotinylated human 3‘UTR sequences 
were incubated with WT murine macrophage lysates. Figure 3-9d demonstrates that 
murine TTP interacts with human TF 3‘UTR sequence, confirming cross-species 
specificity for the TTP and TF 3‘UTR interaction. These data provide evidence that TTP 
interacts specifically with the 3‘UTR of TF. 
 
3.3.8 TTP interacts with 2 nonameric sequences 
Both mouse and human TF 3‘UTR contain many ARE segments (figure 3-10a). The 
most highly conserved ARE across a variety of species including mouse and human is 
the final palindromic ARE sequence (figure 3-10b). For the remainder of this study, the 
murine TF 3‘UTR was used for detailed ARE analyses. There are 7 AREs in the murine 
TF 3‘UTR. These were grouped into 4 hypothetical ARE segments (ARE1-4). To test 
which ARE is functional and mediates TTP binding, the murine TF 3‘UTR was divided to 
yield 6 constructs: 0-5. Constructs 0-1 were devoid of AREs and served as control 
constructs. Constructs 2-5 contained the 4 AREs in progressive summation with 
construct 5 containing all 4 AREs, i.e. the complete 3‘UTR sequence. RNA-biotin 
pulldown assays were performed with both sense and anti-sense RNA strands 
corresponding to each 3‘UTR segment and lysates prepared from LPS-stimulated WT 
murine macrophages. Figure 3-10b shows that TTP associates only with transcripts that 
contain the final ARE. This ARE has a palindromic sequence (AUAAUUUAUUUAAUA) 
which contains 2 overlapping AUUUAUUUA and UUAUUUAAU nonamers, each of 
which represent potential TTP binding sites. Accordingly, 4 mutant sequences were 
generated (AREMut1-4) which tested whether (a) the complete palindromic sequence had 
functional importance (ARE Mut1, GGGAUUUAUUUAAUA) or the individual nonamers 
alone or in combination had functional importance (ARE Mut2, AUAAUUUAUUUAGGG;  
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ARE Mut3, AUAAGGGAUUUAAUA; and ARE Mut4, AUAAUUUAGGGAAUA). RNA-biotin 
pulldown assays were performed with both sense and anti-sense RNA strands 
corresponding to the WT TF 3‘UTR and each of ARE mutant sequences. As above, the 
lysates were prepared from LPS-stimulated WT murine macrophages.  
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Figure 3-11a shows that TTP binding was not affected by mutations within the 
palindromic sequences as long as the nonameric sequences were preserved. However, 
mutations of each of the separate nonamers reduced, but did not abolish, TTP binding. 
Finally, mutations of both nonamers by substituting the shared UUU with GGG 
completely abolished TTP binding. These data would suggest that both sequences 
mediate binding to TTP in a cooperative fashion. To further test this, a competition 
RNA-biotin pulldown assay was performed, using cold unlabelled transcripts (figure 3-
11b). The principle underlying these experiment was, if the final ARE was indeed 
functional and mediated binding to TTP, then the addition of excess WT cold transcripts 
would compete with the biotinylated transcripts for TTP binding, whilst the mutant 
transcripts (AREMut-4) would have no effect. Figure 3-11b demonstrates that the addition 
of the cold WT transcripts significantly reduced TTP binding to the biotinylated 
transcripts captured by the beads. However, the cold mutant transcripts did not affect 
TTP binding to the biotinylated transcripts captured by the beads. These data provide 
further evidence that the 2 nonameric sequences within the final palindromic ARE in TF 
3‘UTR bind TTP in a cooperative fashion.  
 
3.3.9 p38 inhibition does not alter TTP binding to TF 3’UTR 
The above data indicates that p38 inhibition results in destabilization of the TF transcript 
in a TTP-dependent manner. To test whether p38 inhibition directly impairs the ability of 
TTP to bind with the TF transcript, RNA-biotin pull-down assay were used. In these 
experiments, the preparation of the lysates were critical. Lysates were prepared form 
WT murine macrophages which were either treated with LPS 1µg/mL or LPS 1µg/mL 
and SB203580 1µM. First, the cells were cultured with LPS for 90 minutes, and then in 
the p38 inhibitor arm of the experiment, SB203580 was added, with vehicle control in 
the control arm of the experiment. This was allowed to incubate for 30 minutes prior to 
preparation of lysates. Due to the rapid action of SB compounds, this strategy has been 
demonstrated above to efficiently reduce phospho-p38 levels by western blotting 
techniques (figure3-3). Furthermore, the SB compounds were added concurrently with 
actinomycin D in the mRNA decay experiments with an appreciable reduction in TF and 
TNF α mRNA stability, again demonstrating their rapid onset of action and inhibition of 
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TTP activity.   p38 inhibitors could not be added concurrently with LPS as this would 
inhibit LPS-induced transcription and potentially reduce TTP protein levels in the 
lysates. Figure 3-12 shows that a short treatment with SB203580 1µM did not produce 
an appreciable reduction in TTP in the lysate, and more importantly had no effect on 
TTP binding to TF 3‘UTR. These findings are in keeping with previously reported 
findings331. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 DISCUSSION 
 
The above data demonstrate the specific role for the p38 MAPK pathway and TTP in 
the post-transcriptional regulation of TF. Preliminary experiments demonstrated that 
inhibition of p38 led to a reduction in TF expression, both at the level of mRNA and 
protein. This was paralleled by a reduction in procoagulant activity. The p38 pathway 
plays important roles in transcriptional regulation, therefore this observed effect was 
likely a combination of both transcriptional repression coupled with its post-
transcriptional effects. However, the specific role for p38 in the post-transcriptional 
regulation of TF was demonstrated by the ability of a variety of inhibitors (SB202190, 
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SB203580, BIRB796 and LY2228800) to reduce TF mRNA half-life in human 
monocytes. The SB compounds represent an important tool for investigating p38 
function(s) in experimental laboratory science. The drawbacks of these compounds are 
that they may have non-specific effects on other kinases, particularly JNK. However, 
adopting a 1µM dose for all SB compounds, little effect on phospho-JNK levels were 
observed, indicting relative selectivity for p38. These are the standard concentration for 
SB compounds in the reported literature. However, despite the specificity demonstrated 
using western blotting analyses, it is possible that western blotting may not have been 
sensitive enough to demonstrate inhibition specificity for p38. This may have been more 
robustly demonstrated using dedicated kinase assays. Nevertheless, the effect of p38 
inhibition on TF mRNA stability was confirmed and substantiated using more novel and 
different classes of compounds, BIRB796 and LY2228800.  
 
Although the TF transcript is unstable, its half-life has previously shown to be dynamic 
in THP-1 cells, where it is relatively stable early in the LPS induction phase, but it 
becomes unstable later in the response190. This observation has not previously been 
described in primary human and murine macrophages. In this chapter, this was 
demonstrated in primary human monocytes and murine macrophages following LPS 
stimulation, where the TF transcript appeared to be relatively stable at 2 hours, but by 6 
hours the half-life has fallen to less than 30%. This dynamic change in half-life implies 
robust post-transcriptional regulatory mechanisms. Having established a role for p38 in 
regulating TF mRNA half-life, it was intriguing to speculate that a progressive reduction 
in phospho-p38 levels as seen late in the LPS response may in part explain this 
observation.  
 
Following LPS stimulation, steady state TF mRNA and protein levels were increased in 
Ttp-/- macrophages. Whilst this observation may imply a role for TTP in the post-
transcriptional regulation of TF, this has confounded interpretation as TTP deficiency 
results in increased TNFα production which can mediate transcriptional effects. 
However, the specific role for TTP was demonstrated by the observation that the TF 
mRNA half-life was significantly increased in Ttp-/- macrophages. Furthermore, p38 
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inhibitors were able to reduce TF mRNA stability in WT but not in Ttp-/- macrophages. 
This has two important interpretations, (a) the effect of p38 inhibition on TF mRNA 
decay is TTP-dependent; and (b) the effect of p38 inhibition on TF mRNA decay does 
not involve any other RNA-binding proteins whose functions are regulated by p38-
dependent phosphorylation, e.g. AUF1, BRF1 and KSRP278.   
 
Using RNP immunoprecipitation and RNA-biotin pulldown assays, TTP was shown to 
associate with TF mRNA and specifically with TF 3‘UTR. Using truncated murine 3‘UTR 
sequences with AREs in progressive summation,  RNA-biotin assays confirmed that 
TTP binds the sequence that contains the final ARE segment (ARE4 in figure 3-10c). 
This has two interpretations, (a) the final ARE is functional and mediates binding to 
TTP; or (b) all the AREs are required to mediate binding to TTP. The later explanation is 
unlikely, as the 3‘UTR spanning all the AREs is ~700 nucleotides in length, and studies 
have shown that RNA binding to TTP involves short nucleotide sequences423, 424. The 
final ARE segment contains a palindromic ARE, which contains 2 overlapping nonamers 
(AUUUAUUUA and UUAUUUAAU) 264-266. These nonamers have high predictive 
binding for ARE-binding proteins, the later bearing striking resemblance to the 
consensus nonameric sequence with high predictive binding to TTP. Further mutational 
analyses demonstrated that both nonamers bind TTP in a cooperative fashion. The 
functional importance of this ARE was further demonstrated by the ability of unlabelled 
―cold‖ WT 3‘UTR to compete with labeled WT transcript for binding to TTP, whereas the 
cold mutant 3‘UTR had no effect.  
 
In conclusion, these data demonstrate the specific role for the p38-TTP axis in the post-
transcriptional regulation of TF. The functional ARE in this setting is a highly conserved 
palindromic ARE, that comprises of 2 overlapping nonamers (AUUUAUUUA and 
UUAUUUAAU) that both appear to be functionally cooperative. 
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Chapter 4 
 
Results: 
PARP-14 cooperates with TTP to regulate TF 
mRNA stability 
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4.1 INTRODUCTION 
 
Poly(ADP-ribosyl)ation is a unique post-translational modification where negatively 
charged ADP-ribose moieties are adducted onto proteins. It is of central importance to a 
wide variety of cellular processes, e.g. DNA repair, transcriptional regulation, 
proteasomal protein degradation, vesicle trafficking and apoptosis425. This process is 
catalyzed by a family of NAD+ ADP-ribosyl transferases, the poly(ADP-ribose) 
polymerases (PARPs). These contain PARP domains that catalyze the formation of 
ADP-ribose from NAD+, which is then covalently attached to target proteins367.  PARP-1 
has been the subject of extensive research and is of central importance to DNA repair 
and transcriptional regulation 425. In contrast, most of the other PARP family proteins are 
much less well understood. Poly (ADP-ribose) polymerase (PARP)-14 (also known as 
ADP-Ribosyltransferase Diphteria Toxin-like 8, ARDT8) is a ~205 kDa intracellular 
protein that has previously been identified as a nuclear coactivator of STAT-6-mediated 
gene transcription in B cells406, 407. Although PARP-14 has a C terminal PARP domain, 
its enzymatic function is likely to be restricted to ADP-ribosyl monotransferase 
activity425.  
 
However, it has recently become clear that several PARP family members, including 
PARP-14, may have roles in RNA regulation395, 408.  PARP family members including 
PARP-14 have been found to localize with components of the stress granule that 
contains various RNA binding proteins and  components of the RNA decay machinery. 
Work in our laboratory has identified PARP-14 as a novel RNA-binding protein, and 
specifically plays a role in regulating mRNA stability of the chemokine IP-10 following 
IFNγ stimulation (unpublished data).  
 
In this chapter, the specific role for PARP-14 is examined, and whether or not it 
cooperates with TTP to regulate TF mRNA stability. Despite its implication in diverse 
cellular functions, ADP-ribosylation has not been reported to regulate coagulation and 
thrombosis. Thus, the role for ADP ribosylation in regulating TF mRNA turnover is 
investigated. 
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4.2 METHODS 
 
4.2.1 Primary human monocyte isolation and culture 
Monocytes were isolated from citrated venous blood derived from healthy donors. 
Peripheral blood mononuclear cells (PBMCs) were isolated from the cell fraction by 
Ficoll–Paque density-gradient centrifugation and CD14+ monocytes were separated 
using magnetic separation with CD14 MicroBeads and MACS Separator column.  
Monocytes were plated into tissue culture plates according to the experimental protocol 
in IMDM with 10% FCS (25x104 cells/well in 24 well plates or 2x104/well in 96-well 
plates) and incubated overnight in a 37°C incubator with 5% CO2 atmosphere, for 
experiments the following day.  
 
4.2.2 Bone marrow-derived macrophage isolation and culture 
WT and Parp14-/- mice were sacrificed using cervical dislocation. Bone marrow cells 
were flushed from the femur and tibia and cultured in bone marrow culture medium for 6 
days. On day 6, the cells were harvested, resuspended in the bone marrow culture 
medium, and plated in culture dishes/flasks as per the experimental protocol (25x104 
cells/well in 24 well plates or 1x107cells/T75 flask) and incubated overnight in a 37°C 
incubator, for experiments the following day. 
 
4.2.3 RNA extraction and quantitative reverse-transcriptase PCR (qRT-PCR) 
RNA was isolated from cells using RNEasy Mini kit and from tissues using  RNEasy 
Mini Fibrous kit according to manufacturer‘s instructions, incorporating an on-column 
DNase digestion. Tissues were homogenized using TissueLyser and 5mm stainless 
steel beads. 1µg of total RNA was used for cDNA synthesis using  SuperScript III 
reverse transcriptase enzyme. Comparative qRT-PCR was performed using SYBR 
green and gene specific primers (table 2-1). Data was normalized to 2 housekeeping 
controls, GAPDH and HPRT. For mouse TF mRNA expression, data was validated 
using 2 primer sets. Relative gene expression was calculated using the ΔΔCt 
method409. 
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4.2.4 mRNA decay experiments 
All mRNA decay experiments were performed with an identical protocol. Cells were 
stimulated with LPS 1µg/mL. Actinomycin D (5µg/mL) was added at 2 hours following 
LPS stimulation to induce transcriptional arrest. For p38 inhibition, SB203580 was used. 
For PARP inhibition, PJ34 and 3AB were used. In experiments specifically examining 
the effect of these signaling inhibitors on mRNA decay, the inhibitors were all added at 
the time of actinomycin D. Following actinomycin D, RNA was isolated at time 0, 15, 30, 
60 and 90 minutes. mRNA was quantified using qRT-PCR, and levels were normalized 
to levels at time 0. The mRNA decay profiles were modeled mathematically using non-
linear regression analysis and mRNA half-lives calculated. 
 
4.2.5 Western blotting analysis 
Following the experimental protocol, the cells were lysed with 100µL of Cell Lytic M lysis 
buffer with 1µL of protease inhibitor cocktail. For extraction of proteins from tissue, Cell 
Lytic MT lysis buffer was used with mechanical homogenization using TissueLyser and 
5mm stainless steel beads. The lysates were centrifuged at 17,000g for 20 minutes at 
4ºC to pellet cell debris. The supernatants were carefully removed and stored at -80ºC 
until analysis. A Novex XCell II mini gel system was used. 20µg of protein was used per 
lane, and proteins were separated by gel electrophoresis using pre-cast polyacrylamide 
gels, and electrotransferred to polyvinylidene difluoride membranes. The membranes 
were blocked using blocking buffer and primary and secondary antibodies were applied 
in blocking buffer at the appropriate dilutions (table 2-2). Protein bands were detected 
using chemiluminescence. Protein quantification was performed using densitometry 
using ImageJ software (National Institutes of Health, Bethesda) normalized to tubulin.  
 
4.2.6 TF activity assays 
A turbimetric clot assay was used to determine TF activity. Cells were cultured in 96 
well plates (cell density=2x104 cells per well) and treated with LPS 1µg/mL. The 
supernatant was removed and cells were washed with PBS twice, prior to the addition 
of plasma. Organ tissues from mice were homogenized in 15mM N-octyl-
glycopyranoside in HN-Buffer. 5µL of homogenate (final concentration of 1mg/mL) was 
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used for analysis. 100 μL of the citrated PPP (human:mouse plasma = 9:1) was added 
to the wells and recalcified with 2 μL of 1.0M CaCl2 to initiate clotting. Clot turbidity was 
measured by absorbance (A405) every minute for 60 minutes in a spectrophotometer 
with internal thermostatic control at 37°C. Tlag was determined and correlated to a TF 
standard curve generated using relipidated TF to determine TF activity. 
 
4.2.7 Flow cytometric analysis of murine TF 
WT and Parp14-/- macrophages were stimulated with LPS 1µg/mL for 6 hours, following 
which the culture medium was removed. The cells were harvested, washed and blocked 
with goat serum for 30 minutes at 4°C. Primary staining was with either 1µg/ml rabbit 
anti-mouse TF antibody or 1µg/ml rabbit IgG control antibody for 30 minutes at 4°C. The 
cells were washed and secondary staining was with 1µg/ml FITC-conjugated F(ab')2 
fragment of goat anti-rabbit antibody for 30 minutes at 4°C .The cells were washed and 
resuspended in 500 μl PBS for flow cytometric analysis. The cells were read on a 
Coulter EpicsXL flow cytometer, FL1–600V, FL2–600V. The maximum event rate was 
set to 10,000. Data were analyzed and presented using WinMDI software (Scripps 
Research Institute, CA). 
 
4.2.8 TNFα ELISA 
TNFα proteins levels in cell culture supernatants and mouse sera were measured using 
a mouse TNFα Duo-set sandwich ELISA kit (RND systems) according to the 
manufacturer‘s instructions.  
 
4.2.9 RNP immunoprecipitation 
Cell lysates were produced from LPS-stimulated murine macrophages. The cells were 
seeded in T75 culture flasks at a density of 1x107 cells per flask and stimulated with 
LPS 1µg/mL for 2 hours. Cells were washed with ice cold PBS, lysed with polysome 
lysis buffer supplemented with RNase and protease inhibitors and centrifuged at 
17000g  at 4°C for 30 minutes to pellet cell debris.100 µl (3mg protein) of lysate was 
incubated for 2 hours with 100 µl of preswollen Protein-G agarose beads precoated with 
either 20µg of rabbit anti-PARP14 or normal rabbit IgG. The beads were washed with 
149 
 
NT2 buffer and then incubated in 100ml NT2 buffer containing 0.1% SDS and 0.5 mg/ml 
proteinase K (15minutes, 55°C). The beads were pelleted, and the supernatant carefully 
removed. RNA was extracted using TRIzol reagent. cDNA synthesis and qRT-PCR was 
performed using gene-specific primers as above. To determine specificity for mRNA, 
the samples were run in parallel with non-RT samples to control for genomic DNA 
contamination. The PCR reaction products were separated in a 2% agarose gel 
containing ethidium bromide and visualized under UV light. 
 
4.2.10 In vitro transcription 
The murine and human TF 3‘UTRs, truncated and mutant 3‘UTR segments were 
amplified from total murine or human macrophage cDNA with PCR primers listed in 
tables 2-3 and 2-4 using the Advantage 2 PCR cloning kit and cloned using the TOPO 
TA Cloning Kit into the pCRII-TOPO vector. The plasmids were purified using Plasmid 
Miniprep Kit, linearized by restriction digestion using (Hind III or EcoRV for the murine 
sequences, and Sac1 or EcoRV for human sequences). Biotinylated transcripts were 
generated using the SP6/T7 transcription kit in the presence of biotinylated 
oligonucleotides. For competition experiments where cold (non-biotinylated) transcripts 
were necessary, the in vitro transcription reaction was performed replacing the 
biotinylated nucleotide mix with a standard non-biotinylated nucleotide mix. The RNA 
was purified from the reaction mixture using ethanol precipitation. 
 
4.2.11 RNA-biotin pulldown assays 
Cell lysates were produced from LPS-stimulated murine macrophages. The cells were 
seeded in T75 culture flasks at a density of 1x107 cells per flask and stimulated with 
LPS 1µg/mL for 2 hours. Where PARP inhibition was necessary, PJ34 10µM was added 
15 minutes prior to lysis. The adherent cells were harvested, washed with PBS and 
lysed using 1mL lysis buffer supplemented with RNase and protease inhibitors. 100μl 
(100μg protein) of lysate was incubated with either the sense or anti-sense biotinylated 
transcript (2μg) for 1 hour. In the competition experiments, parallel reactions were set 
up  where 1, 5 and 10 fold excess cold transcripts were added in addition to the 2µg of 
biotinylated transcripts. 20μl of magnetic streptavidin-coated Dynabeads® were added 
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and incubated at 4°C for 1 hour. The beads were separated using magnetic separation, 
washed with lysis buffer and boiled in 1x SDS loading buffer at 100°C for 4 minutes. 
The proteins were detected using Western blotting and immunodetection. 
 
4.2.12 Co-immunoprecipitation assay 
Cell lysates were produced from LPS-stimulated murine macrophages. The cells were 
seeded in T75 culture flasks at a density of 1x107 cells per flask and stimulated with 
LPS 1µg/mL for 2 hours. For experiments were RNase treatment was necessary, 
RNase A was added to the lysis buffer (prior to lysis) at a final concentration of 5μg/mL. 
The lysate was added to either 5μg of goat anti-TTP (N-18) antibody (Santa Cruz) or 
5μg IgG control (Santa Cruz) and incubated at 4°C for 1 hour with rotation. 50µL of 
prepared magnetic protein G beads were added to the antibody-lysate mixture and 
incubated for 15 minutes at room temperature with rotation. The beads were isolated 
using magnetic separation and washed with ice cold IP wash buffer (3 times). The 
proteins bound to the beads were eluted by boiling the beads in 20-30µL 1x SDS 
loading buffer at 100°C for 4 minutes. The (co-)immunoprecipitated proteins were 
detected using Western blotting and immunodetection methods as described above. 
 
4.2.13 Statistical analyses 
All continuous variables were expressed as either as mean ± SEM or medians, 
depending on normality tests based on the Shapiro-Wilk statistic. Statistical analyses 
were performed using GraphPad Prism v5.0 (GraphPad Software, San Diego, CA, 
USA) and Microsoft Excel 2007 (Microsoft, Washington, USA). Data was analysed 
using an unpaired Student‘s t-test (2-tailed) or  Mann-Whitney U-test (2 tailed). 
Statistical significance was set at p<0.05. 
 
4.3 RESULTS 
 
4.3.1 LPS induces PARP-14 expression 
To determine the kinetics and magnitude of PARP-14 induction, WT murine 
macrophages were stimulated with LPS 1µg/mL and PARP-14 mRNA and protein levels  
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were quantified. Figure 4-1a,b shows the in vitro induction of PARP-14, where PARP-14 
mRNA levels peaked at 4 hours, and protein levels peaked at 8 hours following LPS 
stimulation. Figure 4-1b also demonstrates that PARP-14 protein was detectable at 
resting basal conditions. PARP-14 induction was also demonstrated in vivo by 
measuring PARP-14 mRNA and protein levels in the heart, lung and liver specimens 
taken from WT mice in the resting basal state and following LPS stimulation (5µg i.p. for 
4 hours) (figure 4-1c-e). Similar to the in vitro findings, PARP-14 was also detectable at 
resting basal conditions in vivo. 
 
4.3.2 PARP-14 deficiency increases TF expression 
To examine the effect of PARP-14 on TF mRNA expression, WT and Parp14-/- 
macrophages were stimulated with LPS 1µg/mL, and steady state TF mRNA levels 
were determined (figure 4-2a). TF mRNA levels were significantly increased in Parp14-/- 
vs. WT macrophages at 2 hours (13.3±2.9 vs. 5.5±0.5 fold induction, p=0.043); at 4 
hours (10.2±2.1 vs. 4.0±0.8 fold induction, p=0.026); and at 6 hours (11.8±2.4 vs. 
2.7±0.4 fold induction, p=0.013). Whilst there was a trend for the basal TF mRNA levels 
in unstimulated cells to be higher in Parp14-/- macrophages, this was not significant 
(p=0.07). The TF mRNA levels peaked at 2 hours in both WT and Parp14-/- 
macrophages, but followed by a decline in WT macrophages, whilst remaining relatively 
stable in Parp14-/- macrophages.  
 
To examine the effect of PARP-14 on TF protein expression, TF activity was initially 
determined. WT and Parp14-/- macrophages were stimulated with LPS 1µg/mL, and TF 
activity was determined at different time points following LPS stimulation (figure 4-2b). 
TF activity was found to be significantly increased in Parp14-/- vs. WT macrophages in 
unstimulated cells and at every time point following LPS stimulation (all p<0.05). In 
parallel experiments, TF protein was quantified using Western blotting (figures 4-2c,d). 
TF protein levels were significantly increased in Parp14-/- vs. WT macrophages in 
unstimulated cells and at 2, 4, and 6 hours following LPS stimulation (all p<0.05). To 
further validate, the TF protein data, TF protein was measured using flow cytometric 
analysis at 6 hours following LPS stimulation (figures 4-2e-g). TF protein was 
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significantly increased in Parp14-/- vs. WT macrophages in both unstimulated cells 
(3.7±0.1vs. 2.3±0.3, p<0.001) and 6 hours following LPS stimulation (4.6±0.2 vs. 
10.6±0.4, p<0.001). 
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Finally, the effect of increasing LPS concentration on TF mRNA induction was tested 
(figures 4-3a,b). WT and Parp14-/- macrophages were stimulated with LPS 10-11-10-
5g/mL and TF mRNA (2 hours) and TF activity (8 hours) were measured. For every 
respective concentration of LPS, TF mRNA levels were higher in Parp14-/- vs. WT 
macrophages with significant increases at 10-8g/mL (p=0.004), 10-6g/mL (p=0.042) and 
10-5g/mL (p=0.028). Similarly, for every respective concentration of LPS, TF activity 
level was significantly higher in Parp14-/- vs. WT macrophages (all p<0.05). A striking 
observation was that for both TF mRNA and activity levels, the TF response generated 
with 10-5g/L in WT macrophages was comparable to that generated with 10-9g/L in 
Parp14-/- macrophages, despite a 10,000 fold difference in LPS concentration. These 
data provided strong evidence that TF expression is increased in Parp14-/- vs. WT 
macrophages following LPS stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3 PARP-14 deficiency increases TF mRNA stability 
To test whether, the increased TF expression in Parp14-/- macrophages was attributable 
to an effect on mRNA stability, TF mRNA decay profiles were determined in WT and 
Parp14-/- macrophages (figure 4-4a). TF mRNA stability was significantly increased from 
60±5 minutes to 181±11 minutes (p<0.001). Having previously shown that p38 inhibition 
reduces TF mRNA stability, the effect of p38 inhibition was tested in WT and Parp14-/- 
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macrophages (figures 4-4b-d).  p38 inhibition using SB203580 1μM reduced TF mRNA 
stability in WT macrophages, but had no effect in Parp14-/- macrophages (figure 4-4c), 
comparable to that seen in Ttp-/- macrophages (figure 3-7). These data provide 
evidence that the increased TF expression seen in Parp14-/- macrophages, may be 
attributed, at least in part, to increased TF mRNA stability.  
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Given that p38 inhibition had no effect on TF mRNA decay in Parp14-/- cells (resembling 
a Ttp-/- phenotype) the possible explanations for the observed increase in TF mRNA 
stability in Parp14-/- macrophages included (a) TTP expression is reduced in Parp14-/- 
cells (thereby reducing the magnitude of the p38-dependent TTP-mediated mRNA 
degradation), or (b) TTP is unable to interact with TF mRNA in the absence of PARP-
14. Thus, the effect of PARP14 on TTP expression was investigated.  
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WT and Parp14-/- macrophages were stimulated with LPS 1µg/mL, and steady state 
TTP mRNA and protein levels were determined (figures 4-5a-c).  TTP mRNA decay was 
also analyzed at 2 hours following LPS stimulation (figures 4-5d-e). TTP expression was 
found to be significantly increased in Parp14-/- macrophages both at mRNA and protein 
level. Given that no significant differences in TTP mRNA stability were observed, these 
data would imply that this exaggerated TTP response is primarily transcriptional. As 
TTP expression was actually increased in Parp14-/- macrophages, the first of the above 
2 explanations could be refuted. The resemblance of a Ttp-/- phenotype in Parp14-/- 
macrophages despite increased TTP expression, implied that TTP was unable to 
mediate its mRNA destabilizing effect, possibly as a result of failure to interact with TF 
3‘UTR. This was specifically tested below. 
 
4.3.4 PARP-14 deficiency increases TF expression in vivo 
Having demonstrated increased TF expression in the absence of PARP-14 in vitro, the 
effect of PARP-14 on TF expression was examined in vivo, both at resting basal 
conditions and following LPS stimulation (LPS 5μg i.p. for 4 hours). In addition to 
determining TF expression from different organs, TF expression was also analyzed in 
peripheral blood leukocytes to provide a comparison with the effect seen in leukocytes 
in vitro. WT and Parp14-/- mice were sacrificed, citrated venous blood samples were 
taken and organs (heart, lung, aorta, kidney, liver) were harvested. Blood samples were 
processed to yield unfractionated leukocyte fractions and sera.  
 
TF mRNA, protein and activity were quantified for all organ tissues, and TF activity was 
determined for unfractionated leukocytes. There was complete concordance between 
TF mRNA and TF activity levels throughout all organs, with the exception of the heart 
following LPS stimulation (figure 4-6, see comments below). In the lungs (figure 4-7), 
aortae (figure 4-8) and liver (figure 4-9), compared to WT mice, the TF mRNA and 
activity levels were significantly increased both in the basal state and following LPS 
stimulation in the Parp14-/- mice, with a significant induction in TF response following 
LPS stimulation, irrespective of genotype. In the kidneys (figure 4-10), the basal TF 
mRNA and activity levels were similar between WT and Parp14-/- mice, but following 
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LPS stimulation there was significantly greater TF mRNA and activity levels in the 
Parp14-/- mice, again with a significant induction in TF response following LPS 
stimulation, irrespective of genotype. In the heart, compared to WT mice, TF mRNA and 
activity levels were significantly increased in Parp14-/- mice in the resting basal state. 
However, following LPS stimulation, a significant reduction in TF mRNA was observed, 
and the TF activity levels did not change, although still remaining higher in the Parp14-/- 
mice. These anomalous findings for TF expression in the heart following LPS 
stimulation were in keeping with previously reported studies173. Next, TF activity was 
determined for freshly isolated unfractionated leukocytes from unstimulated and LPS 
stimulated mice. Although the magnitude of detectable TF activity in peripheral blood 
leukocytes (which did not contain mcrophages as they had not been allowed to 
differentiate) was lower than that seen in organ homogenates, in keeping with the organ 
data, TF activity was increased in Parp14-/- mice both at resting basal conditions and 
following LPS stimulation (figure 4-11a). Taken together, these data indicated that TF 
expression was increased in Parp14-/- mice. 
 
4.3.5 PARP-14 deficiency leads to accelerated thrombus formation in vivo 
To demonstrate the in vivo significance of increased TF expression in the Parp14-/- 
mice, an in vivo thrombosis model was used. Using intravital microscopy, in the 
cremasteric artery model (a murine model for arteriolar thrombosis), time to complete 
vessel occlusion was determined following ferric chloride vessel injury both in WT and 
Parp14-/- mice at resting basal conditions and following LPS stimulation (LPS 10μg i.p. 
for 4 hours) (figure 4-11b). At basal levels, no detectable difference was observed 
between WT and Parp14-/- mice. In the WT mice, LPS did not result in a significant 
reduction in vessel occlusion time. However, in the Parp14-/- mice, LPS resulted in 
significantly accelerated thrombosis with (a) a significant reduction in vessel occlusion 
time compared to the basal state; and (b) a significant reduction in vessel occlusion time 
compared to LPS-stimulated WT mice. Collectively, these data demonstrate that PARP-
14 deficiency is associated with increased TF expression in vivo and increased 
thrombogenicity in an in vivo model of arteriolar thrombosis. 
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4.3.6 PARP-14 interacts with TF mRNA 
Having demonstrated that PARP regulates TF mRNA stability, it was crucial to establish 
whether, indeed, it interacts with TF mRNA. RNP immunoprecipitation assays were 
performed using a rabbit anti-PARP-14 and rabbit IgG control antibody using lysates 
prepared from LPS-stimulated WT and Parp14-/- macrophages. Following 
immunoprecipitation of the ribonucleoprotein complexes, the mRNA species bound to 
PARP-14 were amplified using TF specific primers. HPRT and GAPDH were also 
amplified using the appropriate primers to control for non-specific pulldown. The PCR 
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products were visualized on a 2% agarose gel with ethidium bromide. Figure 4-12a 
demonstrates that TF transcript was bound to PARP-14, which was not observed with 
the IgG control. Given, that PARP-14 antibody recognizes other non-specific proteins 
(as seen in Western blot in figure 4-12b), the specificity of PARP-14 for TF mRNA was 
demonstrated by the inability to detect TF mRNA when using lysates from Parp14-/- 
macrophages. These data confirmed that PARP-14 associates with TF mRNA in murine 
macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.7 PARP-14 interacts with TF 3’UTR 
Having determined that PARP-14 interacts with TF mRNA, to specifically test whether it 
associates with TF 3‘UTR, an RNA-biotin pulldown assay was used. TF 3‘UTR 
sequences for both mouse and human TF 3‘UTR were cloned and corresponding 
biotinylated sense and anti-sense RNA strands were synthesized using in vitro 
transcription. The anti-sense strand served as an internal control for each reaction. The  
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biotinylated RNA strands were incubated with lysates prepared from LPS-stimulated 
murine macrophages. The biotinylated transcripts were captured using Dynabeads® 
and the associated proteins resolved by Western blotting. Figure 4-13a shows that 
PARP-14 associates with murine TF 3‘UTR in lysates prepared from WT macrophages. 
The experiment was controlled by detecting for tubulin which serves as a marker for 
non-specific binding. The 3‘UTR between mouse and human is highly conserved. In the 
previous chapter, inter-species specificity was shown for TTP-TF 3‘UTR binding. To test 
whether inter-species specificity exists for the PARP-14-TF 3‘UTR interaction, an RNA-
biotin pulldown assay was performed where biotinylated human 3‘UTR sequences were 
incubated with WT murine macrophage lysates. Figure 4-13b  demonstrates that murine 
PARP-14 interacts with human TF 3‘UTR sequence, confirming cross-species 
specificity for PARP-14 and TF 3‘UTR interaction. These data provide evidence that 
PARP-14 interacts specifically with the 3‘UTR of TF. 
 
4.3.8 PARP-14 and TTP form a ternary complex with TF 3’UTR 
Both mouse and human TF 3‘UTR contain 4 conserved ARE segments. Using 
truncations and mutational analyses of the murine TF 3‘UTR sequence, TTP was found 
to associate with the final palindromic ARE (AUAAUUUAUUUAAUA), within which 2 
overlapping nonamers (AUUUAUUUA and UUAUUUAAU) were found to be functional 
in mediating TTP binding. Using a similar strategy, the specific binding of PARP-14 to 
the TF 3‘UTR was investigated. RNA-biotin pulldown assays were performed with both 
sense and anti-sense RNA strands corresponding to the WT TF 3‘UTR, truncated and 
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mutant sequences. Lysates were prepared from LPS-stimulated WT murine 
macrophages. PARP-14 binding to the TF 3‘UTR was found to mirror the binding as 
observed with TTP. Figure 4-14b shows that both PARP-14 and TTP associate only 
with transcripts that contains the final ARE. Next, focusing on the final palindromic ARE 
sequence, PARP-14 binding appeared to bind in a similar pattern to TTP, where PARP-
14 binding was not affected by mutations within the palindromic sequence as long as 
the nonameric sequences were preserved. Mutations of each of the separate nonamers 
reduced, but did not abolish, PARP-14 binding, but mutations of both nonamers 
completely abolished PARP-14 binding (figure 4-15a). This was further confirmed using 
a competition RNA-biotin pulldown assay, where the addition of the cold WT transcripts 
significantly reduced PARP-14 binding to the biotinylated transcripts captured by the 
beads. However, the cold mutant transcripts did not affect binding. These data provided 
evidence that the 2 nonameric sequences within the final palindromic ARE in TF 3‘UTR 
mediate PARP-14 interaction in a cooperative fashion (figure 4-15b).  
 
Given that both PARP-14 and TTP bind the same ARE segment of TF 3‘UTR, the inter-
dependency for this interaction was next investigated. RNA-biotin pull down assays 
were performed in LPS-stimulated lysates from WT, Parp14-/- and Ttp-/- macrophages. 
The lysates from the Parp14-/- and Ttp-/- macrophages provide an important 
experimental tool to investigate protein-RNA binding in the absence of specific proteins, 
PARP-14 and TTP respectively. Figure 4-16a shows that in the absence of PARP-14, 
TTP does not bind to the TF 3‘UTR. Similarly, in the absence of TTP, PARP-14 binding 
is significantly reduced. These data demonstrate an inter-dependency for both proteins 
to bind TF 3‘UTR. Next, the specific role for RNA in mediating this interaction was 
investigated. Co-immunoprecipitation studies were performed, where TTP was 
immunoprecipitated using a goat anti-TTP antibody and goat IgG control. Figure 4-16b 
shows that following immunoprecipitation of TTP, PARP-14 could also be co-
immunoprecipitated. However, treatment of the lysates with RNase resulted in the loss 
of PARP-14 in the immunoprecipitate. These data indicate that PARP-14 and TTP form 
a ternary complex with RNA, where TTP, PARP-14 and RNA are all necessary 
components for this complex. 
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4.3.9 PARP-14 enzymatic activity reduces TF mRNA stability 
Given that PARP-14 is necessary for TTP binding to the TF 3‘UTR and mediating 
mRNA decay, the specific role for the PARP enzymatic activity of PARP-14 and its 
relevance to the post-transcriptional regulation of TF mRNA was investigated. TF 
mRNA decay profiles were determined in WT and Parp14-/- macrophages, both in the 
presence and absence of 2 specific PARP inhibitors, PJ34 10μM and 3AB 1mM (figures 
4-17a-c). Parallel experiments were also conducted in WT macrophages where the 
combined effect of both PARP and p38 inhibition was tested using PJ34 10 μM and  
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SB203580 1 μM. Macrophages were stimulated with LPS 1μg/mL and TF mRNA decay 
was determined at 2 hours. The TF mRNA half-life in WT macrophages was 65±12 
minutes, and PARP inhibition using the 2 different compounds resulted in a significant 
reduction in TF mRNA stability (t½=22±7 minutes (p=0.018) and 24±6 minutes 
(p=0.041) for PJ34 and 3AB respectively). This effect was comparable to that achieved 
with p38 inhibition (t½=18±5 minutes; p=0.454 compared to PJ34; and p=0.305 
compared to 3AB). In the Parp14-/- macrophages, PARP inhibition did not have any 
significant effect on TF mRNA stability. Similarly, the effect of PARP inhibition on TF 
mRNA stability was also tested in primary human monocytes (figures 4-17d,e). 
Analogous to the findings in murine macrophages, PARP inhibition with PJ34 10μM 
resulted in a significant reduction in TF mRNA stability (t½=76±9 minutes vs. 166±26 
minutes, PJ34 vs. control, p=0.017). However, the effect of p38 inhibition was greater in 
human monocytes (t½=43±7 minutes; p=0.008 compared to control; p=0.022 compared 
to PJ34). Furthermore, combined p38 and PARP inhibition had no additive destabilizing 
effect. Taken together these data provide preliminary evidence for the importance of the 
enzymatic activity of PARP-14, and particularly, the role for ADP-ribosylation in the 
regulation of TF mRNA stability. 
 
The effect of PARP inhibitors on TF mRNA stability was further characterized. To 
account for the observation that PARP inhibition results in increased TF mRNA decay, 
one may propose that PARP inhibition may result in either (a) reduced phospho-p38 
levels (which may then promote TTP-mediated TF mRNA decay); (b) alter the binding of 
TTP and/or PAPR-14 to TF 3‘UTR; or (c) inhibit ADP-ribosylation of TTP, PARP-14 or 
other candidate protein which may ultimately increase TF mRNA decay. The first of 
these hypotheses was tested using western blotting analyses of total and phospho-p38 
levels in WT and Parp14-/- macrophages following LPS stimulation. As shown in figure 
4-18a, there were no significant differences in phospho-p38 levels following LPS 
stimulation (1µg/mL) in WT and Parp14-/- macrophages, indicating PARP-14 in unlikely 
to affect p38 activity. To specifically examine the role of PARP inhibition on p38 activity, 
western blotting analyses of total and phospho-p38 levels in WT macrophages was 
conducted following LPS stimulation (1µg/mL), where cells were stimulated with LPS for 
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2 hours, and in certain arms of the experiment p38 and PARP inhibition was achieved 
using SB203580 1µM and PJ34 10µM. These inhibitors were added 15 minutes prior to 
protein lysate preparation, following which total and phospho-p38 levels were 
determined using western blotting analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in figure 4-18b, whilst p38 inhibition with SB203580 resulted in a significant 
reduction in phospho-p38 levels, PARP inhibition did not have an effect. To test the 
second of the above hypotheses, and to assess whether or not PARP inhibition altered 
TTP and/or PARP-14 binding to TF 3‘UTR,  RNA-biotin pulldown assays were used. In 
these experiments, the preparation of the lysates was critical. WT murine macrophages 
were cultured with LPS for 105 minutes, and then PJ34 was added to the PARP 
inhibitor arm of the experiment, with vehicle control to the control arm of the experiment.  
 
 
174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cells were then allowed to incubate for a further 15 minutes prior to preparation of 
lysates. Using these lysates PARP-14 and TTP binding to TF 3‘UTR was assessed with 
RNA-biotin pulldown assays. Figure 4-19 shows PARP inhibition had no effect on TTP 
and/or PARP-14 binding to TF 3‘UTR. Collectively these data show that PARP-14 and 
PARP inhibition do not affect p38 activity and, more specifically, PARP inhibition does 
not alter TTP and PARP-14 binding to TF 3‘UTR. These data also indicate that PARP 
inhibition is likely to affect the ADP-ribosylation of a candidate protein which ultimately 
results in increased TF mRNA decay. The identification of the candidate protein(s) and 
the nature of this post-translational modification is beyond the scope of the current 
investigation and remain the focus of ongoing work. 
 
4.3.10 PARP-14 deficiency does not affect TNFα expression 
Having established an inter-dependency of for both PARP-14 and TTP in TTP-mediated 
TF mRNA decay, the next question was if this would be applicable to other TTP-
regulated genes. An important established target for TTP is TNFα. Most of our 
understanding on TTP function emerges from studies that have used TNFα as the 
model transcript426. Therefore, the role of PARP-14 in TNFα expression was 
investigated. 
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WT and Parp14-/- macrophages were stimulated with LPS 1µg/mL, and steady state 
TNFα mRNA levels were determined (figure 4-20a). This demonstrated that the TNFα 
mRNA levels were similar between WT and Parp14-/- macrophages. The effect of 
increasing LPS concentration (10-11-10-5g/mL) on TNFα mRNA induction was also 
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tested (figure 4-20b), where TNFα mRNA levels were determined at 2 hours following 
LPS stimulation. Again, this demonstrated no difference in TNFα mRNA levels 
throughout all concentrations of LPS. Furthermore, examination of TNFα mRNA decay 
curves at 2 hours following LPS stimulation in WT vs. Parp14-/- macrophages found no 
significant differences in TNFα mRNA half-lives (t½=18±3 vs. 23±3, p=0.281) (figures 4-
20c,d). Next, TNFα protein levels in culture supernatants taken from LPS-stimulated WT 
and Parp-14-/- macrophages were analysed by ELISA, and this demonstrated no 
significant differences between TNFα protein levels (figure 4-20e).  
 
p38 inhibition was found to destabilise TF mRNA in WT, but not Parp14-/- macrophages. 
Although TNFα is a TTP-regulated transcript, it does not behave in a similar manner to 
TF, as shown in figure 4-21 where p38 inhibition appears to destabilise TNFα mRNA in 
both WT and Parp14-/- macrophages, with a comparable effect in both cells. Taken 
together, these in vitro data demonstrated no significant difference in TNFα expression 
between WT and Parp14-/- macrophages both at mRNA and protein level.  
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Next, the effect of PARP-14 on TNFα expression was determined in vivo, both at resting 
basal conditions and following LPS stimulation (LPS 5μg i.p. for 4 hours). Analysis of 
TNFα mRNA levels from heart, lung, aorta and kidney demonstrated no significant 
difference between WT vs. Parp14-/- mice both at resting basal conditions and following 
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LPS, although a significant induction in TNFα mRNA was observed in all organs 
following LPS stimulation (figures 4-22a-d). Similarly, analysis of sera taken from WT 
vs. Parp14-/- mice showed no significant difference at resting basal conditions and 
following LPS stimulation (figure 4-22e). These in vitro and in vivo findings provided 
strong evidence that PARP-14 does not affect TNFα expression. 
 
The effect of PARP inhibition on TNFα mRNA stability was also examined. TNFα mRNA 
decay profiles were determined in WT macrophages, both in the presence and absence 
of PJ34 10μM. Parallel experiments were conducted where the combined effect of both 
PARP and p38 inhibition was tested using PJ34 10 μM and SB203580 1 μM. 
Macrophages were stimulated with LPS 1μg/mL and TNFα mRNA decay determined at 
2 hours. The TNFα mRNA half-life in these set of experiments was 18±4 minutes, with a 
significant reduction in TNFα mRNA stability with p38 inhibition (t½=6±1 minutes, 
p=0.02). PARP inhibition did not affect TNFα mRNA stability (t½=18±4 minutes, 
p=0.999) and had no effect when used in combination with p38 inhibition (t½=9±3 
minutes, p=0.339).  
 
These findings were further validated in primary human monocytes. Similar to the 
findings in murine macrophages, PARP inhibition with PJ34 10μM did not result in a 
significant difference in TNFα mRNA stability (t½=39±11 minutes vs. 35±7 minutes, 
control vs. PJ34, p=0.727). p38 inhibition resulted in a significant reduction in TNFα 
mRNA stability (t½=39±11 minutes, p=0.031), whilst combined p38 and PARP inhibition 
had no additive destabilizing effect (t½=9±1 minutes, p=0.556). Collectively, these data 
indicate that whilst TNFα is a TTP-regulated transcript, the presence or absence of 
PARP-14 does not affect TNFα regulation in a similar pattern to TF with no observed 
differences in steady state TNFα mRNA levels; TNFα mRNA decay; and TNFα protein 
levels. Furthermore, PARP inhibition appears to have no effect on TNFα mRNA stability. 
 
Finally, whether or not PARP-14 binds TNFα mRNA was assessed using RNP 
immunoprecipitation assays. Lysates were prepared from WT, Ttp-/- and Parp14-/- 
macrophages treated with LPS (1µg/mL) for 2 hours. RNP immunoprecipitation assays  
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were performed using anti-TTP, anti-PARP-14 and rabbit IgG control antibodies (figure 
4-23e). This demonstrated 2 key findings, (a) PARP-14 does not bind TNFα mRNA but 
binds TF mRNA in only in the presence of TTP; and (b) TTP binds TNFα mRNA both in 
the presence and absence of PARP-14,. This confirms the earlier findings of 
cooperative binding for TTP and PARP-14 as shown using the RNA-biotin pulldown 
assays (figure 4-16a), but further demonstrates how the TTP-PARP-14 interaction may 
provide a means for the differential regulation of TTP-regulated transcripts. 
 
4.4 DISCUSSION 
 
The above data builds upon the findings from Chapter  3, where TTP was found to post-
transcriptionally regulate TF expression. In this chapter, a specific role for PARP-14 and 
ADP ribosylation is demonstrated in TTP-mediated TF mRNA decay. In particular, these 
data have identified what may be a fundamental mechanism by which mRNA stability is 
subject to differential regulation in inflammatory processes, as neither PARP-14 
deficiency nor PARP inhibition appeared to affect TTP-mediated TNFα mRNA decay. 
This is the first time that an ADP-ribosyl monotransferase has been shown to regulate 
mRNA stability under physiological conditions.  
 
Experiments conducted in WT and Parp14-/- macrophages demonstrated that a 
deficiency of PARP-14 resulted in increased TF mRNA, TF protein and TF activity 
following LPS stimulation. The increased expression of TF mRNA, TF protein and 
procoagulant activity in Parp14-/- macrophages following LPS stimulation was paralleled 
by increases in TF mRNA, TF protein and TF activity in organs extracted from Parp14-/- 
mice, suggesting PARP-14 serves to set an appropriate level of TF expression. 
Obviously the organ extracts studied comprised a mixed population of cell types with 
different basal levels of TF expression and different responses to LPS, which no doubt 
accounts for the variability between tissues in TF levels. However, the increased TF 
activity in circulating peripheral blood leukocytes in Parp14-/- mice clearly demonstrates 
the importance of the in vitro observations for leukocyte biology in vivo.  Monocytes are 
the main source of TF amongst circulating leukocytes427, but whether the difference 
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observed between WT and Parp14-/-  leukocytes in procoagulant activity was solely due 
to monocyte TF expression remains to be determined. The paradoxical reduction in TF 
expression in the heart following LPS stimulation has previously been observed173, but 
remains unexplained. One can speculate that mechanisms have evolved to protect the 
heart from enhanced thrombogenicity from endotoxaemia during infections. Further 
work is needed to establish the differential roles of PARP-14 in TF expression in cells 
other than monocyte-macrophages, and indeed whether there are differences in this 
respect between monocyte and macrophage subsets. The functional significance of 
increased TF expression in Parp14-/- mice was supported by intravital microscopy 
experiments showing accelerated thrombosis in vivo as demonstrated by significant 
reduction in vessel occlusion time in cremaster muscle arterioles following ferric chloride 
injury. However, a significant reduction in occlusion time in WT mice following LPS 
challenge was not demonstrated, possibly because of a suboptimal LPS stimulus. 
Nevertheless, occlusion time was significantly faster in Parp14-/- mice after LPS 
treatment, compared both to that in unstimulated Parp14-/- mice and in LPS-stimulated 
WT mice.  
 
The mechanism by which Parp14-/- mice show increased TF expression came from 
mRNA decay experiments which demonstrated increased TF mRNA stability in Parp14-/- 
macrophages treated with LPS. Subsequent RNP immunoprecipitation and RNA-biotin 
pulldown assays demonstrated PARP-14 to associate with TF mRNA and specifically 
with the TF 3‘UTR. An interesting finding from RNA-biotin pulldown assays conducted 
using cellular extracts from WT, Parp14-/- and Ttp-/- macrophages was that whilst in WT 
cells both PARP-14 and TTP associate with TF 3‘UTR, in Parp14-/- cells TTP did not 
associate with TF 3‘UTR and similarly in Ttp-/- cells, PARP-14 binding to TF 3‘UTR was 
significantly reduced. This indicated that both proteins appear to bind, somewhat,  in a 
cooperative fashion. This cooperative binding was further demonstrated using RNP 
immunoprecipitation assays, where anti-TTP antibody was not able to pull down any 
detectable TF mRNA in Parp14-/- cells and anti-PARP14 antibody was not able to pull 
down any detectable TF mRNA in Ttp-/- cells. Further RNA-biotin pull down assays 
demonstrated TTP and PARP-14 to bind the 3‘UTR segment which contained the final 
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ARE in TF 3‘UTR. Focusing mutational analyses on the final palindromic ARE, RNA-
biotin pull down assays incorporating WT or mutant AREs demonstrated that this 
binding was specifically mediated by 2 overlapping nonamer sequences (AUUUAUUUA 
and UUAUUUAAU) which appear to mediate binding to both TTP and PARP-14 in a 
cooperative manner, such that mutating either one of these nonamers reduced binding, 
but mutating both sequences by disrupting the central UUU abolished binding for both 
proteins. These data would indicate that TTP and PARP14 appear to form a ternary 
complex with TF mRNA. Subsequent co-immunoprecipitation assays demonstrated that 
TF mRNA is important for this interaction, as PARP-14 was pulled down along with TTP 
from WT LPS-stimulated cellular lysates using the anti-TTP antibody. However, 
treatment of the lysate with RNase to remove any mRNA resulted in loss of PARP-14 
from the pulled down complex.  This indicated that PARP-14 and TTP are 
interdependent for binding TF mRNA, with which they appear to form a ternary complex. 
TTP is known to bind RNA via the centrally placed two ZFs which coordinate Zn in a 
disc-like structure428-430. Furthermore, PARP-14 is likely to bind RNA via its N-terminal 
RNA recognition motif (RRM)431. Although the above data indicate that the two proteins 
require the central UUU in the conserved ARE, the precise binding sites of the individual 
proteins within or around the ARE and their means of interacting requires further 
analysis.  
 
Using two separate inhibitors of PARP domain function (PJ34 and 3AB), mRNA decay 
experiments in the presence of these compounds demonstrated that TF mRNA stability 
is also regulated by ADP-ribosylation, consistent with an effect of PARP-14-mediated 
ADP-ribosyl monotransferase activity. Interestingly, the destabilizing effect on TF mRNA 
was comparable to that seen with p38 inhibition, and the combination of both p38 and 
PARP inhibition did not appear to have any additive effect. However, as there are 
currently no available PARP inhibitors specific for PARP-14, one cannot exclude the 
possibility that other proteins capable of generating ADP-ribose monomers or polymers 
might be involved. Nevertheless, whilst a direct role for PARP-14 catalytic function in 
the system may be implicated by the failure of PARP inhibitors to destabilise TF mRNA 
in Parp14-/- macrophages, it is also important to remember that this is difficult to 
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interpret, as in the absence of PARP-14, TTP does not bind to TF 3‘UTR, so thus 
irrespective of ADP ribosylation status there will be no TTP-mediated TF mRNA decay. 
RNA-biotin pull down assay confirmed that PARP inhibition did not affect the interaction 
of PARP-14 and TTP with the TF 3‘UTR. Furthermore, PARP inhibition did not alter the 
phosphorylation status and thus p38 activity. These results suggest that ADP-
ribosylation is likely to alter the function of TTP, PAPR-14 or other unknown candidate 
protein within the mRNA decay complex. Irrespective of the precise molecular target for 
ADP-ribosylation, these data certainly suggest that inhibition of ADP-ribosylation 
provides a pharmacological means to increase TF mRNA degradation. ADP-ribosylation 
provides a post-translational modification in which negatively charged ADP-ribose 
moieties are adducted onto acceptor proteins367. The identity and site of the protein 
target(s) of ADP-ribosylation in this system now requires further study, as does 
establishing how this affects TTP function.  
  
TNFα mRNA is a well-established TTP target, and TNFα mRNA stability is regulated via 
the p38 MAPK pathway320, 426.  Ttp-/- mice spontaneously develop a chronic 
inflammatory state that can be prevented by administration of anti-TNFα antibodies313. 
In contrast, Parp14-/- mice are apparently healthy and neither PARP-14 deficiency nor 
PARP inhibition altered TNFα expression.  TNFα mRNA half-life was unaffected in the 
absence of PARP-14. Furthermore, as TNFα transcripts were pulled down in a RNP 
immunoprecipitation assay from WT or Parp14-/- cells by anti-TTP but not by anti-PARP-
14 antibodies, it seems unlikely that PARP-14 has a role in TTP binding to TNFα 3‘UTR 
mRNA. Similarly, TTP is also a subject to post-transcriptional regulation by itself, and 
TTP mRNA half-life was unaffected in the absence of PARP-14. Taken together, these 
data indicate that PARP-14-TTP interaction is not applicable to all TTP-regulated 
transcripts, and provides compelling evidence for how PARP-14 serves to differentially 
regulate TTP-regulated transcripts. 
 
In conclusion, these data demonstrate novel interactions between PARP-14, a new 
protein in post-transcriptional regulation, and TTP, an established protein regulator of 
mRNA stability, and present evidence that PARP-14 allows the actions of TTP to be 
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selectively regulated. Thus, whilst the focus has remained on the regulation of TF 
mRNA turnover, the above findings have significantly wider implications for post-
transcriptional regulatory biology in general and TTP-mediated mRNA decay in 
particular. 
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Chapter 5 
 
Results: 
Glucocorticoids regulate TF mRNA stability 
via TTP-dependent and TTP-independent 
pathways 
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5.1 INTRODUCTION 
In chapter 3, the role for TTP in the post-transcriptional regulation of TF expression was 
presented. TTP exists in two forms: dephosphorylated (active) and phosphorylated 
(inactive). In the dephosphorylated state, TTP binds to the ARE and promotes rapid 
degradation of the mRNA. However, phosphorylation of TTP, at Ser52 and Ser178, leads 
to binding of 14-3-3 adaptor proteins that reduce its mRNA destabilizing activity. The 
phosphatase PP2A competes with 14-3-3 proteins and dephosphorylates TTP. Thus the 
proportion of TTP in the phosphorylated and dephosphorylated form remains in 
equilibrium, and the disruption of this equilibrium, through either increased or decreased 
phosphorylation, is believed to affect the overall activity of TTP.  
 
The p38 signaling pathway is one of the three MAPK pathways that affect gene 
expression346. LPS results in phosphorylation and activation of p38432, and this 
mediates both transcriptional and post-transcriptional effects433. The p38 pathway 
confers mRNA stability by activating MAPKAPK-2 that subsequently phosphorylates 
and inactivates TTP (the primary target for MAPKAPK-2)363. The activity of p38 is 
negatively regulated by a large family of phosphatases, of which MAPK phosphatase 1 
or dual specificity phosphatase 1 (DUSP1) is the founding member. DUSP1 
dephosphorylates and inactivates MAPKs, and most of its effects are mediated via the 
inhibition of p38 activity360, 361, 434.  
 
GCs induce a rapid and sustained expression of DUSP1 in many cell types, resulting in 
p38 inactivation and mRNA destabilization435. GC-induced DUSP1 expression 
represents an important anti-inflammatory mechanism. Studies using TTP-specific 
siRNAs and Ttp-/- cells have shown that TTP plays an important role in the anti-
inflammatory actions of GCs436, 437. LPS upregulates TTP expression438-440 and at the 
same time increases p38 activity432. Whilst, increased p38 signaling further increases 
TTP expression441, at the same time it phosphorylates and inactivates it. Thus, following 
LPS stimulation, the net result is that TTP is predominantly in an inactive state, thereby 
promoting mRNA stability as part of the acute inflammatory response. The effect of 
dexamethasone (Dex) on TTP expression in LPS-stimulated cells has been  variably 
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reported, but is likely to depend on the different cells types studied439, 440. Nevertheless, 
it is important to remember, that whilst LPS ± Dex treatment may result in changes in 
total TTP protein level, it is the net proportion of the active and inactive forms that is 
likely to affect TTP function, and current evidence indicates that Dex treatment 
increases the proportion of the active (dephosphorylated) form of TTP. 
 
Current data on the effect of GCs on human monocyte procoagulant activity are 
ambiguous442-444. Muhlfelder and colleagues demonstrated that methylprednisolone 
reduced procoagulant activity of LPS-stimulated PBMCs442. Bottles and colleagues 
demonstrated that Dex enhanced LPS induction of TF in THP-1 cells and PBMCs, when 
co-stimulated with LPS and Dex, and that this was not a result of increased mRNA 
stability, implicating increased gene transcription to play a role443. Interestingly, pre-
treatment with Dex for 24 hours prior to LPS stimulation, resulted in a reduction in LPS-
induced TF response. Reddy and colleagues demonstrated that Dex enhanced LPS 
induction of TF in THP-1 cells, when pre-incubated with Dex for 30 minutes prior to LPS 
stimulation. They demonstrated that Dex inhibited TF gene transcription, but increased 
mRNA stability, with an overall increase in TF expression444. Thus there remains some 
controversy over the effect of GCs on TF regulation in monocytes, and it is likely that 
experimental conditions, particularly the use of primary human monocytes versus 
unfractionated PBMCs445, 446 or THP-1 cells422, and timing of LPS and GC exposure are 
crucial. 
 
This chapter builds upon the observation that p38 inhibition reduces TF mRNA stability 
via the p38-TTP axis. Given that GCs are potent inhibitors of p38 activity and function, 
the effect of GCs on TF mRNA stability is investigated. 
 
5.2 METHODS 
 
5.2.1 Primary human monocyte isolation and culture 
Monocytes were isolated from citrated venous blood derived from healthy donors. 
PBMCs were isolated from the cell fraction by Ficoll–Paque density-gradient 
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centrifugation. In experiments where PBMCs were used, the buffy layer was carefully 
taken, and PBMCs pelleted and washed with PBS twice, before being resuspended in 
culture medium. In experiments where monocytes were used, CD14+ monocytes were 
separated from the PBMC fraction using magnetic separation with CD14 MicroBeads 
and MACS Separator column.  Monocytes were plated into tissue culture plates 
according to the experimental protocol in IMDM with 10% FCS (25x104 cells/well in 24 
well plates or 2x104/well in 96-well plates) and incubated overnight in a 37°C incubator 
with 5% CO2 atmosphere, for experiments the following day.  
 
5.2.2 Bone marrow-derived macrophage (BMDM) isolation and culture 
WT and Ttp-/- mice were sacrificed using cervical dislocation. Bone marrow cells were 
flushed from the femur and tibia and cultured in bone marrow culture medium for 6 
days. On day 6, the cells were harvested, resuspended in the bone marrow culture 
medium, and plated in culture dishes/flasks as per the experimental protocol (25x104 
cells/well in 24 well plates or 1x107cells/T75 flask) and incubated overnight in a 37°C 
incubator, for experiments the following day. 
 
5.2.3 Glucocorticoid treatment 
Dex was the primary GC used in the experiments. The concentrations used in the 
experiment below were 10-11-10-6M. A water-soluble preparation was used which 
necessitated the addition of an equivalent volume of water as vehicle control. 
 
5.2.4 TF activity assays 
A turbimetric clot assay was used to determine TF activity. Cells were cultured in 96 
well plates (cell density=2x104 cells per well) and treated with LPS 1µg/mL. Dex 1-
1000nm was added in certain experiments. The supernatant was removed and cells 
were washed with PBS twice, prior to the addition of plasma. 100 μL of the citrated PPP 
was added to the wells and recalcified with 2 μL of 1.0M CaCl2 to initiate clotting. Clot 
turbidity was measured by absorbance (A405) every minute for 60 minutes in a 
spectrophotometer with internal thermostatic control at 37°C. The turbimetric curves 
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were modeled mathematically and detailed turbimetric analyses were conducted where 
Tlag, Vmax, ABSmax, TVmax and TABSmax were measured. 
 
5.2.5 RNA extraction and quantitative reverse-transcriptase PCR (qRT-PCR) 
RNA was isolated from cells using RNEasy Mini kit incorporating an on-column DNase 
digestion. 1µg of total RNA was used for cDNA synthesis using SuperScript III reverse 
transcriptase enzyme. Comparative qRT-PCR was performed using SYBR green and 
gene specific primers (table 2-1). Data was normalized to 2 housekeeping controls, 
GAPDH and HPRT. For mouse TF mRNA expression, data was validated using 2 
primer sets. Relative gene expression was calculated using the ΔΔCt method409. 
 
5.2.6 mRNA decay experiments 
All mRNA decay experiments were performed with an identical protocol. Cells were 
stimulated with LPS 1µg/mL. Actinomycin D (5µg/mL) was added at 2 hours following 
LPS stimulation to induce transcriptional arrest. For p38 inhibition, SB203580 and 
SB202190 were used. In experiments specifically examining the effect of these 
inhibitors on mRNA decay, the inhibitors were all added at the time of actinomycin D.  In 
experiments examining the effect of Dex on mRNA stability, Dex was added 30 minutes 
after LPS stimulation. Unlike the SB compounds, the effect of Dex is not immediate, and 
requires induction of anti-inflammatory mediators. On the other hand, adding Dex too 
early would dampen the TF transcriptional response following LPS stimulation. As a 
compromise between dampening the initial TF response and allowing sufficient time for 
induction of anti-inflammatory mediators specifically to examine the effect on mRNA 
decay, Dex was added 30 minutes after LPS stimulation, and actinomycin D added 2 
hours after LPS stimulation. Following actinomycin D, RNA was isolated at time 0, 15, 
30, 60 and 90 minutes. mRNA was quantified using qRT-PCR, and levels were 
normalized to levels at time 0. The mRNA decay profiles were modelled mathematically 
using non-linear regression analysis and mRNA half-lives calculated. It would be 
expected that the starting levels of TF mRNA in the Dex arm of the decay experiments 
would be lower than the control counterparts. However, normalization of TF mRNA 
levels in each arm to that at their respective time 0 would overcome this problem. 
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5.2.7 Flow cytometric analysis of TF 
The supernatant culture medium was removed and cells washed twice in cold PBS. For 
detection of surface human TF expression, the cells were incubated with FITC-
conjugated TF or FITC-conjugated isotype control antibodies for 30 minutes at 4ºC. The 
cells were washed with cold PBS and resuspended in 500µL cold PBS and subjected to 
flow cytometric analysis. The cells were read on a Coulter EpicsXL flow cytometer, 
FL1–600V, FL2–600V. The maximum event count was set at 10,000. Data were 
analyzed and presented using WinMDI software (Scripps Research Institute, CA).. 
 
5.2.8 Western blotting analysis 
Following the experimental protocol, the cells were lysed with 100µL of Cell Lytic M lysis 
buffer with 1µL of protease inhibitor cocktail. The lysates were centrifuged at 17,000g 
for 20 minutes at 4ºC to pellet cell debris. The supernatants were carefully removed and 
stored at -80ºC until analysis. A Novex XCell II mini gel system was used. 20µg of 
protein was used per lane, and proteins were separated by gel electrophoresis using 
pre-cast polyacrylamide gels, and electrotransferred to polyvinylidene difluoride 
membranes. The membranes were blocked using blocking buffer and primary and 
secondary antibodies were applied in blocking buffer at the appropriate dilutions (table 
2-3). Protein bands were detected using chemiluminescence. Protein quantification was 
performed using densitometry using ImageJ software (National Institutes of Health, 
Bethesda, Maryland, USA) normalized to tubulin.  
 
5.2.9 Statistical analyses 
All continuous variables were expressed as either as mean ± SEM or medians, 
depending on normality tests based on the Shapiro-Wilk statistic. Statistical analyses 
were performed using GraphPad Prism v5.0 (GraphPad Software, San Diego, CA, 
USA) and Microsoft Excel 2007 (Microsoft, Washington, USA). Where data was 
expressed as mean ± SEM, the unpaired Student‘s t-test (2-tailed) was used for 
comparison. Where the data was expressed as medians the Mann-Whitney U-test (2 
tailed) was used. Statistical significance was set at p<0.05. 
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5.3 RESULTS 
 
5.3.1 Dex reduces monocyte procoagulant activity using clot turbimetric analyses 
A detailed analysis of the effect of Dex on procoagulant activity of primary human 
monocytes was conducted using clot turbimetric parameters. The effect of Dex 100nM 
was first investigated in unstimulated primary human monocytes. LPS is known to 
enhance monocyte thrombogenicity by increasing TF expression40, whilst IL-10 has 
been shown to reduce thrombogenicity by reducing TF expression73 and increasing 
TFPI expression72,73. Thus both LPS (10ng/mL) and IL-10 (0.5nM) served as important 
controls for these experiments. Monocytes were cultured with these modulating agents 
for 24 hours and clot turbimetric profiles determined. The turbimetric curves were 
modelled mathematically and detailed turbimetric analyses were conducted where Tlag, 
Vmax, ABSmax, TVmax and TABSmax were analysed. Figure 5-1 shows that LPS enhances 
and IL-10 reduces monocyte procoagulant activity (as expected). Furthermore, Dex 
reduced procoagulant activity in unstimulated primary human monocytes with 
statistically significant effects on clot turbimetric parameters with an increase in Tlag 
(13.2min vs. 9.1min, p=0.019); decrease in Vmax (0.03Au/min vs. 0.09Au/min, p=0.049); 
and decrease in ABSmax (0.85Au vs. 1.08Au, p=0.004). A summary of all statistically 
significant changes in turbimetric parameters is shown in figure 5-1g. 
 
Next, the effect of Dex on monocyte procoagulant activity in LPS-stimulated primary 
human monocytes was investigated. Previous published data on GCs on LPS-induced 
procoagulant activity are ambiguous, and this may reflect the timing of GC treatment 
with respect to LPS-stimulation. Most of the published data used pre-treatment with 
GCs following which LPS was added. From a therapeutic perspective, if Dex were to 
reduce procoagulant activity in the context of atherothrombosis or any other 
inflammatory state, it should do so with cells that are already activated. Given this, Dex 
was administered after LPS stimulation. Monocytes were stimulated with LPS (1µg/mL) 
or control for 30 minutes prior to the addition of Dex 100nM or control. Monocytes were 
cultured with these modulating agents for 24 hours and clot turbimetric profiles were 
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determined. Figure 5-2 shows that Dex reduced procoagulant activity of both 
unstimulated and LPS stimulated monocytes with statistically significant effects on clot 
turbimetric parameters (increase in Tlag; decrease in Vmax; and decrease in ABSmax). 
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Finally, the effect of the Dex concentration on procoagulant activity was investigated in 
both unstimulated and LPS-stimulated primary human monocytes. Primary human 
monocytes were cultured with either vehicle control or LPS 1µg/mL, and Dex was added 
after 30 minutes. Turbimetric profiles were established at 24 hours following LPS 
stimulation. Figure 5-3 shows the effects of different concentrations of Dex on clot 
turbimetric parameters in both unstimulated and LPS stimulated monocytes. The 
turbimetric parameters chosen for this anlaysis were Tlag, Vmax, ABSmax. Through a 
range of Dex concentrations (10-10M to 10-6M), Dex was associated with a 
concentration-dependent increase in Tlag; decrease in Vmax and decrease in ABSmax in 
both unstimulated and LPS-stimulated monocytes. 
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Based on the turbimetric analyses, these data provide consistent evidence that Dex 
reduces procoagulant activity of both unstimulated and LPS-stimulated primary human 
monocytes. 
 
5.3.2 Dex reduces LPS-induced TF expression 
Having established that Dex reduces monocyte procoagulant activity, the role of Dex on 
TF expression was next investigated. TF expression was assessed using flow 
cytometric analyses (figure 5-4). Primary human monocytes were cultured with either 
vehicle control or LPS 1µg/mL. After 30 minutes, they were either treated with vehicle 
control or Dex 100nM. After 24 hours, TF protein expression was analyzed using a flow 
cytometric assay. TF mean fluorescence intensities (MFI) normalised to MFI of isotype 
control to yield relative MFI (RLMFI). The representative histograms and associated 
RLMFI values show that in unstimulated monocytes there was very little, if any, TF 
expressed, and treatment with Dex had no effect on TF expression (RLMFI Dex vs. 
Control, 1.38 vs. 1.33, p=0.788) . Given that Dex reduces procoagulant activity in the 
turbimetric clot assay, these results have the following explanations: (a) The levels of 
TF present in unstimulated monocytes are very low and the effect of Dex on these low 
levels of TF cannot be detected using flow cytometry; or (b) Dex may be modulating TF-
independent pathways of coagulation. The former explanation is unlikely, as shown later 
with western blotting, that there is no detectable TF protein in unstimulated monocytes, 
corroborating previous published findings84. The TF-independent pathways, particularly 
in the setting of unstimulated monocytes, raise interesting questions, but are beyond the 
scope of this investigation. LPS is a strong stimulus for TF expression, and following 
LPS stimulation, there was a significant increase in TF expression. However, in LPS-
stimulated monocytes, treatment with Dex resulted in a significant reduction in TF 
expression (RLMFI Dex vs. Control, 2.34 vs. 3.30, p<0.001). The remainder of this 
chapter will focus on the effect of Dex on TF expression in LPS-stimulated monocyte-
macrophages. 
 
Next, the effect of Dex concentration on TF expression in LPS-stimulated monocytes 
was investigated. In the above data, procoagulant activity and TF expression has been 
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evaluated at 24 hours. The effect of Dex was next examined at an earlier time point of 4 
hours. Primary human monocytes were cultured with LPS 1µg/mL. After 30 minutes, 
they were treated with Dex (10-10M to 10-6M). After 4 and 24 hours, TF protein 
expression was analyzed using a flow cytometric assay (figures 5-5a,b). At both time 
points, Dex reduced TF expression in a concentration-dependent manner. At 4 hours, 
Dex produced statistically significant reductions in TF expression at ≥10-8M, whereas at 
24 hours, Dex produced statistically significant reductions in TF expression at ≥10-11M. 
The greater effect in TF reduction with Dex seen at 24 hours is likely to reflect the 
longer duration of treatment. 
 
To validate findings from flow cytometric assays, the TF protein levels were examined 
using Western blotting analysis. As above, primary human monocytes were cultured 
with LPS 1µg/mL. After 30 minutes, they were treated with Dex (10-11M to 10-6M). 
Lysates were prepared at 24 hours, and TF protein levels were determined. Similar to 
flow cytometric findings, figure 5-5c shows that Dex reduces TF expression in a 
concentration-dependent manner using western blotting analysis. When comparing both 
assays for TF detection at 24 hours, as in figures 5-5d,e, although both test modalities 
demonstrate the same effect, there are some differences. Dex starts to have a 
significant effect at lower concentrations (10-11-10-10M) in flow cytometric assays, 
whereas similar effects with western blotting are seen with higher concentrations of 
Dex, notably at 10-9-10-8M. This is likely to be explained by the fact that flow cytometry 
would detect the cell surface TF (cells were not permeabilised), whereas western 
blotting detects the total cellular TF pool, including intracellular and cell surface TF. 
Considering Tlag as the most sensitive clot turbimetric parameter, the clot turbimetric 
assay, which is largely a functional assay, indicates that lower concentration of Dex 
appear to reduce procoagulant activity. As it is the cell surface TF that is of functional 
significance, there appears to be concordance between clot turbimetric analyses and 
cell surface TF detected by flow cytometry. At Dex 10-11-10-10M, there appears to be 
little reduction in total cellular TF as determined by western blotting, whilst a greater 
reduction in cell surface TF. These findings raise the interesting possibility that Dex may  
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be acting at a post-translational level and regulating the shuttling of TF from intracellular 
stores ( where it is functionally inactive) to extracellular sites (where it is functionally 
active). This is beyond the scope of the proposed investigation. Nevertheless, using two 
different assays, these data provide consistent evidence that Dex reduces TF protein 
expression in LPS-stimulated monocytes. 
 
In the literature there is variability in the timings of Dex treatment in relation to LPS 
stimulation and different cells types used. Whether or not these factors may explain 
differences in the reported effects on TF expression is unknown. To test these factors, 
the timing of Dex treatment was first examined. Primary human monocytes were 
cultured with LPS 1µg/mL. Dex 100nM was added either 1 hour pre-, concurrent, or 1 
hour post-LPS treatment. TF expression was quantified using flow cytometric analysis. 
Figure 5-6a shows that irrespective of timing of Dex treatment, Dex treatment resulted 
in a significant reduction in TF expression in LPS-stimulated monocytes. Next, to test 
whether the use of unfractionated PBMCs would yield a different finding, similar 
experiments were conducted in unfractionated PBMCs. Figure 5-6b shows that the 
effect of Dex in LPS-stimulated PBMCs was similar to that seen in primary human 
monocytes. Thus, these data indicate that Dex appears to have a universal effect in 
reducing LPS-induced TF response irrespective of timing of Dex treatment or whether 
or not monocytes vs. PBMCS are used. 
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Finally, the effect of Dex on TF mRNA expression was tested in LPS-stimulated 
monocytes. Primary human monocytes were cultured with LPS 1µg/mL. After 30 
minutes, they were treated with Dex (10-11M to 10-6M). TF mRNA levels were 
determined 2 hours after LPS stimulation. Figure 5-7 shows that throughout all 
concentrations, Dex was associated with a significant reduction in TF mRNA levels. 
Taking all the data together, these data provide strong evidence that Dex reduces TF 
expression in LPS-stimulated monocytes at both protein and mRNA level. This 
reduction in TF expression could reflect (a) reduction in TF transcription; (b) reduction in 
TF mRNA stability; or (c) both. Given that Dex is a transcriptional regulator, and has 
previously been shown to reduce TF transcription444, the observed effect of Dex in the 
above experiments will certainly have a transcriptional component. However, whether or 
not TF mRNA stability is also playing a role is unknown. In Chapter 3, the p38-TTP axis 
was found to regulate TF mRNA at a post-transcriptional level. Given the known effects 
of Dex on p38 inhibition, it is intriguing to test whether Dex, through inhibition of p38 
activity, would also act to reduce TF mRNA stability. 
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5.3.3 Dex is a negative regulator of p38 
Dex is known induce DUSP1, a key phosphatase known to dephosphorylate p38, 
thereby reducing p38 activity and function. LPS induces DUSP1, which acts as a 
negative feedback mechanism to limit an over-whelming pro-inflammatory response. 
Dex is known to further increase LPS-induced DUSP1 expression. To validate these 
findings, primary human monocytes were cultured with LPS 1µg/mL. After 30 minutes, 
they were treated with Dex (10-11M to 10-6M). DUSP1, total p38 and phospho-p38 levels 
were determined using western blotting analysis at 2 hours following LPS stimulation. In 
parallel experiments, DUSP1 mRNA levels were determined at 2 hours. Dex produced a 
concentration-dependent increase in DUSP1 expression both at the level of mRNA and 
protein. This was associated with a decrease in phospho-p38: total p38 ratio (Figure 5-
8). 
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5.3.4 Dex increases TTP expression 
Next, the effect of Dex on TTP expression was investigated in LPS-stimulated 
monocytes. As demonstrated previously, LPS induces TTP expression438-440. The effect 
of Dex on TTP expression in this setting is variably reported, and this is likely to reflect 
the different cell types studied439, 440. Primary human monocytes were cultured with LPS 
1µg/mL. After 30 minutes, they were treated with Dex (10-11M to 10-6M). TTP protein 
levels were determined using western blotting analysis at 2 hours following LPS 
stimulation. Dex produced a concentration-dependent increase in LPS-induced TTP 
expression (figure 5-9). These data would indicate that Dex may potentially act 
synergistically to increase TTP-mediated mRNA decay. Firstly, it increases TTP 
expression resulting in an increase in cellular TTP pool, and secondly, it renders TTP 
active by reducing p38-mediated phosphorylation. Thus, the net effect is increased 
amounts of active TTP within the cell, which may potentially mediate target mRNA 
degradation. 
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5.3.5 Dex reduces TF mRNA stability 
To specifically address whether Dex regulates TF mRNA stability, TF mRNA decay 
profiles were established following LPS stimulation both in the absence and presence of 
Dex. Parallel experiments with p38 inhibitors were also conducted to allow comparison. 
Monocytes were stimulated with LPS (1µg/mL). Dex 100nM was added 30 minutes after 
LPS. Actinomycin D (5µg/mL) was added at 2 hour to induce transcriptional arrest. SB 
compounds, SB202474, SB202190 and SB203580 1µM were added concurrently with 
actinomycin D. Given that all compounds were water soluble, water was added as a 
vehicle control to the control arm of the experiment. TF mRNA levels were quantified at 
time 0, 15, 30, 60 and 90 minutes after actinomycin D using RT-PCR and TF mRNA 
decay profiles determined. The TF mRNA half-life in the control arm of the experiment 
was 166±30 minutesutes. In the presence of Dex, there was a significant reduction in 
TF mRNA half-life to 30±7min (p=0.007). This effect was comparable to the effect seen 
with p38 inhibition (figures 5-10a,b). As Dex is a negative regulator of p38 activity, these 
data would otherwise be in keeping with the earlier observations that p38 MAPK 
pathway post-transcriptionally regulates TF mRNA expression. Figure 5-10c shows that 
unlike SB203580 1µM and SB202190 1µM, in addition to reducing phosphor-p38 levels, 
Dex also reduced phospho-JNK levels. Although this was not specifically tested, it 
would be intriguing to assess whether inhibition of JNK also reduced TF mRNA stability. 
 
5.3.6 Dex reduces TF mRNA stability via a TTP-independent mechanism 
If Dex reduces TF mRNA stability through p38 inhibition, then one would hypothesize 
that Dex would not have an effect on TF mRNA stability in the absence of TTP. This 
would be analogous to the absence of an effect with p38 inhibition seen in Ttp-/- 
macrophages. Thus to test this, the specific role for TTP in Dex-mediated reduction TF 
mRNA stability was examined. Murine macrophages were stimulated with LPS 1µg/mL. 
Dex 100nM was added 30 minutes after LPS.  Actinomycin D (5µg/mL) was added at 2 
hours to induce transcriptional arrest. As above, parallel experiments were also 
conducted with p38 inhibitors, where SB202190 and SB203580 1µM were added 
concurrently with actinomycin D. TF mRNA decay profiles were then determined 
(figures 5-11a-c). 
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In WT murine macrophages, the TF mRNA half-life was 97±15 minutes. Dex resulted in 
a significant reduction in TF mRNA half-life to 41±11min (p=0.017), again comparable to 
p38 inhibition. These finding mirrored those seen in primary human monocytes (figures 
5-10a,b). In Ttp-/- macrophages, TF mRNA half-life was 352±82 minutes. Interestingly, 
whilst p38 inhibitors had no effect on TF mRNA half-life in Ttp-/- macrophages, Dex 
resulted in a significant reduction in TF mRNA half-life to 54±8min (p=0.016). This was 
an unexpected finding, and these data would indicate that whilst Dex may act to reduce 
TF mRNA stability through p38 inhibition, other mechanisms must exist that are 
independent of TTP. 
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5.4 DISCUSSION 
 
In this chapter, we sought to determine if Dex would reduce TF mRNA stability. The 
hypothesis was founded upon the fact that Dex is negative regulator of p38 activity and 
function, and the observation that p38 inhibition reduces TF mRNA stability. The above 
data has a number of interesting findings. Firstly, Dex reduces TF expression in LPS 
stimulated monocyte-macrophages. Secondly, indeed, this effect is in part due to a 
reduction in TF mRNA stability. Thirdly, whilst Dex is a negative regulator of the p38-
TTP axis, other TTP-independent mechanisms are likely to contribute to this effect. 
 
Current data on the effect of GCs on monocyte TF expression are ambiguous442-444. 
Earlier studies had demonstrated that methylprednisolone reduced procoagulant activity 
of LPS-stimulated PBMCs442. Contrary to this finding, Dex enhanced LPS induction of 
TF in THP-1 cells and PBMCs, when co-stimulated with LPS and Dex, and that this was 
not a result of increased mRNA stability, implicating increased gene transcription to play 
a role443. In another study, Dex also enhanced LPS induction of TF in THP-1 cells, when 
pre-incubated with Dex for 30 minutes prior to LPS stimulation. Using TF-promoter-LUC 
constructs, it was shown that Dex inhibited TF gene transcription444. This effect of Dex 
on TF transcription would be in keeping with our current understanding on Dex as the 
TF promoter contains binding sites for transcription factors AP-1, NF-ĸB, that mediate 
the LPS-induced TF response190, 251, 447, and  Dex is known to block NF-ĸB and AP-1 
activity448. In this particular study, however, Dex was found to increase TF mRNA 
stability, with an overall increase in TF expression444. These conflicting findings of the 
effect of Dex on TF expression and TF mRNA stability may be explained by the different 
cells types studied (primary human monocytes vs. THP-1 cells vs. unfractionated 
PBMCs). Certainly, there remain important differences between THP-1 cells and 
primary human monocytes422. Another possible explanation could be the timing of Dex 
treatment. There appears to be variability in the experimental designs of these studies, 
where Dex is administered prior to or with concurrent LPS treatment. To our knowledge 
there are no published data on the effect of Dex on TF expression in primary human 
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monocytes. It was therefore crucial to first characterize the effect of Dex on monocyte 
procoagulant activity and TF expression. 
 
Using functional clot turbimetric assays, Dex was found to reduce procoagulant activity 
in both unstimulated and LPS-stimulated monocytes. Subsequent experiments 
demonstrated Dex reduced TF expression both at mRNA and protein level. An 
interesting observation was that that Dex reduced procoagulant activity in unstimulated 
monocytes, despite there being very little, if any, detectable TF in unstimulated 
monocytes (as shown using western blotting and flow cytometry). This raises the 
possibility that Dex may modulate TF-independent pathways. Macrophages can initiate 
coagulation via the Mac-1 (CD11b/CD18, αMβ2) receptor
69 and through the expression 
of factor VII activating protein (FSAP)72. Mac-1 can bind to factor X and following 
exposure to ADP, macrophages can catalyse the activation of cell-bound factor X to 
factor Xa, independent of TF and factor VIIa69. FSAP is a serine protease, secreted by 
macrophages. The primary substrates for FSAP are factor VII and uPA72, and therefore, 
FSAP may play important roles in initiating the extrinsic pathway and mediating 
fibrinolysis, although there is greater evidence for the latter. Dex has been shown to 
reduce Mac-1 expression in human eosinophils449. Although this has not been 
demonstrated in monocyte-macrophages, one can postulate that Dex may reduce 
monocyte procoagulant activity through a reduction in Mac-1 expression. The 
experimental dissection of the TF-independent pathways was beyond the scope of this 
study. Another interesting finding stemmed from the direct comparison of TF expression 
as demonstrated using flow cytometry vs. western blotting. Both assays demonstrated 
that Dex reduce TF protein expression in LPS-stimulated monocytes. However, flow 
cytometry detects cell surface TF antigen, whereas western blotting detects the total 
cellular TF pool. The functional clot turbimetric assays, demonstrated Dex to reduce 
procoagulant activity at concentrations as low as 10-10M. At this concentration, cell 
surface TF protein expression was reduced, as shown using flow cytometry, However, 
at this concentration, there was very little change in the total cellular TF pool, as shown 
using western blotting. Whilst the differences in sensitivities between the two assays 
may explain this, one may speculate that Dex may play a role at a post-translational 
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level and modulate shuttling of TF from the extracellular to the intracellular 
compartment. Whilst, these alternative explanations are far from conclusive, they are 
certainly hypothesis generating, and further dissection of these potentially interesting 
mechanisms are, again, beyond the scope of this study. 
 
Having established that Dex reduces TF expression in LPS stimulated monocytes, 
whether or not this effect was a result of reduced TF mRNA stability was investigated 
with TF mRNA decay experiments in both primary human monocytes and WT murine 
macrophages. These experiments specifically demonstrated that Dex significantly 
reduced TF mRNA stability, an effect which was comparable to p38 inhibition. This was 
in keeping with the original hypothesis, as Dex is known to increase DUSP1 expression 
which in turn dephosphorylates p38, thereby reducing its activity and function. Earlier 
experiments in Ttp-/- murine macrophages had demonstrated that p38 inhibition had no 
effect on TF mRNA half-life, implicating a TTP-dependent mechanism. On this basis, 
given that Dex is a negative regulator of p38, one would similarly hypothesize that Dex 
would not have an effect on TF mRNA stability in Ttp-/- macrophages. However, 
unexpectedly, Dex reduced TF mRNA stability in Ttp-/- macrophages. This interesting 
observation indicates that Dex is additionally likely to regulate TF mRNA stability 
through other TTP-independent mechanisms, most likely microRNAs  or other RNA-
binding proteins. 
 
In conclusion, these data demonstrate for the first time that Dex reduces TF expression 
in LPS-stimulated monocytes. This effect is, in part, due to a reduction in TF mRNA 
stability – an effect comparable to p38 inhibition. Dex negatively regulates p38 activity 
through induction of DUSP1 that dephosphorylates p38. Dex also increases TTP 
expression, and therefore the net effect of Dex is to increase the dephosphorylated 
(active) form of TTP. Whilst Dex is likely to regulate TF mRNA stability, in part, through 
the p38-TTP axis, experiments in Ttp-/- macrophages demonstrate that other TTP-
independent mechanisms are likely to be contributory. The characterization of these 
TTP-independent pathways warrant further study.   
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6.1 Current understanding of the post-transcriptional regulation of TF 
Tissue factor (TF) is a 47kDa transmembrane cell surface glycoprotein and is the key 
trigger for the extrinsic coagulation cascade resulting in thrombus formation152. 
Monocyte-macrophages are an important source of TF in atherothrombosis, both within 
the plaque and the circulating blood. Throughout plaque formation, the inflammatory 
milieu induces TF expression in plaque macrophages, foam cells and smooth muscle 
cells43. Within the blood, TF is expressed in circulating monocytes and TF-containing 
microparticles which are predominantly derived from monocyte-macrophages77. 
Following plaque rupture, TF within the necrotic core is exposed to the flowing blood 
and initiates thrombosis resulting in acute ischaemia37, 38 or asymptomatic plaque 
growth39. Activation of PARs by coagulation proteases provide an important means for 
TF to mediate cross-talk between coagulation and inflammation71. TF may also 
contribute to plaque development through coagulation-independent mechanisms. For 
example, the TF/VIIa complex has been shown to be a stimulus for smooth muscle 
migration in atherosclerotic plaques220, 221. Furthermore, TF may also promote plaque 
neovascularization154, thereby contributing to plaque growth, haemorrhage and 
instability. Taken together, the multiple roles TF may play in atherothrombosis indicate 
that a detailed understanding of the mechanisms regulating its expression is essential, 
not only for understanding pathophysiology but also for the identification of novel 
therapeutic targets. 
 
The passage of genetic information from DNA through to the effector protein molecule is 
highly regulated. In addition to transcriptional and translational control, there is 
overwhelming evidence for the role of mRNA turnover in determining net gene 
expression. Post-transcriptional controls on mRNA safe-guard against inappropriate 
transcriptional leak, couple steady-state mRNA levels to transcription, and provide the 
means for accelerated mRNA decay to terminate gene expression304. The mRNA 
serves as a template for translation, and the level of steady state mRNA present in a 
cell, depends on the balance between its rate of formation and decay. The concept of 
mRNA decay gives rise to the concept of mRNA stability and half-life. The regulation of 
mRNA stability is complex depending on the dynamic interplay between target mRNA 
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sequence elements; RNA-binding proteins and cofactors; and mRNA degradation 
machinery. In broadest terms, mRNA stability is governed by specific sequences in the 
3‘UTR of transcripts and their interaction with different RNA-binding proteins, which 
depending on their function, mediate either mRNA stabilization or decay. Although the 
TF transcript is known to be intrinsically unstable259, 260, little has been known about its 
post-transcriptional regulation. The TF 3‘UTR contains several AREs that may serve as 
potential binding sites for ARE-binding proteins, and indeed TF mRNA has been 
assigned to the group III cluster of the ARED database261.  These AREs are functional 
and conserved in both human and mouse. Although, the roles for microRNAs in 
regulating TF mRNA stability have recently been reported268, the precise molecular 
mechanisms involved in ARE-mediated TF mRNA decay have not been fully elucidated. 
Furthermore, whether or not other inducible proteins besides ARE-binding proteins are 
required is not known. 
 
The data presented in this thesis breaks new ground in two general areas. First, it 
provides new information on the post-transcriptional regulation of TF, a protein which is 
central to thrombosis and atherosclerosis. Secondly, it identifies a fundamental 
mechanism by which mRNA stability is subject to differential regulation in inflammatory 
processes. These data represent a significant advance in our understanding of the 
regulation of TF mRNA turnover, and thus post-transcriptional control should be 
considered alongside transcriptional177, 249 and post-translational450 regulation as one of 
the critical levels at which expression of this important protein is regulated. 
 
6.2 TTP regulates TF mRNA stability 
TTP is the most widely studied ARE-binding protein and the optimal ARE-binding site is 
considered to be UUAUUUA(U/A)(U/A)264-266. A similar sequence is present in a 
palindromic ARE sequence at the distal end of TF 3‘UTR. TTP exists in two forms: 
dephosphorylated (active) and phosphorylated (inactive). The p38 MAPK pathway plays 
a pivotal role in the regulation of TTP activity. p38 activates MAPKAPK-2, and both 
MAPKAPK-2 and to a lesser extent p38 can phosphorylate and inactivate TTP363. 
Classically, inhibition of p38 reduces the stability of TTP-regulated transcripts. 
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Experiments conducted in LPS-stimulated monocyte-macrophage demonstrated that 
inhibition of p38 reduced TF expression and TF mRNA stability. This was demonstrated 
using a variety of p38 inhibitors (SB202190, SB203580, BIRB796 and LY2228800). A 
direct role for TTP was demonstrated by increased TF expression and increased TF 
mRNA stability in Ttp-/- macrophages. The effect of p38 inhibition was most likely to be 
TTP-dependent as p38 inhibition in Ttp-/- macrophages had no effect on TF mRNA 
stability. This is an important observation as other ARE-binding proteins, e.g. AUF1 and 
KSRP are also regulated by p38-mediated phosphorylation. Using RNP 
immunoprecipitation techniques and RNA-biotin pulldown assays a direct interaction 
between TF 3‘UTR and TTP was demonstrated and further mutational analyses 
highlighted 2 specific overlapping nonameric ARE sequences, AUUUAUUUA and 
UUAUUUAAU, to mediate TTP binding in a cooperative manner. 
 
This is the first time that TTP has been shown to post-transcriptionally regulate TF 
expression. Over the recent years, many studies have revealed numerous targets for 
TTP. Various approaches have been used including small interfering RNA knockdown 
experiments451; ―forced‖ TTP-promoted mRNA degradation, in which overexpression of 
TTP in transfected cells has been shown to stimulate the breakdown of potential target 
mRNAs452-455; in vitro decay studies456; and microarray analyses340. Specifically, a 
genome-wide approach combining RNP immunoprecipitation and microarray analysis in 
RAW264.7 cells, treated with LPS for 2 hours, identified 137 mRNAs as targets for 
TTP340. The major drawback of ―forced‖ TTP expression is that given the major 
determinant of TTP binding is the ARE binding site sequence and that relatively minor 
sequence variations might still permit TTP binding, TTP-mediated mRNA decay may 
still occur if the TTP concentrations are high enough. This may result in identifying false-
positive TTP targets. Using the strict criterion that for TTP-regulated transcripts where 
mRNA stabilization needs to be demonstrated in cells derived from the Ttp-/- mice, a 
microarray analysis of RNA from wild-type and TTP-deficient mouse embryonic 
fibroblast cell lines after serum stimulation and treatment with actinomycin D, identified 
250 mRNAs that were stabilized in the absence of TTP364. It is interesting to note that in 
all reported studies, TF has never been identified as a TTP target. There are a number 
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of possible explanations. Firstly, there are likely to be important differences in the cells 
lines used in these studies. In this thesis, primary human and murine macrophages 
have been used for analysis, and there are no micro-array analyses examining TTP 
targets specifically in primary human and murine macrophages. Secondly, the 
stimulants used in these studies are variable, and in this thesis, LPS has been used as 
the stimulus, as it induces a powerful induction in TF expression. Thirdly, given the 
kinetics of TF mRNA expression, the duration of stimulation prior to analysis of TF 
mRNA decay is critical. TF mRNA levels peak early at 2-4 hours and are followed by a 
rapid decline in levels. In this thesis, the timing for analysis of TF mRNA decay was set 
at 2 hours, as this represented the time at peak TF mRNA levels, and where the 
transcripts were relatively stable, allowing detection of changes in mRNA stability in 
response to different pharmacological inhibitors and/or macrophage phenotypes. For 
example, if the baseline TF mRNA half-life was very high (stable), then it would be 
difficult to detect increased mRNA stability, and conversely, if the TF mRNA half-life was 
very low (unstable), then it would be difficult to detect decreased mRNA stability. It is 
interesting to note, that in a study examining TF mRNA stability in lung epithelial cells, 
the TF 3‘UTR was shown to bind a 37kDa protein which was postulated to confer 
instability267. Although TTP would be a candidate protein, to date, the identity of this 
protein has not been reported. 
 
Similarly, p38 inhibition has not previously been shown to regulate TF mRNA stability. 
There are no specific studies reporting the spectrum of target mRNAs destabilized by 
p38 inhibition  in primary human and murine macrophages. However, a large scale 
comprehensive analysis examining the effect of p38 inhibition, using SB203580, on 
mRNA decay of 470 ARE-containing mRNAs in LPS-stimulated THP-1 cells did not 
identify TF as exhibiting p38-dependent decay457. In this study, THP-1 cells were 
stimulated with LPS for 2 hours prior to transcriptional arrest with actinomycin D, which 
is comparable to our experimental protocol based on TF mRNA kinetics. However, the 
results of this study are far from conclusive. For example, IL-3, TNFα, and uPA have 
been reported to be stabilized by p38 activation458-460, but this study failed to highlight 
these mRNAs. This is particularly surprising for TNFα, which is considered to be the 
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model TTP-regulated transcript. Although the precise basis for these discrepant findings 
are unclear, it is likely to reflect the different cell lines used. 
 
The TF 3‘UTR contains a number of AREs which are conserved in mouse and human. 
The final palindromic ARE in the 3‘UTR is highly conserved throughout different species 
and was found to be functional in mediating TTP-mediated TF mRNA decay. This 
observation is consistent with a previous study where the destabilizing element within 
TF 3‘UTR was found to be confined to the last 150bp sequence260. In this study, the 
more upstream 3‘UTR sequence was also shown to confer some degree of mRNA 
instability, and it is possible that this may be due to miRNA, as the mir-19 binding site is 
located in the more proximal segment of TF 3‘UTR268. The evidence for mir-19 
regulating TF comes from a recent study examining TF expression in breast cancer 
cells, where the use of luciferase reporter constructs demonstrated that deletion of mir-
19 binding site in TF 3‘UTR  resulted in increased luciferase activity to a level 
comparable with that of the control construct, which comprised the anti-sense TF 3‘UTR 
sequence268.  However, one may question this observation, as if the mir-19 binding site 
is disrupted this should not affect ARE-mediated decay, and one should still expect to 
have seen reduced luciferase activity compared to the control construct.  This may be 
explained by closer examination of the TF 3‘UTR constructs and this reveals that the 
cloned sequences used in this study were actually devoid of the final 218bp which 
contains the palindromic ARE. One may presume that the deliberate exclusion of this 
final ARE-rich sequence in this study would reduce potential confounding and allow 
easier detection and assessment of miRNA-mediated degradation. Nevertheless, this 
provides indirect evidence that the non-miRNA-mediated destabilizing elements in TF 
3‘UTR are likely to be located in final 218 bp sequence. 
 
The in vitro analyses in Ttp-/- macrophages demonstrated that TTP deficiency results in 
increased TF expression. Given that TTP deficiency also results in increased TNFα 
expression and that TNFα, itself, increases TF expression, it is very likely that the 
increased TF expression seen in Ttp-/- cells has a transcriptional component. The effect 
of TTP deficiency on the TF transcription was not specifically tested. However, the 
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effect on post-transcriptional regulation can be confidently dissected using mRNA decay 
experiments with actinomycin D which induces transcriptional arrest. The increased 
TNFα in Ttp-/- mice, however, limits the applicability of these mice in determining TF 
expression in vivo. The increased TNFα in vivo can increase TF expression, and thus 
will have confounded interpretation. This problem may be potentially circumvented by 
treating mice with TNFα inhibitors313, however non-specific effects of these inhibitors, 
particularly on TF expression cannot be excluded. A more robust strategy to determine 
whether TTP is acting to destabilize TF expression in vivo would be to investigate TF 
expression using triple knock-out mouse (deficient in TTP and both of the known TNFα 
receptors, TNFR1 and TNFR2)316, 461, 462. Mice deficient in TTP and TNFR1, or in TTP 
and both receptors, are protected from developing the TNF-alpha-induced cachexia and 
inflammation316. Thus the absence of TNFα effects would allow less confounded 
assessment of the in vivo non-transcriptional effects of TTP deficiency on TF 
expression. 
 
6.3 PARP-14 regulates TF mRNA stability 
Poly(ADP-ribosyl)ation is a post-translational modification where negatively charged 
ADP-ribose moieties are adducted onto proteins and this process is catalyzed by 
PARPs. Most of our current understanding of PARPs is centred on PARP-1 and PARP-
2, that have been shown to regulate transcription, chromosome structure, and DNA 
damage repair. As such, there is very little data on the functions of other PARP family 
members. PARP-14, a macroPARP, has been shown to be a co-activator of IL-4/Stat-6-
mediated transcription in B lymphocytes401, 406, 407, acting as a transcriptional switch by 
ADP-ribosylating HDAC 2 and 3, which are then released from IL-4 responsive 
promoters to allow access of histone acetyl transferases. Recently, several PARP family 
members, including PARP-14, have been shown to have roles in RNA regulation395, 408. 
ADP ribosylation plays an important role within the SG where specific PARPs (PARP-
5a; PARP-12, PARP-13, PARP-14, PARP-15), and two PARG isoforms (PARG99 and 
PARG102) have been shown to be SG components. Overexpression of these PARPs 
results in the de novo formation of SGs, whilst overexpression of the PARG isoforms 
result in inhibition of SG assembly and knockdown of PARG delays the disassembly of 
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SG395. These data suggest that the levels of ADP-ribose within the cytoplasm are locally 
regulated for the assembly and maintenance of SG structure. Furthermore, RNA-
binding proteins Ago2, G3BP1, and TIA-1 can be modified by ADP ribosylation; and 
PABP, although not specifically modified by ADP–ribosylation, can bind ADP-ribose 
moieties395. Thus the function of ADP ribosylation in SGs may be analogous to the role 
in other cellular scaffolds, e.g. at the mitotic spindle, Cajal bodies or at DNA damage 
sites396, 397, where the ADP-ribose scaffold in the SG regulates specific interactions 
between different RNA-binding proteins.  The presence of PARGs within the SG further 
adds regulatory complexity, whereby regulation of ADP-ribose synthesis may ultimately 
serve to regulate the recruitment of RNA regulatory proteins. ADP ribosylation has been 
proposed to regulate miRNA function, such that following cellular stress, local high 
concentrations of ADP-ribose around the Ago2 or miRNA complex may either function 
to disrupt electrostatic interactions between similarly charged miRNA and mRNA, or 
cause steric hindrance for effective miRNA silencing395. TTP is also an important 
component of the SG, and it is possible that ADP ribosylation may serve to regulate 
TTP-mediated mRNA decay either through direct modification of TTP or another 
member of the mRNA decay complex. APLF is a novel component of the DNA repair 
machinery and contains two tandem ZF domains that closely resemble the tandem Zn 
fingers present in TTP. Interestingly, APLF has been shown to bind ADP-ribose 
moieties via the ZF domains, indicating the potential for TTP to bind sites of ADP-
ribosylation463. 
 
Preliminary experiments in Parp14-/- macrophages demonstrated that the absence of 
PARP-14 resulted in increased TF expression and that this was due to increased TF 
mRNA stability. Whether or not the absence of PARP-14 also results in increased TF 
transcription was not specifically tested. Nevertheless, the in vitro findings were 
supported by in vivo findings of increased TF expression within different organs 
harvested from unstimulated and LPS-stimulated mice. Clearly, the organ tissues 
comprised of a number of different cells types besides macrophages, which were the 
cell type used for conducting the in vitro experiments. Although not specifically tested, 
this would broadly suggest that PARP-14 may also regulate TF expression in other cell 
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types. However, the finding that PARP-14 deficiency was associated with increased TF 
activity in unfractionated peripheral leukocytes in unstimulated and LPS-stimulated mice 
would specifically support the in vitro findings in macrophages. Importantly, the 
functional and pathological significance of the increased TF expression seen in Parp14-/- 
mice was demonstrated by intravital microscopy where cremasteric artery occlusion 
time following ferric chloride injury was accelerated in LPS-stimulated Parp14-/- mice. 
Thrombosis in this model has been shown to be dependent on TF464-466, although under 
normal circumstances TF expressed by vascular smooth muscle cells (VSMC) may 
make the predominant contribution466. The ferric chloride induces chemical injury when 
applied topically to the outer medial/adventitial artery wall, and is referred to as an 
outside-in model of injury. Ferric chloride reaches the arterial lumen via an endocytic-
exocytic pathway resulting in complete denudation of the endothelium and exposure of 
the blood to medial TF resulting in localised thrombosis467. This small animal model of 
thrombosis is thought to be comparable to arterial thrombosis in large animal models 
because there are cyclic flow variations induced by the presence of thrombi in arteries 
after ferric chloride injury468. The role of TF has been examined in this model using mice 
with either a conditional deletion of the TF gene in VSMCs or with increased expression 
of TFPI in VSMCs465, 466. Both studies demonstrated that a reduction of TF activity was 
associated with an increase in the time to occlusion, indicating that ―vessel wall‖ TF 
mediates ferric chloride-induced thrombosis. It remains to be determined whether the 
increased thrombogenicity in this model in Parp14-/- mice is due to increased VSMC 
expression of TF and/or to the increased TF activity as demonstrated in circulating 
leukocytes. It is also possible that Parp14-/- mice may have increased levels of 
circulating microparticles expressing TF at 4 hours after LPS challenge and that these 
may contribute to the accelerated thrombosis observed in this model. 
 
Subsequent in vitro experiments demonstrated that PARP-14 appears to cooperate with 
TTP, such that both these proteins appear to form a ternary complex with TF 3‘UTR 
involving the same nonameric ARE sequences as determined for TTP. RNA-biotin 
pulldown assays demonstrated that in the absence of PARP-14, TTP does not appear 
to interact with TF 3‘UTR, although low-affinity binding cannot be excluded. Similarly, in 
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the absence of TTP, the binding of PARP-14 to TF 3‘UTR is reduced. Although TTP 
expression appears to be increased in Parp14-/- cells, the TF mRNA is stable, indicating 
that TTP is not able to exert its TF mRNA destabilizing function. One may postulate that 
altered TTP phosphorylation may limit TTP-binding, but this is unlikely as specific 
experiments using p38 inhibition demonstrated that the TTP phosphorylation status 
should not affect TTP-binding. This is in keeping with previously reported studies331. 
Furthermore, phospho-p38 levels were found to be similar in the absence and presence 
of PARP-14. To definitively determine if PARP-14 alters the phosphorylation status of 
TTP, one would need to perform a phosphorylation blot specifically for TTP 
phosphorylation at Ser-52 and Ser-178 sites20, 21. However, there are no reliable 
antibodies available to conduct such analysis. 
 
This is first time a PARP family member has been shown to cooperate with an 
established RNA-binding protein and regulate mRNA stability. Both TNFα and TTP 
(itself) are established targets for TTP, and both TNFα and TTP mRNA stability was 
unaffected by the absence or presence of PARP-14. Given that TF, a TTP regulated 
transcript was found to be co-regulated by PARP-14 at the level of mRNA stability, 
these also data provide evidence, for the first time, how the effects of TTP may 
differentially regulated. One may postulate that PARP-14 serves as an accessory 
protein that regulates TTP binding to a subset of TTP-regulated transcripts where TTP 
binding has insufficient affinity because of the specific ARE sequence and/or RNA 
folded structure. Whether or not an alternative accessory protein(s) is required for 
optimal TTP binding to TNFα mRNA 3‘UTR and other PARP-14- independent TTP 
target transcripts remains to be determined. Further work will also be directed at 
determining the subset mRNA transcripts, or RNA regulon469, coregulated by PARP-14 
and TTP and whether these encode a set of functionally-related proteins that might all 
be simultaneously regulated. The presence of the PARP domain and its catalytic activity 
adds further complexity to the post-transcriptional regulatory mechanisms. Using PARP 
inhibitors, PJ34 and 3AB, mRNA decay experiments in human monocytes and WT 
murine macrophages demonstrated that PARP inhibition reduced TF mRNA stability. 
The drawback of these compounds is that these are non-specific inhibitors and not 
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specific for PARP-14. However, some degree of specificity for PARP-14-TTP interaction 
may be conferred by experiments where PARP inhibition had no effect on TF mRNA 
stability in Parp14-/- cells. Conversely, one may argue that in the absence of either TTP 
or PARP-14 these proteins are not able to bind to TF 3‘UTR, and thus the absence of 
an effect of PARP inhibition would be expected in Parp14-/- and Ttp-/- cells. A definitive 
role for PARP-14 can only be established using PARP-14 specific inhibitors, and these 
compounds are currently in development. Nevertheless, these experiments confirmed 
that the PARP inhibitors are not having a non-specific effect on mRNA decay, given the 
absence of a TF mRNA destabilizing effect in Parp14-/- cells. Interestingly, the effect of 
PARP inhibition did not appear to have an effect on TNFα mRNA stability, again lending 
further lends support to the fact that these compounds are not having a generalized 
non-specific effect on mRNA decay, but more importantly demonstrates how ADP-
ribosylation may potentially serve to differentially regulate TTP-regulated transcripts.  
 
Therefore the data presented in this thesis support two distinct roles for PARP-14 in the 
regulation of TF mRNA stability. Firstly, PARP-14 is an accessory protein required for 
TTP to bind TF mRNA. Secondly, the PARP catalytic activity of PARP-14 serves to 
stabilize TF mRNA, such that inhibition of PARP activity results in increased TF mRNA 
decay. The precise role of ADP-ribosylation in this system is not clear, but it is possible 
that PARP-14-mediated ADP ribosylation is modifying TTP or another candidate protein 
in the mRNA decay complex to ultimately inhibit TTP-mediated mRNA decay. The 
precise molecular targets for ADP-ribosylation in this system remain the focus of 
ongoing work. One mechanism for TTP-mediated decay is interfering with mRNA 
circularization, by binding to PABP and displacing it from the poly(A) tail thereby 
promoting 3′-to-5′ degradation. Given that PABP can be ADP-ribosylated, it is intriguing 
to speculate that ADP-ribosylation of PABP may hinder TTP binding thereby limiting TF 
mRNA decay.  
 
6.4 A proposed model for the regulation of TF mRNA stability 
Taken together, the data presented in this thesis indicates that both p38-mediated 
phosphorylation and PARP-14-mediated ADP-ribosylation regulate TF mRNA stability. 
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A proposed model of how these two events co-regulate TF mRNA stability is presented 
in figure 6-1. As portrayed graphically, TF mRNA is stabilised in Parp14-/- and Ttp-/- cells  
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due to impaired binding of TTP and PARP-14 respectively. In WT cells, both PARP 
enzymatic activity and p38 activity are necessary for inactivating TTP-mediated mRNA 
decay and thus increasing TF mRNA stability during LPS induction. Thus inhibition of 
either PARP-14 mediated ADP-ribosylation and/or p38-mediated phosphorylation 
results in increased TTP-mediated TF mRNA decay. It is known that TF mRNA levels 
are ―super-induced‖ and mRNA stability prolonged by stimulating monocytes in the 
presence of the protein synthesis inhibitor cycloheximide, suggesting down-regulation of 
mRNA stability with time by an induced repressor protein(s)260, 447. Previous 
observations showing the inducibility of TTP and the above data on PARP-14 support 
their involvement in this. Thus, it has already been established that TTP expression is 
transcriptionally regulated by a variety of agonists, including LPS470. This allows the 
quantity of TTP to match the increased number of target mRNA appearing as part of 
transcriptional responses to these agents, and provides a mechanism for accelerated 
mRNA decay to terminate gene expression as part of feedback inhibition. Expression of 
TTP is very low to absent in resting macrophages but was shown to be induced by LPS 
as previously observed320.  PARP-14 was found to be increased by LPS in murine 
macrophages with similar kinetics to TTP.   Furthermore, PARP-14 and TTP proteins 
were increased together in vivo in multiple organs following LPS treatment. Overall, 
these data therefore show that both PARP-14 and TTP are coregulated by an LPS-
mediated signalling pathway, leading to increased availability of these two RNA-binding 
proteins to post-transcriptionally regulate TF expression. 
 
6.5 Glucocorticoids reduce TF mRNA stability 
Following the observation that p38 inhibition reduces TF mRNA stability via the p38-
TTP axis, and given that GCs are potent inhibitors of p38 activity and function, the effect 
of GCs on TF mRNA stability was investigated. Previous data on the effects of GCs on 
LPS-stimulated monocyte-macrophage TF expression is ambiguous, and there are no 
conclusive data on the effects of GCs on TF expression in primary monocyte-
macrophages442-444. Initial experiments provided compelling evidence that Dex reduces 
TF expression in LPS-stimulated monocyte-macrophages. In keeping with an inhibitory 
effect on p38 activity, Dex was found to reduce TF mRNA stability. An interesting 
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observation came from mRNA decay experiments in WT vs. Ttp-/- macrophages in the 
absence and presence of Dex, where unlike p38 inhibition, Dex was still able to de-
stabilize the TF transcript in Ttp-/- macrophages. These data indicate that Dex is likely to 
regulate TF mRNA turnover through both TTP-dependent and TTP-independent 
mechanisms. The most likely candidates are miRNAs and/or other RNA binding 
proteins. 
 
miRNAs are small non-coding RNA molecules that act as post-transcriptional 
repressors by binding to AREs within 3‘ UTRs of their target genes and either block 
translation or promote mRNA degradation280. Recently, GCs have been shown to 
regulate miRNA expression in acute lymphoblastic leukaemic cells471. Whilst, GC-
regulated miRNAs have been identified in alveolar macrophages from asthmatic 
patients following inhaled GC therapy472, to date, miRNA profiling has not been 
performed in Dex-treated primary human monocytes. A bioinformatics search has 
shown that 20miRNAs have TF mRNA as predicted target (figure 6-2). miRNAs have 
been shown to regulate many genes, and recently the first miRNA (mir19) to regulate 
TF expression has been identified in breast cancer cells268. Whether Dex regulates TF 
expression in monocytes at the level of miRNAs, and whether or not mir19 is implicated, 
are yet unanswered questions and remain the focus of further investigation. 
Modulation of gene transcription is considered to be the central feature of GC-mediated 
gene regulation473. Binding of GC to the glucocorticoid receptor (GR) induces its 
dissociation from a cytoplasmic multimeric complex of chaperone proteins and its 
translocation to the nucleus, where it dimerizes and acts as a transcription factor, 
through binding to a glucocorticoid response element (GRE) within the 5′ promoter 
region of target genes474, 475. The GR can also bind different transcription factors such 
as AP-1, NF-κB subunits and members of STAT and Forkhead box families, resulting in 
transcriptional inhibition of proinflammatory genes473, 475. However, the effect of GCs is 
now increasingly recognized to occur through the regulation of mRNA turnover. 
Examples of genes regulated by GCs at a post-transcriptional level include TNFα, GM-
CSF, COX-2, IL-4Rα, IL-6, iNOS, vascular endothelial growth factor (VEGF), CCL11, 
CCL2 and CCL7 and many others436, 476-478. As mentioned above, most studied RNA-  
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binding proteins bind to AREs in the 3‘UTR of target mRNAs. However, these specific 
regulatory elements are not exclusive to the 3‘UTR. Research in the last decade has 
identified a growing number of additional non-ARE destabilizing elements within the 5‘ 
and 3‘UTR of many genes479-481. It has been shown that the GR can interact with CCL2 
mRNA in rat smooth muscle cells482. The GR has recently been shown to bind 5‘UTR of 
CCL2 and CCL7 mRNA in human airway epithelial cells483. Using computational 
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analyses a novel GC-rich motif in the 5‘UTR was found to bind GR, and this sequence 
was present in the 5‘ UTRs of 7889 predicted mRNA targets, or in the entire sequences 
of 25,672 predicted mRNA targets (21% of the UniGene transcript pool)483. Interestingly, 
the GR binding motif is also found in TF 5‘UTR. This raises the possibility that the GR 
may contribute to the acceleration of TF mRNA decay seen above in the Ttp-/- 
macrophages. A hypothetical working model for the role of Dex in the post-
transcriptional regulation of TF is presented in figure 6-2. 
 
6.6 Therapeutic targeting of TF expression 
Given that the TF pathway is the primary mechanism for initiating thrombosis, the TF 
pathway is an attractive therapeutic target. The development of new pharmacological 
approaches to target TF-mediated coagulation at several different levels remains an 
exciting research field. It is well established that other anti-thrombotic approaches such 
as glycoprotein IIb/IIIa blockade and inhibition of thrombin increase bleeding time and 
the risk for bleeding. A remarkable feature of anti-thrombotic therapies targeting TF, e.g. 
FVIIa or the TF-FVIIa complex, is that the antithrombotic effect is similar to heparin or 
warfarin but with less severe bleeding tendencies484-487.  
 
One approach has been to directly target the TF molecule using anti-TF monoclonal 
antibodies (D3H44, AP-1)63, 488-490. Antagonizing membrane-bound TF through the 
administration of a recombinant truncated extracellular form of TF (hTFAA) has been 
shown to limit thrombosis in animal models without significantly increasing bleeding 
risk485, 486. This recombinant peptide has been further modified (hTFAA-3) to enhance 
its affinity for FVIIa491. A small-molecule TF inhibitor PHA-927F, has also been shown to 
limit thrombosis in a primate model of acute thrombosis without increasing bleeding 
risk492. Another approach has been to target the activated form of FVII by administering 
active site-inactivated FVIIa (FVIIai, FFR-rFVIIa, DEGR-FVIIa, or ASIS)
493, 494. FVIIai is 
an active site-blocked version of rFVIIa that is rendered catalytically inactive, and acts 
as a competitive inhibitor of TF. The resulting TF-FVIIai complex is very stable and 
incapable of activating the downstream coagulation cascade. ASIS competes with FVIIa 
for complex formation and does not replace FVIIa already bound to TF495. Intravenous, 
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topical and intracarotid administration of FVIIai  in various animal models has 
demonstrated good antithrombotic effects496-498. Similarly, small protein inhibitors of the 
TF•FVIIa complex (XK1 and rNAPc2) have been shown to have antithrombotic effects in 
animal models499, 500. Recombinant TFPI (rTFPI) (e.g. Tifacogin and Ixolaris) has been 
shown to limit thrombosis in various animal models and to inhibit thrombin generation in 
human volunteers infused with endotoxin501-505. Clinical application of rTFPI has 
predominantly focused on treatment of sepsis rather than thrombosis due to the 
requirement of large doses of rTFPI to inhibit thrombus formation506. The effect of local 
overexpression of the TFPI gene has also been investigated using a ‗hemagglutinating 
virus of Japan'–artificial viral envelope liposome-mediated TFPI gene therapy in 
rabbits507. 
 
Over the recent years, post-transcriptional regulation has emerged as an important 
determinant of gene expression. In the current advancing era of molecular biology, 
targeting post-transcriptional pathways is now emerging as a promising therapeutic 
strategy in a wide spectrum of diseases508, 509. Inhibition of TF expression at the post-
transcriptional level may be accomplished by several different methods. Various 
approaches using ribozyme, antisense and RNA interference technologies have been 
reported. Delivery of antisense nucleic acid molecules into the cells results in 
hybridization between the antisense molecule and the TF mRNA thereby preventing 
translation. Administration of antisense TF oligonucleotides has been demonstrated to 
limit thrombosis in various animal models510, 511. However, the stoichiometric nature of 
antisense therapy limits their usefulness in situations characterized by very high levels 
of mRNA induction, as seen with TF512. Catalytic RNA, or ribozymes, are a class of 
RNA molecules that possess enzymatic properties512, 513. Ribozymes are thought to be 
more useful than conventional antisense RNAs and DNAs, since ribozymes possess the 
properties of antisense RNA with the additional ability of catalytic cleavage512. TF gene 
silencing using RNA interference, has also been reported, but has limited efficiency514. 
The main limitation for these approaches is the development of an efficient and safe 
delivery mechanism. 
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The data presented in this thesis advances our understanding of the post-transcriptional 
regulation of TF and presents a novel role for PARP-14 and ADP-ribosylation in 
selectively regulating TF mRNA turnover. This raises the possibility of pharmacological 
therapies that may “selectively” target TF expression. There has already been 
considerable pharmaceutical interest in p38 MAPK as a target for drug development for 
treating inflammatory diseases 515-517, and one might predict that destabilisation of TF 
mRNA and a reduction in TF expression and activity would give these compounds anti-
thrombotic as well as anti-inflammatory properties. However, therapeutic targeting of 
pro-inflammatory pathways such as NFkB or p38 MAPK pathways, contrary to intuitive 
thinking as having potential anti-inflammatory and anti-thrombotic effects, would have 
diverse non-specific and potentially undesirable effects due to the important roles 
played by these pathways in both inflammatory and anti-inflammatory signalling. Having 
shown that the PARP-14-TTP interaction applies to TF but not TNFα regulation, this 
selectivity for TTP targets shows great promise for PARP-14 inhibitors as therapeutic 
agents. Specific PARP-14 inhibitors518 might be advantageous in having less ubiquitous 
effects compared to p38 MAPK inhibition. As TF not only activates blood coagulation 
but is also pro-inflammatory via activation of PARs by thrombin28, PARP-14 inhibition 
may have wider therapeutic effects in atherothrombosis, severe sepsis and cancer 
where the pathology is linked to increased TF expression.  
 
6.7 Limitations 
This study has a number of limitations. LPS has been used as the model stimulus as it 
produces a strong and consistent induction in TF. Whilst endotoxaemia is 
atherogenic519 and may precipitate ACS520, it may be of limited relevance to 
cardiovascular disease and atherosclerosis in general. It would have been ideal to test 
other stimuli relevant to cardiovascular disease, e.g. CD40L, TNFα and IL-1. To 
investigate the effect of TTP and PARP-14 deficiency on TF expression, transgenic 
mice (Ttp-/- and Parp14-/-) were used. Whilst transgenic mice are a powerful tool to 
investigate the effect of a target protein, the major drawback is the potential for any 
unknown genetic compensation. To further confirm the effects of TTP and PARP-14 
deficiency on TF expression and TF mRNA stability, experiments should also have 
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been conducted in human monocytes or WT murine macrophages using siRNA 
technology. However, the off-target effects of siRNA approaches would remain a 
potential problem. The majority of the experiments, particularly the determination of the 
mechanisms underlying the PARP-14-TTP interaction have been conducted in vitro. 
Whilst, the in vitro findings of increased TF expression and thrombogenicity were 
confirmed in vivo, whether or not the in vitro mechanisms reflect the in vivo mechanisms 
for mRNA stability remain to be determined. This will always be a limitation of any in 
vitro analysis. However, most of our understanding of the mechanisms regulating 
mRNA stability is derived from in vitro studies, and as such, determining in vivo 
molecular mechanisms regulating mRNA stability is somewhat challenging270. All the in 
vitro work was conducted in monocyte-macrophages, and the observed mechanisms 
were not tested in other cell types. However, the in vivo organ analyses were in keeping 
with the in vitro monocyte-macrophage results, and given the multiple cell types besides 
macrophages that make up the organs, it is likely that these mechanisms may be 
broadly applicable to other cell types. The p38 inhibitors used in this study were 
experimentally controlled for by using the inactive analogue compound SB202474. 
However, despite analyses demonstrating specificity for p38, one cannot definitively 
exclude non-specific effects, especially as dedicated kinase assays to demonstrate 
specificity were not used. The PARP inhibitors used in this study are not specific for 
PARP-14, and this has been acknowledged. The concentration of PARP inhibitors used 
in this study are based on those in previously reported studies. However, the efficacy of 
these compounds would have best been demonstrated using dedicated PARP assays.  
 
6.8 Future directions 
(a) To determine whether TTP can be ADP-ribosylated 
The novel finding that the PARP-14-TTP interaction selectively regulates TF mRNA 
stability needs further clarification. Whilst the inhibition of ADP-ribosylation appears to 
increase TF mRNA decay, the effect of ADP-ribosylation on TTP or other proteins in the 
mRNA decay complex requires further study. In the first instance this can be assessed 
by immunoprecipitation of candidate target proteins, including TTP, and assessing ADP-
ribosylation using mass spectrometry. 
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(b) To determine the subset of TTP-regulated transcripts co-regulated by PARP-
14 
Whilst the PARP-14-TTP interaction does not appear to regulate TNFα mRNA, the pool 
of mRNA or subset of TTP-regulated transcripts that may also be regulated by PARP-14 
remain to be determined. Although the putative ARE sequences in mediating PARP-14-
TTP interaction have been identified, the detailed analysis of how PARP-14 interacts 
with mRNA needs to be conducted. To establish which other genes are coregulated by 
PARP-14 and TTP, PAR-CLIP (Photo-Activatable Ribonuceoside Cross-Linking and 
ImmunoPrecipitation) and ―next generation‖ RNA sequencing can be used. This 
technique chemically cross-links RNA-binding proteins to RNA prior to 
immunoprecipitation, and has the advantage over simple RNP immunoprecipitation in 
allowing the identification of protein-RNA interactions that are of insufficiently high 
affinity to be survive conventional immunoprecipitation protocols521. Furthermore, PAR-
CLIP reduces the false-positive hits due to indirect interactions identified by pulling 
down large RNA-protein complexes. A major added advantage of PAR-CLIP is that it 
also enables the identification of protein contact points on mRNA, as T to C mutations 
occur at cross-linking sites521. Using a PAR-CLIP protocol, immunoprecipitation with 
anti-PARP-14 and anti-TTP antibodies can determine the mRNAs bound to these 
proteins. Based on T to C cDNA mutations that occur at cross-linking sites, a common 
RNA footprint(s) for PARP-14 binding can be determined, albeit recognising the 
possibility that tertiary RNA structure may be more important than precise nucleotide 
sequence.  Following this, the putative PARP-14 binding sites may be validated on 
selected PARP-14 target mRNA by appropriately mutating the 3‘UTR and assessing 
effects on mRNA-PARP-14 interactions using RNP immunoprecipitation and RNA-biotin 
pulldown assays. 
 
(c) To determine the role of PARP-14 catalytic activity 
A major limitation of the PARP inhibitors is lack of specificity for PARP-14. Although 
PARP-14 specific compounds are in development, they are not currently available for 
use. Another way to address this problem is to generate of catalytically-inactive PARP-
14 knock-in mouse. Rather than make a PARP-14 mutant mouse (Parp-14mut) lacking 
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the PARP domain, one can simply mutate the conserved glutamate in the 5th conserved 
 strand, which is critical for catalytic function in several enzymatically-active PARP 
protein, including PARP-14522-524. This is less likely to cause non-specific steric 
confounding effects compared to a PARP domain deletion, and this mutant should 
predict the effects of drug targeting PARP-14 catalytic activity. These mice can then be 
used in a similar way for conducting the in vitro and in vivo work as above. 
 
(d) To determine the effects of PARP-14 deficiency and PARP-14 catalytic activity 
on thrombosis and atherosclerosis in hyperlipidaemic mice 
There is good evidence that hyperlipidaemia leads to a procoagulant state, both in 
humans and mice231, 525. Furthermore, this has been linked to an increase in circulating 
TF, both on circulating monocytes and microparticles231. Given that a deficiency of 
PARP-14 increases LPS-induced TF expression, replacing the ―LPS‖ stimulus with 
―hypercholesterolaemia‖ and assessing whether TF expression is increased in the 
context of  PARP-14 deficiency would provide a more suitable disease model for 
thrombosis and atherosclerosis. One can hypothesise that Parp14-/- mice will show 
accelerated atherosclerosis, possibly with a novel thrombotic phenotype related to the 
inappropriately high TF levels, whereas Parp14mut mice will be protected. However, as 
PARP-14 also regulates IFNγ-driven genes, its effects on atherosclerosis will probably 
be more complex than acting via a single pathway. This can be examined further by 
cross-breeding Parp14-/- mice with Ldlr-/- mice and obtaining double knock-out mice. By 
establishing a breeding colony of Ldlr-/- homozygous / Parp-14-/+ mice, one can compare 
Ldlr-/- homozygous / Parp14-/- mice versus Ldlr-/- homozygous / Parp14+/+ offspring. 
Similarly, Parp14mut homozygous mice can be cross-bred with Ldlr-/- mice to obtain a 
double homozygous colony. These can then be bred with heterozygous Cre-expressing 
mice, with a view to comparing Ldlr-/- homozygous / Parp14mut  mice which do not 
express Cre (i.e. inactive knock-in) versus mice homozygous for Cre (i.e. active knock-
in). These mice would provide a valuable resource for evaluating the effect of PARP-14 
deficiency and/or PARP-14 catalytic activity on thrombosis and atherosclerosis (using 
intravascular thrombosis models) and on atherosclerotic lesion and morphology (using 
lesional immunohistochemistry). 
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Conclusions 
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The primary aim of this thesis was to determine the molecular mechanisms regulating 
TF mRNA decay. TF is a key stimulus for thrombus formation, with diverse effects in the 
context of cardiovascular disease. Most of our understanding is centred on the 
transcriptional regulation of TF. Despite the fact that that the TF transcript is reported to 
be intrinsically unstable, the molecular mechanisms governing its post-transcriptional 
regulation are poorly understood. 
 
The data presented in this thesis have shown that TTP, an important well-studied 
mRNA binding protein, interacts with PARP-14, a new protein in post-transcriptional 
biology, to regulate TF mRNA stability in LPS-stimulated monocyte-macrophages, such 
that TF expression and TF mRNA stability are increased in the absence of either of 
these proteins. These findings are supported by in vivo demonstration of increased TF 
expression and thrombogenicity in PARP-14 deficient mice. Both TTP and PARP-14 
appear to bind cooperatively with TF mRNA and the final palindromic sequence in the 
TF 3‘UTR (AUAAUUUAUUUAAUA) which contains 2 overlapping AUUUAUUUA and 
UUAUUUAAU nonamers, both of which appear to be critical in mediating this 
interaction.  
 
The TTP-PARP-14 interaction allows pharmacological modulation of TF mRNA stability. 
As TTP regulates TF mRNA stability, TF mRNA decay can be accelerated with p38 
inhibition – an effect classically seen with TTP-regulated transcript. PARP-14 appears to 
have two distinct roles in regulating TF mRNA turnover. Firstly, it serves as an 
accessory protein required for TTP to bind TF mRNA. Secondly, the PARP catalytic 
activity of PARP-14 serves to stabilize TF mRNA, such that inhibition of ADP-
ribosylation  results in increased TF mRNA decay. Thus one may propose that both 
PARP-14 mediated ADP-ribosylation and  and p38-mediated phosphorylation events 
are necessary for inactivating TTP-mediated TF mRNA decay. Furthermore, the PARP-
14-TTP interaction applies to TF but not TNFα or TTP, which are other TTP-regulated 
transcripts. This selectivity for TTP targets shows great promise for PARP-14 inhibitors 
as therapeutic agents, potentially, with less ubiquitous effects.  
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These data have also shown for the first time that Dex reduces TF expression in LPS-
stimulated monocyte-macrophages. Dex is negative regulator of p38 activity, and is 
known to increase TTP-mediated mRNA decay. However, the unexpected observation 
that Dex reduces TF mRNA stability in TTP-deficient cells indicates that Dex is acting to 
regulate TF mRNA stability through both TTP-dependent and TTP-independent 
mechanisms, perhaps involving miRNAs or other RNA-binding proteins. 
 
Collectively, these data provide novel molecular mechanisms governing the regulation 
of TF mRNA turnover, and represent a significant advance in our understanding of the 
regulation of TF. A better understanding of the regulation of TF holds considerable 
therapeutic potential. As TF not only activates blood coagulation but is also pro-
inflammatory via activation of PARs, targeting TF may have wider therapeutic effects in 
pathological states such as atherothrombosis, sepsis and cancer which are associated 
with increased TF expression.  
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